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Overview 
Mycoplasma (M.) suis belongs to the uncultivable hemotrophic mycoplasmas (HM), which 
have become more important over the last few years. M. suis is primary found on pigs eryth-
rocytes and causes the infectious anemia of pigs (IAP) (Hoelzle et al., 2008). Red blood cells 
are destructed by adhesion, invasion, immune mediated lysis and eryptosis and also other 
pathogenic mechanisms like endothelial targeting could be observed (Hoelzle et al., 2014). 
IAP is a multifactorial disease and appears in pigs of all ages and different livestock categories. 
Animals can suffer from an acute or chronic form of IAP. Clinical signs of acute IAP range from 
high fever, anemia, icterus, and cyanosis to hypoglycemia and allergic skin reactions (Heinritzi, 
1989; Hoelzle et al., 2008; Stadler et al., 2014). The chronic form manifests as mild anemia, 
general unthriftiness, growth retardation, and decreased reproductive efficiency in sows (Henry 
et al., 1979, Hoelzle et al, 2003, Groebel et al., 2009).  
In addition, chronical or latent infections lead to immunosuppression induced by M. suis itself 
and therefore go along with other respiratory and intestinal diseases (Heinritzi, 1989). Once 
infeceted animals become life-long carriers and have much economic impact all over the world. 
This goes along with big problems in the affected populations clinically heavily ascertainable. 
Antibiotic treatment only reduces the clinical signs of an infection with M. suis but cannot elim-
inate the bacteria from the host. A zoonotic potential is discussed (Wu et al., 2006; Yuan et al., 
2009). Farmers and veterinarians were infected with M. suis In China and Brazil (Hu et al., 
2009, Biondo et al., 2009). 
HMs were strictly host specific in many mammalian species (Neimark et al., 2001). Despite a 
high metabolic adaption, it is less known about the interaction between M. suis and its target 
cells. Also the understanding of the biology and pathogenicity of M. suis is rather limited yet, 
mostly explained by the uncultivabiltiy in vitro (Hoelzle, 2008). There are no genes found en-
coding virulence factors during sequencing and comparative analysis of two M. suis strains 
(Guimaraes et al., 2011). Nevertheless, some identified characteristics of M. suis are essential 
for pathogenesis: the switchover from extra- to intracellular lifestyle (Groebel et al., 2009), the 
induction of an immunomodulation and the persistent infections, as well as the destruction of 
erythrocytes as a result of different mechanisms and endothelial targeting (Hoelzle et al., 
2008). 
Mycoplasmas are among the smallest self-replication organisms known so far and character-
ized by very small genomes (580 kilo base pairs (kbp) – 1.3 mega base pairs (mpb) 
(Guimaraes et al., 2014). Although the genome sequence of M. suis is available, there is only 
limited information either on several metabolic pathways and transport-systems, non on ex-
pression of selected genes, which have not been examined on the transcriptomic level so far 
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(Guimaraes et al., 2011; Groebel et al., 2009). Clinical, pathologic and some immunologic as-
pects of IAP are relatively well-known, but the molecular mechanisms comprising the patho-
genic mechanisms of IAP are still poorly understood. Therefore, it is essential for our under-
standing of pathogenesis to study transcriptional changes that occur during an infection with 
M. suis. New findings in the pathogenesis of M. suis could offer researchers new opportunities 
for the development of protective vaccines, and for establishing therapy and prophylaxis ap-
proaches. 
In different studies microarrays were the method of choice to investigate global transcriptome 
changes in infected pigs and thus to understand pathogenic mechanisms and candidate genes 
or biochemical pathways involved in the regulation and development of a disease (Orihuela et 
al., 2004; Madsen et al., 2006; Fernandes et al.,2012). Microarray technology measures 
mRNA levels of genes and investigated gene expression profiles of different tissues and cell 
lines, what could lead to a better understanding of the host-pathogen interaction (Fernandes 
et al. 2012). 
Up to now, there are only two proteome studies which experimentally analyze the actual ex-
pression of the predicted M. suis genes during an acute infection (Felder et al., 2012; Dietz et 
al., 2015) and one new RNA-Seq study from do Nascimento et al. (2018) based on the porcine 
whole blood transcriptome from immunocompetent pigs experimentally infected with M. suis 
strain Illinois. Instead of microarrays RNA-sequencing methods allow the comparison and 
analysis of thousands of genes within one experiment (Zenoni et al., 2010). For example, a 
study of Siewert et al. (2014) provides insights into expression of metabolic and putative viru-
lence-related key genes of “Ca. P. mali”. Another study of Wang et al. (2013) describes the 
transcriptome profiling of M. marinum and analyzes the functions for differentially expressed 
genes between two phases. 
In current work, analyses on the gene expression profiles during different infection times with 
M. suis strain KI_3806 were performed by transcriptome approaches. The study includes the 
experimental infection of splenectomized pigs with M. suis strain KI_3806. Further the isolation 
of RNA out of blood samples during an infection course (4 and 8 days p. i.) and then the 
analysis of the transcriptome of M. suis and Sus scrofa. Therefore the transcriptome of M. suis 
was investigated by RNA-sequencing analyses and the transcriptome of Sus scrofa was ana-
lyzed by microarray analysis. 
12 
 
 
1 Introduction 
1.1 Historical perspective 
First infections were described in eight-week old pigs, characterized by icterus and anemia, in 
the early 1930s in the USA (in Moulder, 1974; according to Messick, 2004; Henry, 1979). An-
aplasma-like structures in the blood smears of infected pigs were observed by Kinsley (1932). 
These observations were confirmed by Doyle (1932), who describes beside clinical signs, like 
icterus and anemia further symptoms, like apathy, dyspnoe and lethargy. Due to the morpho-
logical similarities between these agents and the already known Eperythrozoon-species of ru-
minants (Eperythrozoon wenyonii, Eperythrozoon ovis), Splitter (1950) named this infectious 
agent into Eperythrozoon suis. In Germany, the first detection of HM in pigs was described 
1968 by Korn and Musgay. 
 
1.2 Mycoplasma suis 
1.2.1 Microbiology and taxonomy 
M. suis is a small (380–600 nm diameter) cell-wall less, pleomorphic bacterium that attaches 
to the surface of host red blood cells (Messick, 2004; Hoelzle, 2008). The mycoplasmas can 
also found free floating in the blood plasma of the host cells, which can be observed by micro-
scopic examination of the blood-smears during an acute infection. With Wright-Giemsa stain 
the bacteria stain blue to purple and with acridine-orange the structures of M. suis on and 
between the erythrocytes also become visible (Zachary and Basgall, 1985; Neimark et al., 
2001). The very close contact between M. suis and their host cell indicates a high metabolic 
adaption and seems to be crucial for the life-cycle of the bacterium. Three different replication 
forms can be found in form of rings, cocci and rods attached to and forming deformations and 
invaginations on the membrane of the erythrocytes (Figure 2). Moreover, electron microscopic 
investigations showed M. suis and porcine erythrocytes connected by fibrillary structures which 
are obviously responsible for the attachment to the host cell membrane (Zachary and Basgall, 
1985; Messick, 2004) (Figure 4). Nevertheless, the mechanisms of adhesion and replication 
of M. suis on erythrocytes are still unknown. M. suis is enclosed by a single membrane and 
ultrastructural investigations showed small granules and few short filaments in the cytoplasm 
of the parasite (Pospischil and Hoffmann, 1985). Two strains were identified for the circular, 
double-stranded genome of M. suis-strain Illinois with 745 kbp (Messick et al., 2000; Messick, 
2004) and strain KI_3806 with 709 kbp (Oehlerking et al., 2011). 
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Sequence-analyses of the 16S rRNA-genes of Eperythrozoon spp. and Haemobartonella spp. 
led to their reclassiﬁcation as members of the Genus Mycoplasma, Family Mycoplasmataceae, 
Order Mycoplasmatales, Class Mollicutes (Rikihisa et al., 1997, Neimark et al., 2001, Messick 
et al., 2002). HMs formed a new cluster within the “pneumonia” group of Mycoplasmas and 
were given the trivial name “hemoplasmas” (Rikihisa et al., 1997, Neimark et al., 2001; Tasker 
et al., 2003; Messick et al., 2002). Due to the biological characteristics of HMs and the lack of 
an in vitro culture system the classification was very difficult. The current Bergey´s Manual of 
Systematic Bacteriology classifies the HMs within the family Mycoplasmatales as insertae 
sedis (Hoelzle et al., 2014) (Figure 1). 
 
Figure 1: Classification of HMs within Bergey´s Manual of Systematic Bacteriology 
 
1.3 Infectious anemia of pigs 
M. suis causes an often multifactorial disease in pigs known as infectious anemia in pigs (IAP). 
M. suis infections occur worldwide and bear its importance in economic losses to the swine 
industry (Ritzmann et al., 2009). Studies from Guimaraes et al. (2007) and Ritzmann (2009) 
revealed the prevalence of M. suis infection, determined by qPCR, varies from 13.9% in Ger-
many to 18.2% in South America. Feeder and weaning pigs were often affected by an infection 
with M. suis worsening by stress, weaning, sickness and other inappropriate influences (Hein-
ritzi, 1989; Heinritzi, 1990). The course of M. suis infections can be acute or chronic – often 
clinically unapparent depending on the M. suis virulence and the host susceptibility. An infec-
tion with M. suis results in a high morbidity with an simultaneously low mortality (Groebel et al., 
2008). In China (2002), IAP caused a total morbidity of 30% and a mortality of 10–20% (Wu et 
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al., 2006). Furthermore, it is reported about its zoonotic potential especially in China (Wu et 
al., 2006; Yuan et al., 2009; Hu et al., 2009; Yang et al., 2000).  
Figure 2: Electron microscopy picture of M. suis 
infected red blood (SEM); B: Invaginations on red blood cells (TEM) (HOELZLE ET AL., 2014) 
 
1.3.1 Acute infection  
The acute form of IAP is associated with heavy M. suis bacteremia causing severe up to lethal 
hemolytic anemia mainly on feeder and weaning pigs or on pregnant sows (Zachary and 
Basgall, 1985; Messick, 2004). Severity of acute infection depends on animals’ age, concom-
itant diseases, immunosuppression, or splenectomy (Messick, 2004). Typical clinical signs are 
fever, icterus, and cyanosis at the acra (Figure 3, 4, 5), apathy, anorexia and dyspnoe. In 
addition, blood glucose levels of pigs decreased proportionally with the decline in the percent-
age of parasitized erythrocytes, resulting in hypoglycemia (Heinritzi et al., 1984; Smith et al., 
1990; Nonaka et al., 1996). Moreover, mild anemia and poor growth rates are observed in 
infected small piglets and feeder pigs. IAP in sows results in pyrexia, anorexia, depression, 
decreased milk production, and reduced maternal behavior (Messick, 2004). Tetracycline de-
creases the incidence of the acute form of IAP and alleviates the clinical signs, but pigs may 
still become persistently infected, asymptomatic carriers (Bugnowski et al., 1990; Heinritzi, 
1990; Smith, 1992). 
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Figure 3 A, B, C: Cyanosis at the acra in young pigs 
 
1.3.2 Chronic infection 
Most notably IAP has its meaning in subclinical cases and in chronically infected carrier ani-
mals accompanied by anemia, mild icterus and allergic skin reactions (Morbus maculosus, 
Figure 6, 7, 8) (Heinritzi, 1990). Chronic M. suis infections manifest in decreased reproductive 
performance in sows, as well as early embryonic deaths and abortions. In feeder pigs IAP is 
associated with growth retardation and a higher susceptibility to other infections that cause 
porcine respiratory and enteric diseases (Zachary and Smith, 1985; Messick, 2004). One of 
the most important problems with chronic IAP is to have major economic losses within the 
diseased pigs. Despite an intense immune response and antibiotic treatment, animals become 
asymptomatic carriers without obvious clinical signs. Moreover, the infection is able to return 
under stress conditions (Hoelzle, 2008). 
 
Figure 4 A, B,C:: Pigs with allergic skin reactions (Morbus maculosus) 
 
1.4 Epidemiology 
In nature, M. suis could only observed in in domestic pigs and in wild boars especially in Eu-
rope. Wild boars could be a possible wildlife reservoir for these bacteria. (Hoelzle et al., 2010). 
The epidemiological significance of the diseases is concentrated on its prevalence in feeder 
pigs. Under experimental conditions, only transmission via intraperitoneal, oral, subcutaneous 
A 
B 
C 
A 
B 
C 
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and intravenous inoculation of infected blood has been described (Hoelzle et al., 2008). There-
fore, iatrogenic blood transfer by contaminated surgical instruments and zootechnical han-
dlings occurs mostly (Henry 1979; Heinritzi, 1992). Moreover, intra-uterine transmission (Hen-
derson et al., 1997) and transmission by blood suckling arthropods were described (Heinritzi, 
1992; Prullage et al., 1993). Findings of Dietz et al. (2014) showed shedding of M. suis via 
saliva, nasal and vaginal secrets as well as via urine from day 6 post infection (p.i.) on. Dust 
and water samples of pig drinking troughs were also found positive for M. suis, what could also 
be a potential infection source. 
. 
1.5 Pathogenesis and immunology of IAP 
Our knowledge on the pathobiology of M. suis is rather limited, mainly based on the lack of an 
in vitro cultivation system. Previous insights into the pathogenesis of M. suis was obtained from 
experimentally infected pigs after splenectomy (Zachary and Basgall, 1985; Heinritzi, 1990). 
The cellular adhesins that mediate attachment of M. suis to porcine erythrocytes, and the mo-
lecular basis of adherence, have not been clarified fully (Hoelzle et al., 2014). Two immuno-
genic proteins have been identified involved in the adhesion, MSG1 and α-enolase. Both pro-
teins produce a strong immunological response by blocking adhesion with the help of anti-
MSG1 and anti-α-enolase antibodies (Hoelzle et al., 2007c; Schreiner et al., 2012b). Moreover, 
genome analysis has identified one more protein potentially involved in adhesion; the heat 
shock protein HspA1, which is immunodominant, surface-localized and expressed during 
acute IAP (Hoelzle, 2007b; Felder et al., 2012). Typically tip structures found in other Myco-
plasma species in form of cell adhesion complexes have not been observed in M. suis 
(Messick, 2004). 
Beyond adhesion to porcine erythrocytes, M. suis is also capable to invade erythrocytes in an 
endocytosis-like process (Groebel et al., 2009). This shift from an epi- into intra-erythrocytic 
location seems to be a possible strategy of M. suis to avoid either damage by antibiotics or the 
host immune response ending in persistence (Rottem, 2003, Hoelzle et al., 2014). Adhesion 
and/ or invasion leads to alterations of the erythrocytes membrane inducing eryptosis. Eryp-
tosis is the programmed cell death of erythrocytes, which is marked by cell shrinkage, blebbing, 
microvesiculation, activation of proteases and exposure of phosphatidylserine on the outer 
membrane, leading to recognition of erythrocytes by macrophages and successive phagocy-
tosis (Lang et al., 2006; Felder et al., 2011). 
Invasion into host cells may be involved in nutrient gaining (Groebel et al., 2009; Guimaraes 
et al., 2011). There is a substantial decrease in blood glucose during acute IAP observed by 
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Heinritzi et al. (1990), Simth et al. (1990) and Nonaka et al. (1996). Genome sequence analysis 
of Guimaraes et al. (2011) confirmed these observations finding M. suis acquires some me-
tabolites from erythrocytes. This nutrient scavenging might lead to reduced energy production, 
oxidative stress and reduced life span of erythrocytes (Hoelzle et al., 2014). 
Furthermore, M. suis can cause an autoimmune hemolytic anemia due to "cold" reactive anti-
erythrocyte antibodies, so called cold agglutinins (CA; Zachary and Smith, 1985; Schmidt et 
al., 1992; Hoffmann et al., 1981). Injuries in the erythrocyte membrane could serve as the 
stimulus for the synthesis of such IgM CA that are not directed against bacterial antigens but 
against carbohydrate antigens located on the erythrocyte surface (Zachary and Smith, 1985; 
Jüngling et al., 1994). Zachary and Smith (1985) described also a suppression of T-lymphocyte 
blastogenic response indicating that T-helper lymphocyte activities may be altered during an 
IAP. Simultaneously, the activation of polyclonal B-lymphocytes and CAs occurs, misdirected 
against the injured erythrocyte. In addition, warm autoreactive IgG antibodies are upregulated 
during an infection recognizing the host actin, leading to a dysregulation of the host’s immune 
response and helping M. suis to avoid destruction (Felder et al., 2010; Hoelzle et al., 2006). 
A novel mechanism in the pathogenesis of M. suis is endothelial attachment. M. suis can attach 
to endothelial cells singly or as bioﬁlm-like microcolonies. Electron microscopic investigations 
based on experimental infections showed that M. suis and M. suis-infected erytrocytes interact 
with endothelial cells triggering activation responses and coagulation processes (Sokoli et al., 
2013). Endothelial activation results in formation of microvilli in M. suis infected animals, which 
could increase the frequency of adhesion of infected erythrocytes (Sokoli et al., 2013). 
 
1.6 Diagnosis 
1.6.1 Clinical and hematological alterations 
Clinical diagnosis can be done during an acute infection characterized by typical clinical signs 
for IAP like fever (up to 42°C), anemia, icterus, apathy, anorexia, and cyanosis at the acra 
(Heinritzi et al., 1990), as wells as necrosis and skin alterations (Heinritzi et al., 1984). Red 
blood cell count shows a decreased number of erythrocytes, simultaneous the hemoglobin 
concentration indicates a normochromic, normocytic anemia (Heinritzi et al., 1990). White 
blood cell count shows a neutrophilic leukocytosis, as well as an increase of lactic acid (means 
= 62.7 mg/dL) and bilirubin resulting in a blood acidosis (means pH = 7.13) (Heinritzi et al., 
1990; Zachary and Basgall, 1985; Zachary and Smith, 1985). 
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1.6.2 Bacteriological diagnosis 
Due to the fact that M. suis is not cultivable, the bacteriological diagnosis is not possible. 
1.6.3 Microscopy 
Microscopic diagnosis is performed by blood smear staining using Giemsa or acridin-orange 
solutions. M. suis can be observed as single bacterium, pairwise or in strains located on the 
erythrocytic surface. However, microscopic examination has proven to be of low sensitivity and 
speciﬁcity. A secure diagnosis is only possible with pathogen quantities greater than 106 M. 
suis cells/ml blood (Ritzmann et al., 2009). Thereby, M. suis can only be microscopically de-
tected during an acute phase of infection when high levels of bacteria are within the blood. In 
chronic phases of infection with low bacterial numbers in the blood microscopy is not really an 
option for diagnosis. (Heinritzi, 1990). Furthermore, false positive microscopic results are pos-
sible due to misinterpretations (Heinritzi, 1990; Henry 1979; Hoelzle et al., 2003) of erythrocytic 
structures. 
1.6.4 Serology 
Serological detection methods are mainly important as surveillance instrument and for popu-
lation diagnostic, because clinical diagnoses beyond acute IAP are hardly possible (Bollwahn, 
1982; Heinritzi et al., 1984; Heinritzi, 1990) and methods to detect carrier animals are neces-
sary. M. suis infections induce a strong immune response over a long period of time (Hoelzle 
et al., 2006). Three different serological assays were described before the era of molecular 
techniques: complement fixation assay (CFA; Splitter, 1958), indirect hemagglutination assay 
(IHA, Smith and Rahn, 1975) and enzyme-linked-immunosorbent assay (ELISA; Schuller et 
al., 1990). Disadvantages of those assays were poor sensitivities and speciﬁcities and the 
usage of complex and undeﬁned M. suis antigens obtained from the peripheral blood of exper-
imentally infected pigs (Hoelzle et al., 2006). By detection of the three main antigens, of which 
two were recombinantly expressed, (MSG-1 and HspA-1) sensitivity and speciﬁcity could be 
clearly improved (Hoelzle et al., 2007). Zang et al. (2012) developed a blocking ELISA for 
serodiagnosis of M.suis, where monoclonal antibodies produced by immunizing BALB/c mice 
with recombinant MSG1 protein were used. And Guimaraes et al. (2014) developed a multiplex 
microbead immunoassay using a heat-shock protein (GrpE), a nicotinamide adenine dinucle-
otide-dependent glyceraldehyde 3-phosphate dehydrogenase (GAPN), and 4 proteins from 
paralogous gene families (PGFs). 
19 
 
 
1.6.5 Molecular diagnosis 
Oberst et al. (1990a) developed a procedure for the identification of M. suis infected blood 
samples using radio-labelled whole-organism M. suis DNA as the probe. A disadvantage of 
this method was that large amounts of bacteria propagated in splenectomized pigs were nec-
essary. In the same year Oberst et al. (1990b) developed an M. suis specific recombinant 
clone by hybridization and a gene bank. Due to these new findings a novel more sensitive PCR 
was developed. Now M. suis could be already detected after 24 hours of an infection (Gwaltney 
et al., 1993). After optimizing of their PCR protocol, the detection of M. suis also proved to be 
successful in latently infected pigs (Gwaltney and Oberst, 1994). Four years later a quantitative 
Light Cycler™ PCR assay based on the msg1 gene of M. suis (LC MSG1 PCR) was devel-
oped. Test sensitivity was found to be 100%, and test specificity 96.7% (Hoelzle et al., 2007a). 
 
1.7 Therapy and prophylaxis 
Like all other mycoplasmas M. suis is sensitive against tetracycline (Hoelzle 2007; Hoelzle 
2008). Antibiotic treatment is able to cure the clinical signs, but animals once infected remain 
persistent and clinically inapperently infected carrier animals (Hoelzle, 2008; Ritzmann et al., 
2009). IAP can also be treated by the application of iron dextran.  For prevention of IAP pigs 
should be hindered from bloodsucking and protected from biting insects. The hygienic rules 
when vaccinating or castrating the animals should be maintained, for example, sterilization/dis-
infection of zootechnical instruments and usage of disposable needles are necessary. Moreo-
ver, infected animals should be removed to avoid the spreading within the herd. To date, no 
vaccine is available against M. suis infections. A vaccine candidate of Hoelzle et al. (2009) 
failed to protect against M. suis challenge. Vaccine candidates based on recombinant MSG1 
and Escherichia coli (E. coli) transformants expressing MSG1 resulted in a strong humoral and 
cellular immune response against M. suis. But protection against an M. suis challenge infection 
and subsequent IAP development could not be achieved. (Hoelzle et al., 2009). 
 
1.8 Transcriptome 
The transcriptome is the complete set of transcripts in a cell representing the small percentage 
of the genetic code in an organism. Transcriptomic analyses are important for understanding 
the features of the genome and the molecular constituents of cells and tissues, and also for 
understanding development and disease. Transcripts include mRNAs, non-coding RNAs and 
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small RNAs (Van Vliet, 2010; Febrer et al., 2011). Transcriptome studies of numerous of bac-
teria have already been made by using hybridization or microarrays (Venkatasubbarao, 2004; 
Van Vliet, 2010). Microarrays comprise microscopic spots of DNA oligonucleotide probes at-
tached to a solid surface, which is used to hybridize cDNA. To determine the level of gene 
expression an existing genome sequence of the involved organism should be available. In 
contrast, RNA-Sequencing (RNA-Seq) enables to sequence cDNA directly from the organism 
of interest to evaluate the gene expression level. RNA-Seq does not need a prior annotation 
or information about the genome sequence (Febrer et al., 2011). 
1.8.1 Microarrays 
Microarrays are important research tools for life sciences and are also used in diagnostics, 
treatment and monitoring applications (Venkatasubbarao, 2004). Biomolecules commonly im-
mobilized on microarrays comprise oligonucleotides, PCR products, proteins, lipids, peptides 
and carbohydrates (Venkatasubbarao, 2004). Research questions apply to gene expression 
analyses, localization of specific genetic variations as well as investigations of microRNA or 
proteome-analyses. 
Microarray-based expression profiling experiments typically use either a one-color or a two-
color microarray to measure mRNA abundance, differing in labeling the samples. A one-color 
procedure includes the hybridization of a single sample to each microarray after it has been 
labeled with a single fluorophore (such as phycoerythrin, cyanine-3 (Cy3) or cyanine-5 (Cy5)), 
whereas in a two-color procedure two samples (e.g., experimental and control) are labeled 
with different fluorophores (usually Cy3 and Cy5 dyes) and hybridized together on a single 
microarray (Patterson et al., 2006). Production of arrays starts with the selection of the probes 
(mainly chosen from databases). Then, chosen DNA oligonucleotides are spotted on the mi-
croarray platform (solid surface) which is used for the hybridization of cDNA samples (Febrer 
et al., 2011). For this, plastic, glass-, or silica-carriers are used (Duggan et al., 1999; Hedge et 
al., 2000). 
After purification and controlling of the RNA, the arrays are produced by spotting PCR products 
representing specific genes onto a matrix. (Duggan et al., 1999). For synthesizing both cDNA 
strings reverse transcriptase from an oligo-dT primer is used (Duggan et al., 1999; Hedge et 
al., 2000). After that, products of the labeling reactions must be purified to remove unspecific 
bindings and to reduce the background products (Hedge et al., 2000). Finally, hybridization 
and washing steps are necessary for scanning the arrays using laser DNA microarray scanner. 
However, microarrays have several limitations that include dependence on an existing genome 
sequence of the examined organism, background hybridization limits, and limited detection 
range due to saturation of fluorescent signals (Febrer et al., 2011). 
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Known platforms are for example Applied Biosystems, Affymetrix, Agilent, Illumina, LGTC 
home-spotted arrays (Pedotti et al., 2008). 
 
Figure 5: Schematic description of a cDNA-microarray (Duggan et a., 1999) 
 
1.8.2 RNA-Sequencing  
Rapid improvements in technology and decreased sequencing costs in recent years has been 
established a new market referred to next generation sequencing (NGS) (Li et al., 2015). In 
NGS, sequencing is performed by repeated cycles of polymerase-mediated nucleotide exten-
sions or by iterative cycles of oligonucleotide ligation resulting in high-throughput sequencing 
(Voelkerding et al., 2009). Using NGS to study the RNA in a sample (e.g. RNA-Seq) facilitates 
whole transcriptome analyses in different ways. 
RNA-Seq differs from other transcriptional analyses methods. First, the probe sequences are 
not specified, which is beneficial for bacteria with large amounts of genetic variation between 
strains (Tettelin et al., 2008). Second, mapping of sequence data is more specific than hybrid-
ization between oligonucleotides (Croucher et al., 2010). And third, RNA-Seq uses the quantity 
of data matching a given coding sequence (CDS), usually quantified as reads per kilobase 
CDS length per million reads analyzed (RPKM; Mortazavi et al., 2008). 
RNA is typically purified using organic diluents or commercially available kits. After extraction 
of RNA and enzymatic removal of DNA, ribosomal RNA (rRNA) may be depleted to increase 
the sequence coverage of other transcripts. Then, cDNA is generated through random hex-
amer-primed reverse transcription followed by second DNA strand synthesis (Oliver et al., 
2009; Yoder-Himes, 2009; Mao et al., 2008) or alternatively, the RNA could be fragmented, 
and information on the template strand for transcription retained through orientation-specific, 
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stepwise attachment of adapters (Vivancos et al., 2010; Sharma et al., 2010). Selection of a 
suitable cDNA library construction depends on the sequencing platform being used (Febrer et 
al., 2011). Sequencing platforms are Illumina (Chen et al., 2014), 454 Roche (Clark and 
Thorne, 2015) or SOLID (Shendure et al., 2005). These platforms differ in read length and 
depth of coverage. After sequencing, reads can be assembled using different software pro-
grams. Alternatively to software, reads can be mapped onto a reference sequence (Delcher et 
al., 2002; Croucher et al., 2010). 
RNA-Seq is less limited compared to microarrays - no hybridization methods, no limitations in 
measurement accuracy and more sensitivity for transcript detection (Chu and Corey, 2012; 
Marioni et al., 2008). However, the sequence data produced are frequent and more compli-
cated to interpret (Li et al., 2015). 
One disadvantage of RNA-Seq is its greater cost of sequencing compared to microarray hy-
bridization methods (Croucher et al., 2010). Moreover, there are still problems with RNA splic-
ing, sequencing depth and obtaining quantified transcription data (e.g. read errors, short read 
mapping and SNPs) (Mortazavi et al., 2008). 
 
ILLUMINA GENOME ANALYZER 
For Illumina platforms amplification is generated by a so called bridge PCR (Adessi et al., 2000; 
Fedurco et al., 2006; Shendure und Ji, 2008). For this method, forward and reverse PCR pri-
mers are linked to a solid substrate by a flexible linker (5´-attached), resulting in immobilized 
amplicons remaining locally linked to a single point of the surface. After PCR each clonal clus-
ter contains of approximately 1000 amplicons. After cluster generation, the amplicons are sin-
gle stranded. A modified DNA-Polymerase and a mixture of four nucleotides, which have a 
reversible terminator on the 3´-hydroxyl position and one of four is fluorescent labeled, are 
used for sequencing the region of interest (Shendure und Ji, 2008; Turcatti et al., 2008). DNA-
synthesis is stopped after integration of a nucleotide due to the terminator side and strands 
are fluorescent labeled after washing. At the end of the cycle terminator side and labeling of 
each strand will be removed and the cycle starts again. After single-base extension and 
achievement of images in four channels, chemical cleavage arranges for the next cycle (Shen-
dure und Ji, 2008). 
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Figure 6: Illumina Genome Analyzer Workflow (Tucker et al., 2009) 
  
454 ROCHE 
The 454 system of Roche was the first NGS platform available as a commercial product 
(Margulies et al., 2005). The method is based on a so called emulsion PCR (Dressmann et al., 
2003). First, a library of template DNA is prepared by fragmentation via nebulization or sonifi-
cation. Fragments are end-repaired and ligated to adapter oligonucleotides. After library dilu-
tion to single molecules and denaturation, amplicons are fixed to the surface of special beads 
containing sequences complementary to adapter oligonucleotides and then captured in water-
in-oil microemulsion of the PCR (Margulies et al., 2005; Voelkerding et al., 2009). One of the 
PCR primers is bound (5´-attached) to the surface of the beads that are also included in the 
reaction. After PCR cycling, the microemulsion will be broken and beads are treated with de-
naturant to remove untethered strands. Sequencing by itself is performed by the pyrosequenc-
ing method (Ronaghi et al., 1996). Therefore, smaller beads are added onto an array already 
containing immobilized enzymes (ATP sulfurylase and luciferase). After each several hundred 
cycles, a single unlabeled nucleotide is integrated. As soon as a complementary nucleotide is 
integrated, via ATP sulfurylase and luciferase a burst of light is released (Shendure und Ji, 
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2008). So base for base can be detected and the sequence is shown above the flow gram 
(Margulies et al., 2005). 
 
Figure 7: Roche 454 GS FLX sequencing (Voelkerding et al., 2009) 
 
AB SOLID 
SOLID is an acronym standing for “Sequencing by Oligonucleotide Ligation and Detection”. 
Clonal sequencing features are also generated by emulsion PCR, which uses 1 µM paramag-
netic beads (Dressmann et al., 2003). After breaking the emulsion beads bearing the ampli-
cons, amplicons are recovered and then fixed to a solid planar substrate, e.g. to glass plates. 
Sequencing is performed using a DNA ligase instead of a polymerase (Brenner et al., 2000; 
Housby and Southern, 1998). A universal primer complementary to adaptor sequence is hy-
bridized to the array. Fluorescently labeled octamers are given to each cycle of sequencing. 
Octamers have two known base pairs in their middle, which are enclosed by three unknown 
base pairs. After ligation and imaging in four channels the labeled octamer is cleaved via a 
modified linkage between bases 5 and 6, leaving a free end for another cycle of ligation. After 
repeating this procedure for several cycles, the system is then reset by denaturation of the 
extended primer and the process is repeated (Shendure und Ji, 2008). 
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Figure 8: Applied Biosystems SOLiD sequencing by ligation (Voelkerding et al., 2009) 
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2 Objective 
As all hemotrophic mycoplasmas M. suis has not been cultured under in vitro conditions so 
far, although a kind of maintenance after nanotransformation can be obtained in a cell free 
culture system (Schreiner et al., 2012). M. suis can be maintained and propagated by inocula-
tion of pigs, causing an experimental infection that resembles either the acute stage of IAP in 
splenectomized animals or chronic IAP in non-splenectomized animals (Stadler et al., 2014). 
To get further inrformation on diverse mechanisms of pathogenesis including RBC adhesion 
and invasion, cell tropism and immunopathology (Hoelzle et al., 2007a; Hoelzle et al., 2007b; 
Felder et al., 2011; Schreiner et al., 2012; Felder et al., 2012; Sokoli et al., 2013) the proper 
pig infection model has to be established.  
Genome sequencing projects of both M. suis strains (Oehlerking et al., 2011; Guimaraes et 
al., 2011) have produced a significant amount of data thus, providing the sequence basis for 
proteomic and transcriptomic studies. So far, only three proteomic studies took advantage of 
the new high-throughput technologies to describe the expression profiles of M. suis during an 
acute infection (Congli et al., 2010; Felder et al., 2012; Dietz et al., 2015). Furthermore, only 
data on whole blood transcriptomic response to M. suis strain Illinois infections are available 
(do Nascimento et al., 2018). Other studies applying high-throughput “omics” technologies for 
M. suis and other hemotrophic mycoplasmas (e.g. transcriptomics) are missing, even though 
transcriptomes would be very valuable because they represent the part of the transcripts in-
cluding important hypothetical proteins with unknown functions expressed in a certain condi-
tion (e.g. acute phase of infection).  
The aim of this study was to establish an appropriate pig model, demonstrating the tran-
scriptomic changes on host and pathogen side during an infection with M. suis, herby espe-
cially looking at the host immune response and identifying further pathways and genes involved 
in the pathophysiology of M. suis. 
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The objectives are listed in detail as follows: 
 
2.1 Establishment of an acute IAP model under experiment conditions 
- Experimental infection with the highly virulent and invasive M. suis strain KI_3806 in splenec-
tomized pigs lead to acute IAP 
- Such infection models are important for further pathogenesis studies in M. suis. 
- Clinicial and hematological parameters allow insights into the host immune response during 
acute IAP 
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2.2 Mechanisms used by M. suis to cause disease and to avoid the immune 
system and to persist in the host, respectively 
- Differential expressed genes involved in anemia, endothelial cell damage and psoriasis could 
be identified 
- Identification of different immune pathways and genes involved in immune response 
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2.3 Transcriptional map of M. suis and analysis of differentially expressed 
genes during the course of acute infection 
- Within the differentially expressed genes the largest group encoding for hypothetical genes 
were found 
- Two hypothetical genes encoding for a membrane protein could be identified 
30 
 
 
3 Material and Methods 
3.1 Materials 
3.1.1 Chemicals 
Alsever´s Solution (Sigma-Aldrich, Steinheim) 
Biozym LE Agarose (Biozym, Oldendorf) 
Chloroform (Roth, Karlsruhe) 
Ethanol absolute (Roth, Karlsruhe) 
Glacial acetic acid (Roth, Karlsruhe) 
Gene Ruler 1 kb DNA ladder (Fermentas, St.Leon-Rot) 
Isopropanol (Roth, Karlsruhe) 
Magnesium-dichlorid (Sigma-Aldrich, Steinheim) 
2-Mercaptoethanol (Roth, Karlsruhe) 
Nuclease-Free Water (Qiagen, Hilden) 
PBS Dulbecco (Biochrom, Berlin) 
RNAse free water (Biochrom, Berlin) 
RNaseZap® (Ambion-Life Technologies, Darmstadt) 
RNASE Away (Promega, Mannheim)  
Saccharose (Roth, Karlsruhe) 
TRI Reagent® BD (Sigma-Aldrich, Steinheim) 
TritonX-100 (Sigma-Aldrich, Steinheim) 
Venno Vet 1 (Menno Chemie-Vertrieb GmbH, Norderstedt) 
3.1.2 Drugs 
Azaperon, Stresnil®, 2 mg/kg body weight (Janssen-Cilag GmbH, Neuss) 
Isofluran, Isoba®, MAC ca. 1.5 Vol % (MSD Tiergesundheit, Unterschleißheim) 
Ketamin, Urostamin®, 10-25 mg/kg body weight (Serumwerk-Bernburg AG) 
Meloxicam, Metacam® 5 %, 0.4 mg/kg body weight equates to 2 ml/100 kg (KGW, Boehringer 
Ingelheim) 
Metamizol, Vetalgin®, 15-20 mg/kg body weight equates to 0.3-1 ml/10 kg KGW (MSD Tier-
gesundheit, Unterschleißheim) 
Penicillin, Vetri-Proc® 30 % 1 ml/10 kg body weight (CEVA Tiergesundheit GmbH, Düsseldorf)  
 
  
31 
 
 
3.1.3 Buffer and solutions 
for 100 ml Lysisbuffer:  5 mM MgCl2  
320 mM saccharose  
1 % Triton X-100  
10 mM Tris-HCl, pH 7.5 
 to 100 ml Aqua dest.  
RNeasy mini Kit (Qiagen, Hilden): 
RLT-buffer: 10 ml RLT-buffer 
100 µl 2-mercaptoethanol 
RPE-buffer: fill up with 44 ml ≥ 99.9 % ethanol  
TRI Reagent® BD (Sigma-Aldrich, Steinheim):  
70 % ethanol: 35 ml ≥ 99.9 % ethanol 
15 ml RNase-freies Wasser 
5 N glacial acetic acid: 1 ml glacial acetic acid 
2.48 ml RNase free water 
10x Tris-Borat-EDTA-buffer (TBE, Sigma-Aldrich, Steinheim): 
Working solution (1x): 100 ml 10x TBE-Puffer + 900 ml Aqua dest. 
3.1.4 Kits 
Agilent RNA 6000 Nano Kit (Agilent, Waldbronn) 
GenElute™ Bacterial Genomic DNA Kit (Sigma-Aldrich, Steinheim) 
LightCycler™ FastStart DNA MasterPLUS Hybridization Kit (Roche Diagnostics, Mannheim) 
RNeasy mini Kit (Qiagen, Hilden) 
3.1.5 Instruments 
Awel Centrifuge MF 48-R (Integra Biosciences, Fernwald) 
BDK (Luft- und Reinraumtechnik GmbH, Sonnenbühl-Genkingen) 
Bioanalyzer 2100 (Agilent, Waldbronn) 
BioShake iQ (Analytik Jena, Jena) 
Chip Priming Station (Agilent, Waldbronn) 
DNA Engine® Peltier Thermal Cycler (BIO-RAD, München) 
Electrode Cartridge (Agilent, Waldbronn) 
Heraeus Pico17 Centrifuge (Thermo-Scientific, Karlsruhe) 
Herasafe KS (Thermo-Scientific, Karlsruhe) 
Hermle Z 233 MK (neoLab, Heidelberg) 
IKA® MS-3 Vortexer (Agilent, Waldbronn) 
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LCTM 2.0 PCR  (Roche Diagnostic, Mannheim) 
LightCyclerTM Centrifuge Adapters (Böhringer-Mannheim, Mannheim) 
Mikrowelle R-210A Sharp Corporation (Osaka, Japan) 
MiniSpin® Plus (Eppendorf, Hamburg) 
Mini Sub-Cell GT (BIO-RAD, München) 
MJ Research PTC-200 Peltier Thermal-Cycler (Biozym, Hessisch Oldendorf) 
Power Pac Universal  (BIO-RAD, München) 
Vilber Lourmat (Marne-la-Vallee Cedex, Frankreich) 
Vortex Mixer (neoLab, Heidelberg) 
3.1.6 Consumabels 
Cellstar tubes (15 ml / 50 ml) (Greiner bio-one GmbH, Frickenhausen) 
Eppendorf pipettes (1000 µl, 100 µl, 10 µl) (Eppendorf, Hamburg) 
Filter tipps (1000 µl, 100 µl, 10 µl) (Greiner bio-one GmbH, Frickenhausen) 
Reactionstubes (2.0 ml, 1.5 ml, 0.5 ml ) (Greiner bio-one GmbH, Frickenhausen) 
LightCycler® capillares (Roche Diagnostic, Mannheim) 
 
3.2 Animal experiment procedure 
3.2.1 M. suis strain 
The highly virulent M. suis strain KI_3806, which invades porcine RBCs, was used in our study 
(Groebel et al., 2009; Oehlerking et al., 2011). The strain was maintained in splenectomized 
pigs by subsequent experimental infection as described elsewhere (Hoelzle et al., 2009). M. 
suis was quantified by LightCycler msg1 PCR (Hoelzle et al., 2007a), and blood was stored at 
-70°C until further use. 
3.2.2 Animals, experimental design and sampling 
Three 28-days old piglets were used in this study. All animal experiments were performed in 
accordance with the German animal welfare law using a protocol officially approved by the 
Government Office of the Upper Bavaria, Munich, Germany (Az. 55.2.1.54-2532-87-12). Pigs 
were kept under hygienically optimal conditions in the Clinic for Swine, Ludwig-Maximilians-
University Munich, Germany. The health status of the piglets was determined by clinical ex-
amination and the M. suis negative status was confirmed by M. suis-specific quantitative LC 
msg1 PCR and ELISA (Hoelzle et al., 2007a; Hoelzle et al., 2007b). Seven days after housing, 
pigs were splenectomized and 7 days after splenectomy the three pigs were infected subcu-
taneously with 1 x 108 M. suis KI_3806 cells in 2 ml blood. Clinical monitoring was performed 
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using a scoring system as described in Table 1 (Hoelzle et al., 2008; Stadler et al., 2014) 
including the evaluation of skin and ear alterations, body temperature, mucosa, feed intake 
and behavior. EDTA-anti-coagulated blood was taken 2 days before infection, and on days 2, 
4, and 8 post infection (p.i.). 
 
Table 1 Score System 
Organ/parameter Alteration Score 
Ears no alterations 0 
 mild cyanosis 1 
 moderate cyanosis 2 
skin no alterations 0 
 mild pallor 1 
 moderate pallor/urticaria/petechiae 2 
mucosa no alterations 0 
 pale 1 
 icteric 2 
body temperature < 40°C 0 
 40-42°C 1 
 > 40°C 2 
behaviour no alterations 0 
 reduced 1 
 apathy 2 
feed intake no alterations 0 
 reduced 1 
 anorectic 2 
 
3.2.3 Splenectomy 
After one week of adaption all 3 pigs were splenectomized. Splenectomy was done after 
method of Heinritzi (1984) at the LMU-Munic in Oberschleißheim. Anesthesia was anesthe-
tized with Azaperon (Stresnil®, 2mg/kg body weight, Janssen-Cilag GmbH, Neuss) and Keta-
min (Urostamin®, 10-25mg/ kg body weight, Serumwerk-Bernburg AG) i.v. For anesthesia 
maintenance Isofluran (Isoba®, MAC ca. 1,5 Vol %, MSD Tiergesundheit, Unterschleißheim) 
was used. For reducing the conservative and post-conservative pain animals were applied 
Meloxicam i.m. (Metacam® 5 %, 0.4 mg/kg body weight equates 2 ml/100 kg body weight, 
Boehringer Ingelheim) and Metamizol i.m. (Vetalgin®, 15-20 mg/kg body weight equates 0.3-1 
ml/10 kg body weight, MSD Tiergesundheit, Unterschleißheim). Pigs received Metamizol until 
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the third day after splenectomy. In addition an antibiosis was given for prevention of an infected 
wound: Penicillin i.m. (Vetri-Proc® 30 % CEVA Tiergesundheit GmbH, Düsseldorf 1 ml/10 kg 
body weight). 
3.2.4 Detection of M suis via RT-PCR 
200 µl of EDTA-blood from evey pig was used for RT-PCR M. suis positive detection. 200 µl 
of lysis buffer (10 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 320 mM Saccharose, 1 % Triton X-100) 
was added to 200 µl EDTA-blood and then centrifuged at 8000 x rpm for 1 minute. After de-
canting the supernatant pellet was reabsorbed two times in 400 µl lysisbuffer, then centrifuged 
one more time (8000 x rpm, 1 min) and at the end the supernatant was discarded. Whole-DNA 
extraction was then prepared after manufactures protocol with the GenElute™ Bacterial Ge-
nomic DNA Kit. Detection and quantification was performed by LightCycler 2.0 Systems 
(Roche Diagnostics, Mannheim) and the established protocol of Hoelzle et al. (2007c). 
For qRT-PCR LightCycler™ FastStart DNA MasterPLUS Hybridization Kit was used. Temperatur 
program was as follow: 1. initial denaturation and hot-start enzyme activation: 1 cycle/95 °C/15 
min., 2. Denaturation: 40 cycles/95 °C/5 s, 3: Annealing-cyclus: 60 °C/20 s, 4. Elongation: 72 
°C/10 s (Hoelzle et al., 2007c). Used primer and probes are listed in Table 2. 
 
Table 2: Sequences of M. suis primer and probes 
Primer/ Probe Oligonucleotide-sequence (5´-3´) msg11 position (nt) 
Msg1-F ACAACTAATGCACTAGCTCCTATC 478-501 
Msg1-R GCTCCTGTAGTTGTAGGAATAATTGA 631-656 
probe msg1-1 TTCACGCTTTCACTTCTGACCAAAGAC-
fluorescin 
554-580 
probe msg1-2 LCRed-640-CAAGACTCTCCTCACTCT-
GACCTAAGAAGAGC-phosphat 
583-614 
1Gene Bank accession no. CAL51267 (17). 
 
3.2.5 RNA preparation 
M. suis RNA was isolated from 200 µl whole blood by using 750 µl TRI Reagent® BD and 20 
µl 5 N acetic acid to protect and stabilize the RNA. Then, samples were stored at -70°C until 
further processing. After thawing, 200 µl chloroform was added and the mixture was separated 
by centrifugation (12.000 x g, 15 min, 4°C). The upper aqueous phase containing the RNA was 
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subjected to RNA isolation by using the Qiagen RNeasy mini Kit including DNase treatment 
according to the manufacturer´s protocol. RNA quality was measured on an Agilent 2100 Bio-
analyzer using the RNA 6000 Nano Kit. Only total RNA with RNA integrity number (RIN) ≥ 8.0 
was used for RNA sequencing and microarray analyses. Exclusion of signals from rRNA and 
high-quality RNA preparation are critical steps of RNA-Seq technology. The high abundance 
of rRNA can reduce the coverage of mapped results and decreases the sequencing depth 
(Wang et al., 2013). Thus, an rRNA removal step was included to deplete both, porcine and 
bacterial rRNA. For this, RiboZero kits with mixed rRNA removal solution from the bacterial 
and eukaryotic depletion kit were used according to the manufacturer`s recommendations (Ep-
icentre, Illumina Company).  
3.2.6 Agarose-gel electrophoresis 
To check the quality of the isolated RNA an agarose gel electrophoresis was performed. There-
fore a TBE-buffer was used. For preparing a 1% agarose gel, 1 g Biozym LE Agarose in 100 
ml 1x TBE-Puffer was dissolved in a microwave. After cooling down the agarose of approx. 60 
°C, 3 µl of ethidium bromide was added. The melted agarose solution was poured into a cast. 
A comb was placed in the cast to create wells for loading samples, and the gel was completely 
set before use. After that 5 µl of RNA sample and 5 µl of a 1 kb standard were mixed with 2 µl 
Loading-Dye and were loaded into the gel. Electrophoresis ran at a voltage of 50 V for approx. 
90 min in 1x TBE-Puffer. DNA bands were visualized by staining with the ethidium bromide, 
which intercalates into the major grooves of the DNA and fluoresces under UV light. 
3.2.7 Agilent 2100 Bioanalyzer 
The Agilent Bioanalyzer uses a micro-capillary based electrophoretic cell that allows rapid and 
sensitive investigation of nucleic acid samples like RNA. Microfabricated chips (Figure 9) were 
used for electrophoretic separation of RNA samples. The samples were then detected via laser 
induced fluorescence detection. The bioanalyzer software produces an electropherogram and 
gel-like images and shows results like sample concentration and the ribosomal ratio. The elec-
tropherogram offers a detailed visual valuation of the quality of an RNA sample. The software 
provides information about the ratio of the 18S to 28S ribosomal subunits and calculates the 
RNA Integrity Number (RIN). A RIN of 1 means that the RNA is highly degraded, whereas a 
RIN of 10 shows an intact RNA (Mueller et al., 2004). 
Before running the bioanalyzer all chemicals were placed at room temperature for 30 minutes. 
For gel preparation 50 µl of RNA 6000 NanoGelMatrix (red) were pipetted on a column and 
then centrifuged at 1500 x g for 10 min. After that 65 µl filtered gel were separated on seven 
0.5 ml reaction tubes, respectively. Then RNA 6000 NanoDyeConcentrate (blue) was vortexed 
for 15 s and centrifuged. 1 µl of the RNA 6000 NanoDyeConcentrate was then pipetted into 
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the 65 µl aliquot filtered gel, following vortexing and then centrifuging at 13000 x g for 10 min. 
(geldye-mix). 
350µl of RnaseZap and 350 µl of nuclease-free water was pipetted into a cleaner-electrode for 
decontamination. Therefore first the RnaseZap electrode were put into the bioanalyzer for 1 
min and then the nuclease-free water electrode were put into the instrument for 10 seconds.  
Samples and ladder were denatured at 70 °C for 2 min. 9 µl of the gel dye-mixes were then 
pipetted onto the field “G” of a new chip with the help of a Chip-Priming-Station for better 
allocating on the rest of the chip. Procedure was repeated with 9 µl on the other fields “G”. 
Then 5 µl RNA NanoMarker (green) was pipetted on all other fields. Each 1 µl of ladder and 
samples were loaded on fields 1-12. After loading the chip, chip was centrifuged for 1 min at 
2000 rpm, vortexed and at the end put into the bioanalyzer for measuring. 
 
Figure 9: RNA Nano Chip 
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3.3 RNA-Seq and transcriptome analysis 
Single read sequencing was performed by Illumina´s sequencing by synthesis approach 
(TruSeq®Stranded Total RNA Sample Preparation Kit with Ribo-Zero TM). Barcoded libraries 
were sequenced on a HiSeq 2000 Genome Analyzer (Illumina, San Diego, California, USA) in 
a single read multiplex run. Mapping of reads to reference sequences (M. suis KI_3806, Sus 
scrofa) was performed using STAR (version 2.3.0e, http://code.google.com/p/rna-star/). Mean 
mapped length represents 98.6%. Raw read counts were created using HTSeq (http://www-
huber.embl.de/users/anders/HTSeq/ doc/overview.html). Only reads with unique mapping po-
sitions were considered for read counting. Paired-end reads that were mapped to the same 
reference with about the expected insert size were counted as one read. Paired-end reads 
(mapped to different references or with an unexpected insert size) were counted as two reads. 
If only one read of a pair was mapped, it was counted as one read. Single-end reads were 
used straightforwardly. Only reads overlapping exon-features were counted. All reads mapping 
to features with the same identifier were summed. Reads mapping to multiple features with 
different identifier were ignored for read counting. A Trimmed Mean of M-values (TMM) nor-
malization was performed using the edgeR package (Robinson and Oshlack, 2010; Robinson 
et al., 2010; http://bioconductor.org/packages/release/bioc/html/edgeR.html). For this calcula-
tion, the most expressed features and the features with the largest log ratios are excluded. 
Differential expression analysis was performed using the edgeR package (Robinson and 
Oshlack, 2010, Robinson et al., 2010; http://bioconductor.org/packages/release/bioc/html/ 
edgeR.html). Finally, differential expression was assessed for each gene using an exact test 
analogous to Fisher's exact test, but adapted for over dispersed data (excerpt from Robinson 
et al., 2010). Prior to differential expression analysis, features with very low expression values 
were removed, as weakly expressed features are in general noninformative. 
3.3.1 Analysis of gene expression level 
To compare the expression levels of different genes, reads per kilobase per million reads 
(RPKM values) were calculated (Mortazavi et al., 2008). Furthermore, we simply defined genes 
with P-value less than 0.05 as differential expressed genes (DEGs). 
3.3.2 Functional analyses of expressed genes and proteins 
Functional classification of Clusters of Orthologous groups of proteins (COG) was assigned to 
all identified M. suis proteins (Acc. No. FQ790233) using RPSBLAST. Using the bioinformatics 
pipelines Prophane a maximal e-value of 10-5 was defined (www.prophane.de). Proteins which 
could not be related by RPSBLAST to COG classifications, were manual assigned using 
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HMMER3 functional predictions based on Hidden Markov Model profiles provided by TIGR-
FAMs and PFAMs (listed in Supplementary Table 1). Highly expressed M. suis genes and DE 
genes both encoding hypothetical proteins were further characterized by integrating a variety 
of protein classiﬁcation systems, motif discovery tools as well as methods that are based on 
characteristic features obtained from the protein sequence and metabolic pathways. The phys-
iochemical properties such as isoelectric point, molecular weight, instability index, extinction 
coefﬁcient, grand average of hydropathicity (GRAVY) and aliphatic index were predicted by 
using ProtParam server (http://web.expasy.org/ protparam/). Sub-cellular localization predic-
tion was performed using the PSORTb tool (Yu et al., 2010). The SignalP 4.1 (Emanuelsson 
et al., 2007), SMART (Letunic et al., 2015), and SecretomeP (Bendtsen et al., 2005) servers 
were used to identify signal peptides in HPs and their involvement in non-classical secretory 
pathways respectively. Furthermore, TMHMM (Krogh  et al., 2001), SMART (Letunic et al., 
2015), and HMMTOP (Tusnady and Simon, 2001) servers were used to identify the trans-
membrane helices in hypothetical proteins. To get insights into putative functions and to iden-
tify functional homologues similarity searches in diverse biological databases were performed 
including BLAST (Altschul et al., 1990), FASTA (Pearson and Lipman, 1988), and HMMER 
(Finn et al., 2011). In the BLAST searches, the HPs showing identities > 20% and query cov-
erage > 50% were considered as hit, FASTA search results showing e-value < 0.005 were also 
considered as a reliable hit. Low sequence identities (<20%) as well as low query coverage 
(<50%) were excluded. A sequence similarity search based on domain architecture and 
proﬁles was performed using the SMART server (Letunic et al., 2015). Additional prediction of 
functional domains present in HPs was performed using various online databases such as 
NCBI (Marchler-Bauer et al. 2017), Pfam (Finn et al., 2013), and ProtoNet (Sasson et al., 
2006). Furthermore, the InterPro (Robert et al., 2017) resource was used for functional analy-
sis of protein sequences by classifying them into families and predicting the presence of do-
mains and important sites. The STRING database (Szklarczyk et al., 2017) of known and pre-
dicted protein-protein interactions (i.e. co-expression, indirect (functional) and direct (physical) 
associations) was used to predict functional partners of HPs in a biological network and to 
perform a functional enrichment (KEGG pathways). In addition, gene ontology analysis were 
performed along the three aspects: molecular function, cellular components, and biological 
processes (Ashburner et al., 2000) (listed in Supplementary Table 2). 
3.3.3 Quantitative real-time RT-PCR (qRT-PCR) validation 
Oligonucleotides for the selected genes were designed with Primer-BLAST (Ye et al., 2012) 
using the reference sequence of M. suis (Accession: FQ790233.1, Table 3) and approved by 
PCR on genomic DNA isolated following the instructions of Hoelzle et al., 2007 (LC MSG1 
PCR) (data not shown). In addition, DNase-treated total RNA samples were used for PCR to 
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verify DNA absence (data not shown). Then, cDNA was synthesized by reverse transcription 
with DNAse I treated RNA samples using Transcriptor First Strand cDNA Synthesis Kit (Roche, 
Mannheim, Germany) according to the manufacture´s protocol. Selected genes were exam-
ined by Real-time quantitative reverse transcription PCR (qRT-PCR) using Fast SYBR® Green 
Master Mix (Life Technologies, Darmstadt, Germany) and the StepOne Real Time PCR system 
(Applied Biosystems) performing a relative qRT-PCR. The mixed solution of qRT-PCR reaction 
(20 µl) contained 10 µl Fast SYBR® Green Master Mix, 0.2 µl forward and reverse Primer, 7.6 
µl nuclease-free water and 2 µl cDNA. PCR condition were 20 s at 95°C, followed by 40 cycles 
of denaturation at 95°C for 3 s and annealing at 60°C for 30 s. Each sample and water control 
was run in replicates. CT (Cycle threshold) values of each gene were normalized using Eubac-
teria gene sequence as endogenous control (StepOneTM Software v2.2.2.; Life technologies, 
Darmstadt, Germany). ΔCT, used as CT value of a sample was normalized with respect to the 
endogenous control, and average CT, were calculated by the instruments software. 
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Table 3: Primer pairs used in (q)RT-PCR reactions 
Gene Oligonucleotides Expected size 
MSUIS_00350 5‘ -  ATG GGA TTG TTG CAG GAT CAG T - 3‘        241 bp 
 5‘ - TGT GAT TGA TCG GTC TGT TCT G - 3‘   
MSUIS_01630 5’ - CCT GTA GCA TTA GTT TTT ACC GGC - 3‘         250 bp 
 5’ - ATT GTT GTG ATT CTT CCT CCC CTC - 3’          
MSUIS_02110 5’ - GAA CAA GGC ACA CAG GGG AT - 3’        284 bp 
 5’ - ACA TCT CCG AAA AGG AGA TTG TA - 3’        
MSUIS_05010 5’ - ATC CAG CGT CTT TGA AGC TTT TT - 3‘ 88 bp 
 5‘ - ACT TGG CTC CTC TAG TGT CT - 3‘       
MSUIS_05540 5’ - TAT CTC CAT CAT TCT CCT TCA TCG T - 3’       167 bp 
 5’ - CTA TGA GTT TTG TTG GCT GGC TC - 3’        
MSUIS_06910 5’ - ACA ACA GCA GCA CTT TAC ACT TC  - 3’       227 bp 
 5’ - GAG GCG GCG GAG GAT ATC TAA C - 3’       
MSUIS_04810 5’ - GCT CTC TTC CAA GCG CCA TAG -  3’        263 kb 
 5’ - AAGAAA TAC TGA GGA GAG GGA TGC - 3’         
MSUIS_06300 5’ - AGA TCA GTA AGT TAG GCA TTC TTC T - 3’         252 bp 
 5’ - ACT TTA AAG GTT GCT GCT CTT GC - 3’          
MSUIS_00470 5’ -  ATC TTG TGA TTT ATC TTC TTC CCC C - 3’         226 bp 
 5’ - TGG TGG AGG ATT TGC TGT CTA T - 3’        
MSUIS_07030 5’ - ATG ACA CTT AAG AAA ATG  - 3’ 117 bp 
 5’ - TTA GGA CCT TTC TTC ACT - 3’  
msg1 5´- ACA ACT AAT GCA CTA GCT CCT ATC - 3´  
 5´- GCT CCT GTA GTT GTA GGA ATA ATT GA-3  
hspA1 5´ - ATT CCA GCT TGA ACA GAA GCT C - 3´ 289 bp 
 5´ - TCC TTT CAA TGG TTC GTG GAG A - 3´  
eno 5´ - AGT ACA GTA AAG GTC GTC ACC A - 3´ 263 bp 
 5´ - TAG ACT GTG CAG CTA GTG AGC - 3´  
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3.4 Microarray hybridizations and data analysis 
RNA labeling, hybridizations and scanning were conducted by a commercial Affymetrix array 
service (University Hospital Tuebingen, Germany, Microarray Gene Chip Facility). Double-
stranded cDNA was synthesized from 100 ng of total RNA using the WT Expression Kit (Am-
bion, Kaufungen, Germany) according to the manufacturer’s instructions. 15 µg of labeled and 
fragmented cDNA was hybridized to PorGene-1_0-st Array, 6 pk chip (Affymetrix, Regensburg, 
Germany). The microarrays were washed and stained with fluorescent molecule SAPE that 
binds to biotin in combination of biotinylated anti streptavidin antibody on GeneChip Fluidics 
Station 450 (Affymetrix). Subsequently the arrays were scanned with GeneChip Scanner 3000 
7G (Affymetrix) to generate fluorescence intensity image for data analysis. Scanned images 
were subjected to visual inspection to control for hybridization artefacts and proper grid align-
ment and analyzed with AGCC 3.0 (Affymetrix) to generate CEL files. The software grids the 
array image to specify the region and location of each probe and calculates a single intensity 
for each probe based on the 75th percentile of remaining pixel intensities after excluding the 
border pixels. The resulting files, containing a single intensity value for each probe region de-
lineated by a grid on each array image, were imported into Partek Genomics Suite (version 
6.6, Partek, St. Louis, MO, USA) for probe set summarization and statistical analysis. Model 
based Robust Multichip Analysis was performed as the method for probe set summarization 
to obtain a single intensity value representing transcript abundance for each probe set and 
thus enable comparisons between arrays, by normalizing and logarithmically transforming ar-
ray data and stabilizing variance across the arrays. 
3.4.1 Statistical analysis 
For the microarray analyses ANOVA was used to calculate a P value from evaluating statistical 
significance of the difference observed in mean transcript abundance for each probe set be-
tween day 2 and day 8. P < 0.05 indicates statistically significant differential expression. The 
probe sets exhibited significant, greater than 1.5-fold difference in mean transcript abundance 
between described two conditions. Additionally, all P values were corrected for multiple testing 
with the 5%-FDR-based method of Benjamini and Hochberg (1995). Following statistical anal-
ysis, we used Ingenuity Pathways Analysis (IPA, Ingenuity Systems, http://www.ingenu-
ity.com) and available gene ontology for functional annotation of DE genes among clusters. 
The purpose herein was to identify candidate biological or biochemical processes that play a 
key role in pigs infected blood. IPA functional analysis recognized genes linked to biological 
functions and/or diseases that were most significant to the data set. DE genes associated with 
biological functions and/or diseases in Ingenuity's Knowledge Base were considered for the 
analysis. IPA uses prediction calculations based on the direction, the amount of DE genes and 
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what is known in the literature. A z-score is determined for each DE gene; z-scores ≤−2 are 
considered to have lower function, while z-scores ≥2 are considered to have greater function. 
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4 Results 
4.1 M. suis infection  
Based on previous studies reporting the course of an acute M. suis infection in splenectomized 
pigs  experimentally infected pigs in our study were monitored daily for clinical signs (daily; 
fever, behavior, skin alterations) according to an established clinical scoring system (Hoelzle 
et al., 2008; Stadler et al., 2015). In addition, blood parameters (blood glucose, hematocrit, 
hemoglobin values and RBC counts), and M. suis blood loads were deterimined on days -2, 2, 
4, 6, and 8 post infection. Three biological replicates (piglets) were included in the study. In 
line with expectations, the experimental M. suis infection of the splenectomized piglets resulted 
in lesions that resemble acute IAP with moderate to severe clinical signs (i.e. high fever, 
lethargy, remarkably reduced feed intake, skin pale, and ear cyanosis) from day 4 to 8 p.i. 
(Figure 10). In all pigs, the clinical outcome was accompanied by a massive hypoglycemia with 
mean blood glucose values of 0.43 mmol/l. Hematological examinations revealed signs of a 
massive anemia with strongly decreased RBC counts as well as hemoglobin and hematocrit 
values far below the reference ranges. All inoculated pigs became M. suis positive at latest on 
day 4 p.i. with mean bacterial blood loads of 7.4 x 105 M. suis cells/ml blood at day 4 p.i., and 
mean M. suis blood loads of 4.2 x 109 M. suis cells/ ml blood at day 8 p.i. (Figure 10). 
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Figure 10: Score: Clinical scoring system between animals over infection course. RBC: mean 
red blood cell (RBC) count against time. Glucose: mean blood glucose values on all animals 
showing decreased values from day 4 p.i. on. Load: Mean M. suis blood loads of all M. suis 
positive animals within 8 days p.i.. Blood loads are presented as log DNA copy number per ml 
blood as determined by quantitative LightCycler PCR. 
 
4.2 RNA- Seq-results 
4.2.1 RNA-Seq analysis during acute infection 
Transcriptome analysis of the uncultivable M. suis has become possible since complete 
genome sequences of M. suis were published in 2011 (GenBank: FQ790233 + Illinois; 
Oehlerking et al., 2011; Guimaraes et al., 2011). In the present study we used the highly 
virulent and RBC invasive strain KI_3806 which has a 709 kilobase circular genome carrying 
844 CDS of which 795 are protein encoding. From the blood of the M. suis-infected pigs we 
constructed RNA-Seq libraries at day 4 and 8 p.i. in order to analyse the transcriptional map 
of M. suis and additonally perform analysis of differentially expressed genes during the course 
of acute infection. For each time point the constructed RNA-Seq libraries from the three 
biological replicates were sequenced on an Illumina® HiSeq 2000 sequencing apparatus. After 
removing eukaryotic and prokaryotic rRNA as well as low quality reads, RNA sequencing gen-
erated mean values per library of 3.28 million raw reads (all reads that went into the mapping) 
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on day 4 p.i. and 20.29 million raw reads on day 8 post infection. The filtered RNA-Seq reads 
were aligned to the published genome of M.suis KI_3806 (FQ790233; Oehlerking et al., 2011). 
On day 4 p.i., the alignment to the M. suis reference genome yielded mean values per library 
of 44569 mapped reads. Therefore, a mean value of 44445 reads was mapped to unique lo-
cations in the M. suis genome, and 124 reads mapped to multiple locations in the genome 
(reads were ignored for read counting). A total of 3.24 million reads not mapped to any M. suis 
genome location on day 4 post infection. On day 8 p.i., the alignment to the M. suis reference 
genome yielded mean values per library of 18.60 million mapped reads. Thereof, 18.55 million 
reads mapped to unique locations in the genome, and 42314 reads mapped to multiple loca-
tions in the genome. On day 8 p.i. we found 819976 reads not mapping to any M. suis genome 
location. In addition, reads were also aligned to the published pig genome data (Sscrofa10.2). 
On day 4 p.i., a mean value of 10.65 million reads could be mapped to unique locations in the 
pig genome, 7.76 million reads mapped to multiple locations in the genome (reads were ig-
nored for read counting), and 3.28 million reads not mapped to any genome location. On day 
8 p.i., alignment of the filtered RNA-Seq reads yielded mean values per library of 969628 reads 
mapping to unique locations in the pig genome, 755189 reads mapping to multiple locations in 
the genome, and 19.42 million reads not mapping to any genome location (mean values of day 
4 and 8 p.i. are shown in Figure.11). 
 
 
Figure 11: Mean value of mapped reads on day 4 p.i. and day 8 p.i. 
  
Day 4 p.i. Day 8 p.i.
M.suis pig
44600
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18.61 Mio
0.96 Mio
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4.2.2 Quantitative and functional analyses of M. suis transcripts expressed during acute 
infection 
RPKM (reads per kilo base per million reads) values were calculated to sort the identified gene 
transcripts according to their relative abundances, and thus, expression levels. According to 
our defined criteria (log2(RPKM) ≥ 1), transcript analysis of M. suis mapped reads on day 4 p.i. 
resulted in the identification of 676 (84.61%) out of the 799 predicted encoded proteins. The 
not-identified CDS (n=123) mainly included hypothetical proteins (n=119) with unknown func-
tion, a ruvB DNA helicase which is critical to bacterial DNA repair, the replication initiator pro-
tein DnaA and the restriction endonucleases hsdS and hsdR. On day 8 p.i. during high bacte-
remia and acute phase of infection we identified 799 (100%) of the predicted protein se-
quences, one ssu rRNA, and one lsu rRNA. Full lists of the transcribed genes in M. suis on 
day 4 and 8 after experimental infection in the three pigs are presented as supplementary data 
(Supplementary Table 1). Table 4 shows the top 30 CDS and their respective normalized tran-
scription level based on the RPKM values on day 4 and 8 post infection. 
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Table 4: Ranking of the most abundant coding transcripts on day 4 and 8 post infection 
Name Length RPKM COG 
day 4 p.i. 
MSUIS_07810, hypothetical protein 345 208.13 Unknown function 
MSUIS_04270, hypothetical protein 264 197.03 Unknown function 
MSUIS_07760, hypothetical protein 216 146.63 Unknown function 
MSUIS_07870, hypothetical protein 324 139.66 Unknown function 
MSUIS_06750, hypothetical protein 834 144.42 Unknown function 
MSUIS_06590, hypothetical protein 624 119.21 Unknown function 
MSUIS_01630, hypothetical protein 777 113.01 Unknown function 
MSUIS_00090, hypothetical protein 192 110.61 Unknown function 
MSUIS_05230, hypothetical protein 501 74.52 Unknown function 
MSUIS_07510, hypothetical protein 1089 72.29 Unknown function 
rpoA, DNA-directed RNA polymerase subunit alpha 
(RNAP subunit alpha) 1014 107.23 Transcription 
rnr, Ribonuclease R truncated 534 81.82 Transcription 
rpoBC, DNA-directed RNA polymerase subunit beta 
and beta' 7932 89.83 Transcription 
guaB, Inosine-5'-monophosphate dehydrogenase 
(IMPDH/GuaB) 1092 91.27 Purine matabolism 
upp, Uracil phosphoribosyltransferase 630 80.95 Purine matabolism 
rplL, 50S ribosomal protein L7/L12 393 189.28 Protein synthesis 
rpmG, Ribosomal protein L33 165 153.36 Protein synthesis 
rpmE, 50S ribosomal protein L31 228 123.02 Protein synthesis 
rpsK, 30S ribosomal protein S11 390 68.79 Protein synthesis 
dnaK, Chaperone protein DnaK (Heat shock protein 
70) (HspA1) 1830 83.14 
Protein folding and stabi-
lization, Translation 
pfkA, 6-phosphofructokinase 984 116.68 Energy metabolism 
pykF, Pyruvate kinase 1611 114.34 Energy metabolism 
gapA, glyceraldehyde-3-P dehydrogenase 
(gapd/msg1) 1011 100.87 Energy metabolism 
eno, 2-phospho-D-glycerate hydrolyase (enolase) 1623 96.31 Energy metabolism 
ldh, L-lactate dehydrogenase 972 80.55 Energy metabolism 
tpiA, Triosephosphate isomerase 711 84.50 Energy metabolism 
gpmI, 23-bisphosphoglycerate-independent phospho-
glycerate mutase  1359 71.93 Energy metabolism 
himA, Histone-like DNA-binding superfamily protein 
HimA/HU/Integration host factor (himA/hup_2) 279 263.98 
DNA replication, recom-
bination, and repair 
himA, Histone-like DNA-binding superfamily protein 
HimA/HU/Integration host factor (himA/hup_1) 309 295.72 
DNA replication, recom-
bination, and repair 
crr, Phosphotransferase system protein sugar-specific 
permease EIIA 1 domain 600 71.82 
carbohydrate transport 
and metabolism 
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Name Length RPKM COG 
day 8 p.i. 
MSUIS_07810, hypothetical protein 345 15678.69 Unknown function 
MSUIS_04270, hypothetical protein 264 12407.37 Unknown function 
MSUIS_07760, hypothetical protein 216 11053.15 Unknown function 
MSUIS_07510, hypothetical protein 1089 4859.05 Unknown function 
MSUIS_06750, hypothetical protein 834 10576.89 Unknown function 
MSUIS_06590, hypothetical protein 624 7593.21 Unknown function 
MSUIS_07870, hypothetical protein 324 10936.74 Unknown function 
MSUIS_00090, hypothetical protein 192 7740.24 Unknown function 
MSUIS_05230, hypothetical protein 501 5583.17 Unknown function 
MSUIS_05710, hypothetical protein 282 4985.66 Unknown function 
MSUIS_04270, hypothetical protein 264 12407.37 Unknown function 
MSUIS_07760, hypothetical protein 216 11053.15 Unknown function 
MSUIS_07510, hypothetical protein 1089 4859.05 Unknown function 
dnaK, Chaperone protein DnaK (Heat shock protein 
70) (HspA1) 1830 5820.24 Translation 
rpoA, DNA-directed RNA polymerase subunit alpha 
(RNAP subunit alpha) 1014 7876.12 Transcription 
rpoBC, DNA-directed RNA polymerase subunit beta 
and beta' 7932 6018.90 Transcription 
rnr, Ribonuclease R truncated 534 5766.62 Transcription 
guaB, Inosine-5'-monophosphate dehydrogenase 
(IMPDH/GuaB) 1092 6418.16 Purine matabolism 
upp, Uracil phosphoribosyltransferase 630 6424.28 Purine matabolism 
rpmG, Ribosomal protein L33 165 12724.84 Protein synthesis 
rpmE, 50S ribosomal protein L31 228 8655.53 Protein synthesis 
rplL, 50S ribosomal protein L7/L12 393 14797.98 Protein synthesis 
rpsK, 30S ribosomal protein S11 390 5105.87 Protein synthesis 
rpsJ, 30S ribosomal protein S10 312 5549.70 Protein synthesis 
pfkA, 6-phosphofructokinase 984 8063.96 Energy metabolism 
pykF, Pyruvate kinase 1611 8372.95 Energy metabolism 
gapA, glyceraldehyde-3-P dehydrogenase 
(gapd/msg1) 1011 7310.77 Energy metabolism 
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Name Length RPKM COG 
day 8 p.i. 
eno, 2-phospho-D-glycerate hydrolyase (enolase) 1623 7082.04 Energy metabolism 
ldh, L-lactate dehydrogenase 972 5620.08 Energy metabolism 
tpiA, Triosephosphate isomerase 711 6411.51 Energy metabolism 
gpmI, 23-bisphosphoglycerate-independent phospho-
glycerate mutase  1359 4870.13 Energy metabolism 
himA, Histone-like DNA-binding superfamily protein 
HimA/HU/Integration host factor (himA/hup_1) 309 22282.87 
DNA replication, recom-
bination, and repair 
himA, Histone-like DNA-binding superfamily protein 
HimA/HU/Integration host factor (himA/hup_2) 279 18726.59 
DNA replication, recom-
bination, and repair 
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The expressed CDS were assigned to their respective clusters of orthologous groups (COG; 
Figure 12). On day 4 p.i., the most abundant CDS could be categorized to 8 COGs. On day 8 
p.i. the top 50 CDS were assigned 11 COGs. Interestingly, the group of proteins with “unknown 
function” (hypothetical proteins) represented the largest group at both time points (day 4 and 
8 p.i.) investigated (39.4% and 29.4%, respectively), followed by the groups “carbohydrate 
transport and metabolism”, “transcription”, “translation”, “nucleotide transport and metabolism”, 
and “inorganic ion transport and metabolism”.  
 
 
Figure 12: Expressed CDS were assigned to their respective clusters of orthologous groups 
 
A total of 71 genes met the criteria for differential expression (DE) analysis (P ≤ 0.05; see 
Materials and Methods). Up-regulation of 51 and down-regulation of 20 protein coding genes 
were identified between day 4 and day 8 post infection. The complete list of the DE genes is 
provided in Table 5.
51 
 
 
Table 5: COG categories enriched of differentially expressed genes between day 4 p.i. and day 8 p.i 
Feature Description alogFC bPValue cFDR dProteome epsortB eTMHMM 
Unknown function   
MSUIS_01440 MSUIS_01440, hypothetical protein -1.13739717 0.04679467 1 no Unknown 1 
MSUIS_00340 MSUIS_00340, hypothetical protein -0.90778492 0.04321537 1 yes Cytoplasmic 1 
MSUIS_01520 MSUIS_01520, hypothetical protein 2.03064669 0.03374085 1 no Unknown 0 
MSUIS_05580 MSUIS_05580, hypothetical protein 10.9435118 0.02631552 1 no Unknown 1 
MSUIS_02190 MSUIS_02190, hypothetical protein 11.2059346 0.01761361 0.8169579 no Unknown 0 
MSUIS_05540 MSUIS_05540, hypothetical protein 11.2253897 0.01761361 0.8169579 no Unknown 1 
MSUIS_01150 MSUIS_01150, hypothetical protein 11.3143793 0.01677262 0.8169579 no Unknown  0 
MSUIS_00820 MSUIS_00820, hypothetical protein -1.06833116 0.01452235 0.8169579 yes Unknown  1 
MSUIS_01700 MSUIS_01700, hypothetical protein -1.20755971 0.01082338 0.72155883 no Cytoplasmic 0 
MSUIS_05680 MSUIS_05680, hypothetical protein 10.495931 0.04820044 0.71408061 no Unknown 1 
MSUIS_01130 MSUIS_01130, hypothetical protein -0.78665287 0.04367018 0.67184895 yes Unknown 0 
MSUIS_00290 MSUIS_00290, hypothetical protein 0.79172063 0.04016561 0.63004879 yes Unknown  1 
MSUIS_04820 MSUIS_04820, hypothetical protein 10.8208599 0.03788529 0.60616464 no Unknown 0 
MSUIS_06370 MSUIS_06370, hypothetical protein 1.20655458 0.03782948 0.60616464 yes Unknown  0 
MSUIS_04270 MSUIS_04270, hypothetical protein -0.56003787 0.0351857 0.59890548 no Unknown 0 
MSUIS_02610 MSUIS_02610, hypothetical protein 1.17305707 0.03313686 0.58577502 no Cytopl.Membrane 5 
MSUIS_07810 MSUIS_07810, hypothetical protein -0.55777062 0.02857873 0.53169734 no Unknown 1 
MSUIS_02110 MSUIS_02110, hypothetical protein 11.5292089 0.00727427 0.5290375 yes Unknown  1 
MSUIS_05840 MSUIS_05840, hypothetical protein 11.5998545 0.00713001 0.5290375 no Unknown  0 
MSUIS_01270 MSUIS_01270, hypothetical protein 10.8711277 0.02711363 0.51645014 no Unknown 1 
MSUIS_06980 MSUIS_06980, hypothetical protein 11.0094031 0.02441473 0.500815 no Unknown  1 
MSUIS_01300 MSUIS_01300, hypothetical protein -1.38752363 0.02387266 0.500815 no Cytoplasmic 0 
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MSUIS_06340 MSUIS_06340, hypothetical protein rapamycin associated -1.39931173 0.02131615 0.47369214 yes Unknown 1 
MSUIS_03800 MSUIS_03800, hypothetical protein 1.49370212 0.02129756 0.47369214 no Unknown 0 
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Feature Description alogFC bPValue cFDR dProteome epsortB eTMHMM 
Unknown function 
MSUIS_02870 MSUIS_02870, hypothetical protein 10.9404508 0.0193005 0.45412938 no Unknown 1 
MSUIS_05260 MSUIS_05260, hypothetical protein 10.9315953 0.0193005 0.45412938 no Cytoplasmic 0 
MSUIS_01180 MSUIS_01180, hypothetical protein 2.76926979 0.01779951 0.44498777 yes Unknown 0 
MSUIS_06300 MSUIS_06300, hypothetical protein -1.72506779 0.00460821 0.4096185 yes Unknown 1 
MSUIS_05010 MSUIS_05010, hypothetical protein 11.6795968 0.00427525 0.4096185 no Cytopl.Membrane 1 
MSUIS_01570 MSUIS_01570, hypothetical protein 11.3005668 0.01465389 0.40424525 no Unknown 1 
MSUIS_05800 MSUIS_05800, hypothetical protein contains pleckstrin  1.21024887 0.01095793 0.33716714 no OuterMembrane  0 
MSUIS_01690 MSUIS_01690, hypothetical protein 11.314258 0.01076465 0.33716714 no Cytopl.Membrane 0 
MSUIS_06010 MSUIS_06010, hypothetical protein 11.3412566 0.01076465 0.33716714 no Cytoplasmic 0 
MSUIS_06180 MSUIS_06180, hypothetical protein 11.350145 0.01076465 0.33716714 yes Cytoplasmic 1 
MSUIS_05600 MSUIS_05600, hypothetical protein 11.3655692 0.00787994 0.31519774 no Unknown 1 
MSUIS_05490 MSUIS_05490, hypothetical protein 11.4589183 0.0073396 0.3090357 no Unknown 1 
MSUIS_04560 MSUIS_04560, putative competence protein 1.60574907 0.00345996 0.39542429 no Cytopl.Membrane 4 
MSUIS_06910 MSUIS_06910, hypothetical protein 11.9029336 0.00205595 0.27412644 no Unknown 1 
MSUIS_04900 MSUIS_04900, hypothetical protein 12.0709696 0.00168149 0.26903853 no Unknown 0 
MSUIS_05410 MSUIS_05410, hypothetical protein 11.9936577 0.0016508 0.26903853 no Unknown 1 
MSUIS_01590 MSUIS_01590, conserved hypothetical protein 11.4002172 0.0057499 0.25555129 yes Unknown 1 
MSUIS_07610 MSUIS_07610, hypothetical protein 11.5978687 0.00508401 0.23924753 no Cytoplasmic 0 
MSUIS_05080 MSUIS_05080, hypothetical protein 11.6108702 0.00377282 0.18864122 no Cytoplasmic 0 
MSUIS_05530 MSUIS_05530, hypothetical protein 11.6274161 0.00377282 0.18864122 no Unknown 0 
MSUIS_06320 MSUIS_06320, hypothetical protein 11.612718 0.00377282 0.18864122 no Unknown 0 
MSUIS_02810 MSUIS_02810, hypothetical protein 11.6900158 0.00357357 0.18864122 no Unknown 0 
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MSUIS_07010 MSUIS_07010, hypothetical protein 11.7091419 0.00357357 0.18864122 no Unknown 1 
MSUIS_06990 MSUIS_06990, hypothetical protein 11.7683637 0.0033817 0.18864122 no Extracellular 0 
MSUIS_02740 MSUIS_02740, hypothetical protein 11.8124439 0.00254636 0.18864122 no Unknown 0 
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Feature Description alogFC bPValue cFDR dProteome epsortB eTMHMM 
Unknown function 
MSUIS_02860 MSUIS_02860, hypothetical protein 11.8124439 0.00254636 0.18864122 no Unknown  1 
MSUIS_04800 MSUIS_04800, hypothetical protein 3.30782494 0.00139276 0.15917201 no Cytoplasmic 0 
MSUIS_06070 MSUIS_06070, hypothetical protein 12.04371 0.00102045 0.13606016 no Unknown 0 
MSUIS_00470 MSUIS_00470, hypothetical protein 12.8995997 1.69E-05 0.00450712 yes Unknown  
MSUIS_04810 MSUIS_04810, hypothetical protein 13.2903577 2.44E-06 0.00097494 no Cytoplasmic 0 
MSUIS_01630 MSUIS_01630, hypothetical protein -2.8013687 1.23E-17 9.87E-15 yes   Unknown 0 
Translation 
MSUIS_04580 valS, Valyl-tRNA synthetase -0.62130631 0.02615195 0.51645014       
MSUIS_02625 MSUIS_02625, 50S ribosomal protein L32 -1.36899344 0.02294007 0.49600142       
MSUIS_ssuRNA MSUIS_ssuRNA -0.94203936 0.00957507 0.33716714       
MSUIS_03860 rpmJ, Ribosomal protein L36 11.9163412 0.00183769 0.18376929       
MSUIS_02410 rpsO, 30S ribosomal protein S15 12.7037345 6.13E-05 0.00980046       
MSUIS_lsuRNA MSUIS_lsuRNA -0.99183966 4.89E-05 0.0097826       
MSUIS_03690 rplN, 50S ribosomal protein L14 -1.68777899 4.22E-06 0.00112565       
MSUIS_ssuRN
A MSUIS_ssuRNA -1.78834708 3.87E-06 0.00112565       
Transport 
MSUIS_00650 
potC, Spermidine/putrescine transport system permease 
PotC ABC-type 1.17546928 0.04132057 1       
MSUIS_02590 nrdI, Ribonucleoprotein 0.73394528 0.03619392 1       
MSUIS_03230 MSUIS_03230, ferrichrome ABC transporter ATP-binding -0.74387457 0.03083114 0.56056627       
MSUIS_04160 trkG, Cation transport protein -0.67131175 0.02683679 0.51645014       
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Feature Description alogFC bPValue cFDR dProteome epsortB eTMHMM 
Transcription 
MSUIS_06550 
rpoBC, DNA-directed RNA polymerase subunit beta and 
beta' -0.71048603 0.01838155 0.8169579       
MSUIS_00110 nusG, NusG protein 0.64992355 0.03660368 0.60616464       
MSUIS_06610 rnr, Ribonuclease R truncated 0.68183423 0.0125848 0.37288289       
Energy  metabolism 
MSUIS_07320 trxA, Thioredoxin 1.78975671 0.00887233 0.33716714       
 
aLogFC ≥ 1represented up-regulated and LogFC ≤ 1 represented down-regulated 
bPValue of ≤ 0.05 was considered statistically significant 
cFDR False discovery rate (Genes with a FDR value below 0.01 were considered to be differentially expressed) 
dProteom genes were also foud by proteome analyses 
epsortB bacterial localization prediction tool (only for hypothetical genes) 
eTMHMM Server v. 2.0 Prediction of transmembrane helices in proteins (http://www.cbs.dtu.dk/services/TMHMM/) 
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The RNA-Seq expression data were validated by qRT-PCR based on the relative quantification of 10 differ-
entially expressed genes (Table 6). Based on the qRT-PCR validation, the RNA-Seq data properly estimated 
the DE transcription levels of the selected M. suis genes. 
 
Table 6: Validation by qRT-PCR based on the relative quantification of 10 differentially expressed genes 
Gene Days p.i. CT CT mean ΔCT mean Negative Positive 
Eubacteria 0 25.45 25.51487 11.05874 30.87712 14.45613 
0 25.58 
4 20.62 20.65988 6.203751 
4 20.70 
8 8.07 7.933266 -6.52286 
8 7.80 
msg-1 
↑ 
0 37.02 35.5116 26.89757 36.55229 8.61404 
0 33.40 
4 23.93 24.02822 15.41418 
4 24.13 
8 16.83 16.78317 816913 
8 16.74 
hspA-1 
↑ 
0 35.49 35.10236 26.00375 37.10611 9.098608 
0 34.71333 
4 20.22061 19.84187 10.74326 
4 19.46313 
8 35.25023 35.56846 26.46985 
8 35.88669 
enolase (1) 
↑ 
0 36.25835 36.36027 28.45312 undeter-
mined 
7.907146 
0 36.46219 
4 25.01643 25.47795 17.5708 
4 25.93947 
8 19.66341 19.78087 11.87372 
8 19.89832 
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Gene Days p.i. CT CT mean ΔCT mean Negative Positive 
enolase (2) 
↑ 
0 21.3534 21.31422 12.78 33.52225 8.538609 
0 21.27504 
4 21.39024 21.46378 12.93 
4 21.53731 
 
8 15.89416 15.05818 6.52   
8 14.22219 
Eubacteria 0 25.34548 25.11833 11.17212 28.87777 13.94621 
0 24.89118 
4 20.60124 20.55748 6.611272 
4 20.51372 
8 6.472788 7.167272 -6.77894 
8 7.861756 
MSUIS_0035
0 
↑ 
0 23.91729 23.91377 16.27256 23.93929 7641212 
0 23.91025 
4 24.02354 23.97849 16.33728 
4 23.93344 
8 15.83055 15.80824 8.167024 
8 15.78592 
MSUIS_0163
0 
(1) ↓ 
0 36.09247 35.61674 25.94894 35.856 9.667803 
0 35.14103 
4 36.68158 35.82027 26.15247 
4 34.95897 
8 23.91052 22.29195 12.62415 
8 20.67339 
MSUIS_0163
0 
(2) ↓ 
0 32.7229 32.70293 18.70 33.91537 14.00008 
0 32.68296 
4 29.80503 29.85572 15.86 
4 29.9064 
8 25.34311 25.42786 11.43 
8 25.51262 
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Gene Days p.i. CT CT mean ΔCT mean Negative Positive 
MSUIS_0211
0 
(1) ↑ 
0 34.994 34.75807 5.460628 undeter-
mined 
29.29745 
 0 34.52214 
4 35.95277 35.86095 6.5635 
4 35.76912 
8 32.4244 32.35225 3.054799 
8 32.28009 
MSUIS_0211
0 
(2) ↑ 
0 36.99387 35.99892 0.58 undeter-
mined 
35.42235 
0 35.00398 
4 35.89969 36.47161 1.05 
4 37.04354 
8 3.60598 36.60598 1.18 
8 undetermined 
Eubacteria 0 24.365 24.3486 10.50998 28.85226 13.83863 
0 24.3322 
4 17.2351 17.2219 3.383274 
4 17.2087 
8 9.896002 9.885679 -3.95295 
8 9.875358 
MSUIS_0501
0 
↑ 
0 undetermined --- --- 37.01806 8.964779 
 
 
 
 
 
 
0 undetermined 
4 26.24339 26.48391 17.51913 
4 26.72443 
8 22.21288 22.23319 13.26841 
8 22.2535 
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Gene Days p.i. CT CT mean ΔCT mean Negative Positive 
MSUIS_0554
0 
↑ 
0 33.16559 33.16559 25.26288 37.14084 7.90271 
 
 
 
 
 
0 undetermined 
4 18.71599 18.72429 6.583819 
4 18.7326 
8 14.62257 14.48653 10.82158 
8 14.35049 
MSUIS_0691
0 
↑ 
0 31.38398 30.10123 23.90064 32.12573 6.20059 
0 28.81848 
4 20.81309 20.89133 14.69074 
4 20.96957 
8 22.81222 19.85277 13.65218 
8 16.89331 
Eubacteria 0 24.91914 24.90698 10.5147858 28.86189 14.3922 
0 24.89483 
4 19.8972 20.05775 5.67 
4 20.21829 
8 10.44692 10.48455 -3.91 
8 10.52217 
MSUIS_0481
0 
↓ 
0 30.62337 30.80603 20.29 34.19257 10.51618 
0 30.98868 
4 33.48948 33.461 22.94 
4 33.43252 
8 19.61482 19.70197 9.19 
8 19.78913 
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Gene Days p.i. CT CT mean ΔCT mean Negative Positive 
MSUIS_0630
0 
↓ 
0 32.82524 32.81509 0.25 32.29068 32.56857 
 
 
 
 
 
0 32.80495 
4 31.56969 31.62049 -0.95 
4 31.6713 
8 31.93451 31.95776 -0.61 
8 31.981 
MSUIS_0047
0 
↑ 
0 26.89415 26.84767 18.47 26.75568 8.379626 
0 26.80119 
4 26.89683 26.84098 18.46 
4 26.78514 
8 23.45788 23.49259 15.11 
8 23.5273 
MSUIS_0703
0 
(1) ↓ 
0 Undetermined --- --- --- Un- 
determined 
0 Undetermined 
4 Undetermined --- --- 
4 Undetermined 
8 Undetermined --- --- 
8 Undetermined 
MSUIS_0703
0 
(2) ↓ 
0 Undetermined --- --- --- 36.94089 
0 Undetermined 
4 Undetermined --- --- 
4 Undetermined 
8 Undetermined --- --- 
8 Undetermined 
 
  
62 
 
 
4.2.3 Characterization of highly expressed and differentially expressed hypothetical 
proteins 
Our transcriptome data support the expression of several hypothetical proteins with unknown 
function. In M. suis 65.3% (strain Illinois) and 65.9% (strain KI_3806) of the genes encode 
hypothetical proteins and only 6.3% were identified at the proteome level. Both strains com-
prise large regions of hypothetical proteins that do not exist in the other genome (Felder et al., 
2012). In this study 39.4% hypothetical genes were found on day 4 p.i. and 29.4% were found 
on day 8 p.i. The hypothetical genes within the highest RPKM and within the DE genes were 
additionally observed intensively by different databases, resulted in two hypothetical genes 
(MSUIS_02610, MSUIS_06750) encoding for a membrane protein (listed in Supplementary 
Table 2). 
4.3 Microarray results 
4.3.1 Transcriptome profile changes between M. suis infected and non-infected animals 
The whole blood transcriptome expression profiles of M. suis-infected pigs were defined with 
blood samples taken 2 days (no clinical signs), 4 days (mild clinical signs), and 8 days (massive 
clinical signs) after experimental infection. We found a total of 27.558 genes to be expressed 
in the blood of infected pigs (Supplementary Table 3). To interpret the biological processes in 
which these genes are involved, gene ontology (GO) annotation was performed with all 27.558 
transcripts for the most relevant biological process category of the GO database  
Differential expressed gene patterns (infected vs. non-infected animals) were determined: Rel-
ative transcription levels showing a fold change (FC) ≥ 2 (P≤0.05) were considered to be up-
regulated, and those with a FC ≤ 2 (P≤0.05) down-regulated. On day 2 p.i. 589 transcripts were 
significantly differentially expressed when compared to the non-infected controls, of which 359 
(60.59%) were up-regulated and 230 (39.04%) were down-regulated. On day 4 p.i. 703 tran-
scripts were significantly altered when compared to non-infected controls, with 406 (57.75%) 
transcripts up-regulated and 297 (42.25%) transcripts down-regulated. On day 8 p.i. (peak of 
clinical signs with high fever, anemia, and hypoglycemia) 5998 DE transcripts were detected 
with 2931 (48.86%) transcripts significantly up-regulated and 3067 (51.14%) significantly 
down-regulated. The ten most up- and down-regulated transcripts of the days 2, 4 and 8 p.i. 
are listed in Table 7, 8 and 9.  
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Table 7: The top molecules of day 2 p.i. 
Up FC Function Down FC Function 
GPR82 4.688 Signal transduction MMP1                                                                                                                                                                              -10.406 Blood coagualtion 
PTPRO       3.547 Signal transduction CXCL8            -9.078 Inflammatory response 
CKAP2L*                                                                                                                                                                           3.062 Cell cycle HERC3*                                                                                                                                                                          -5.374 Protein ubiquitination
MKI67     2.991 Cell cycle ACSL1         -5.077 lipid biosynthesis + fatty acid 
degradation 
DDX60               2.929 Immune response AGPAT6         -3.980 glycerolipid biosynthesis 
PSMD14     2.817 Antigen processing + presen-
tation 
S100A9       -3.871 Apoptose, Immune + inflamma-
tory response 
TTK         2.798 Signal transduction ALOX12       -3.504 fatty acid metabolism 
RASGRP3                  2.773 Signal transduction BMX     -3.388 Apoptose 
CENPI         2.724 mitotic progression S100A8       -3.271 Apoptose, Immune + inflamma-
tory response 
MS4A2   2.663 Immune + inflammatory 
response 
SMAP2      -3.232 Signal transduction 
 
 
Table 8: The top molecules of day 4 p.i. 
Up FC Function Down FC Function 
GPR82     4.880             Signal transduction CXCL8   -51.784 Inflammatory response 
DDX60        3.152 Innate immune response MMP1            -11.289 Blood coagulation 
CLIC2     2.984 Chloride channel HERC3*                                                                                                                                                                            -6.873 Protein ubiquitination 
SGOL2    2.981 Cell cycle ACSL1     -6.564 fatty acid metabolism 
PTPRO   2.966 Signal transduction ADAM19         -5.315 Signal transduction 
DCTN6       2.965 Antigen processing, MHC 
class II 
S100A9      -5.043 Apoptose, Immune + inflamma-
tory response 
TTK       2.952 cell proliferation AGPAT6 -5.005 fatty acid metabolism 
COPS2       2.905 signalosome complex S100A8    -4.503 Apoptose, Immune + inflamma-
tory response 
CKAP2L      2.802 cytoskeleton RGS2       -4.495 Signal transduction 
TAF13             2.779 transcription SMAP2 -4.445 transport 
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Table 9: The top molecules of day 8 p.i. 
Up FC Function Down FC Function 
FBXO11       18.795 Protein ubiquitination CXCL8        -59.740 Inflammatory response 
TNFRSF11
B        
5.681                                                                                                                                            Apoptose VNN2 -19.637 Inflammatory response
mir-133                                                                                                                                                                              4.950 Micro-RNA VNN1   -18.462 Inflammatory response
AUTS2   4.320 unknown ARHGAP
15      
-18.199 Signal transduction 
COL1A1*                                                                                                                                                                           3.901 Blood coagulation SAMSN1 -15.849 Immune response
GABRA6    3.776                                                                                                                                                                        Transport JMJD1C -15.105 Blood coagulation
H2AFZ        3.580 Chromatin structure HERC3*                                                                                                                                                                           -13.439     Protein ubiquitination 
mir-183                                                                                                                                                                              3.566 Micro-RNA BAZ2B*                                                                                                                         -12.490 Transcription
SLC8A3    3.491 Blood coagulation MARCH7     -10.876 Protein ubiquitination 
CALB1   3.454 Calcium binding ACSL4 -10.772                                                                                                                                                                                                                                                                                                                                    fatty acid metabolism 
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4.3.2 Differential gene expression analysis identifies most affected biological functions and 
gene clusters in M. suis-infected animals 
To gain insight on the functions of the blood transcriptome that differed significantly between 
the infection course all genes were annotated on the basis of Ingenuity Knowledge Base soft-
ware (IPA, Qiagen Hilden) and were assigned to different biological functions. IPA categorized 
and subcategorized modulated genes according to p-values and z-scores, revealing the most 
modulated top functions of the three different days, summarized in Supplementary Table 4. In 
detail, on day 2 p.i., the top functional groups with increased or decreases prediction were as 
follows: Cell Death and Survival (e.g. ADAM15, ALOX12, BCAS2, BLNK, BMX), Cancer (e.g. 
ASPN, BMX, CBL, CD200R1, CDA, PTEN), Organismal Injury and Abnormalities (e.g. CSPP1, 
CXCL8, DEPDC1B, EEA1, EEF1B2), Reproductive System and Disease (e.g. KIF11, PTEN, 
NFIL3, PDE4B, PHF12), such as Cellular Growth and Proliferation (e.g. BMX, CD44, CLU, 
CXCL8, DACH1). On day 4 p.i., the following groups could be observed: Besides Cell Death 
and Survival and Cellular Growth, Cell Cycle (e.g. AATF, CEBPB, COPS2, FOXO3, KIF11), 
Hematological System and Development (e.g. ADK, BLM, CAMLG, CP, DIAPH1) and Tissue 
Morphology (e.g. CXCR4, ITGB3, PRKG1, SDPR, VEZF1) appears at top function. In addition 
to the functional groups observed of the first four days, these functional groups of differential 
genes were found on day 8 p.i.: cancer, cell death and survival, cellular growth and proliferation 
and new adding gastrointestinal diseases (e.g. ABCB11, ABCC2, CDX2, ACAN, PPARD) and 
gene expression (e.g.  ATXN7L3, BACH1, CTNNB1, DACH1, MAP3K). Moreover, a big num-
ber of immune and inflammatory genes involved in inflammatory and immune response were 
detected on day 8 p.i. (IL8, SAMSN1, COX2, CXCR4, IL7R, IL13RA1, IFNGR1, IL-1beta, IL9, 
COX6C, IL9, IL17F). 
To better understand the biological significance of the DE genes, we also used IPA bio-function 
analysis. All top decreased and increased functions were subcategorized into bio-functions by 
IPA. On day 2 p.i., biofunctions, which play an important role in immune related patterns, were 
observed. For example, “quantity of lymphatic system cells, inflammation of organ, quantity of 
mononuclear leukocytes, inflammation of body region, quantity of follicular B lymphocytes, 
quantity of lymphocytes, quantity of B lymphocytes and dermatitis”. Moreover, 2 biofunctions, 
which indicates that M. suis is involved in glucose uptake were found: “uptake of carbohydrate 
(9 genes) and glucose metabolism disorder” (28 genes). Furthermore, 9 genes, such as ADK, 
CAMLG, CBL, CD44, CXCL8 and LGALS3, represent the subcluster “response of liver”, which 
has a z-score of 1.987.  
On day 4 p.i. subclusters, (apoptosis of chronic lymphocytic leukemia cells, apoptosis of leu-
kemia cells; z-score 1.214 and 1.491) involved in cell death and survival, showed an increased 
expression, while “cell viability of chronic lymphocytic leukemia cells” (-1.177) showed a de-
creased expression. Noteworthy, most of the genes in subcluster “apoptosis of endothelial 
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cells” (0.431) and “apoptosis of vascular endothelial cells” (1.408) were down-regulated induc-
ing apoptosis of the endothelial cells. Immune related subclusters were found for cell viability 
of mononuclear leukocytes (z-score 1.088), cell viability of lymphocytes (z-score 1.135), cell 
viability of B lymphocytes (0,411), aggregation of leukocytes (0,612), adhesion of antigen pre-
senting cells (0,152), inflammation of liver (0,922), quantity of B lymphocytes (0,932), produc-
tion of antibody (1,115), quantity of IgG (1,171), quantity of immunoglobulin (1,371), quantity 
of IgG3 (1,571), chronic inflammatory disorder (0,132) and antibody response (0,492). In ad-
dition, there are many genes involved in hematological system disease and development such 
as ALOX12, BTK, ITGA2B, ITGB3, MMP1, PECAM1, BLM, CXCL8, DOCK8, NFIL3 and 
NQO1. Two specific subclusters are annotated as “flux of Ca2+ (0,212) and quantity of Ca2+ 
(0,591)”, which were involved in cell signaling and molecular transport. Most of the genes rep-
resenting these two subclusters were significantly down-regulated (CXCL8, CXCR4, MMP1, 
S100A8, S100A9). 34 genes, including genes like AMICA1, ANGPTL4, BLNK, CD44, CEBPB, 
and CIRBP, represent the subcluster “inflammatory response”. Genes in this cluster were sig-
nificantly down-regulated and had a decreased expression direction (-2,110) comparing with 
day 2 post infection. 
And last but not least comparing day 8 p.i. with the other days, inflammatory response was still 
decreased (-2,089), but now, also the antibody response (-3,239) decreased clearly. An addi-
tional subcluster of “apoptosis” (0,925) and other “cell death and survival” patterns showed a 
high expression amounting to the biggest number of the clusters on day 8. Herein “Organismal 
death” (6,676) had a large increase in expression, while subclusters of “cell viability (-6,039) 
and cell survival (-6,364)” had decreased expression levels. Furthermore, a final subcluster of 
69 genes annotated to “anemia” definitely increased having one of the highest z-score with 
4,935. 
To identify over-represented functional GO terms for DE genes the DAVID database was used 
(Supplementary Table 5) for up- and down regulated genes. On day 2 p.i. the top GO term 
related to inflammatory response. On day 4 p.i. the top four terms related to “response to 
wounding, inflammatory response, defense response and cytoskeleton”. And on day 8 p.i. en-
richment analysis revealed the four top over-represented terms associated with “host-virus 
interaction, T cell receptor signaling pathway, regulation of programmed cell death and im-
mune response” (P<0.05), indicating that these terms represent the major responses in the M. 
suis infected animals. 
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4.3.3 Pathway analyses 
With the help of IPA the top canonical pathways on day 2, 4, and 8 p.i. could be identified and 
were listed in Table 10, 11 and 12. 
 
Table 10: Top canoncial pathways day 2 p.i. 
Day 2 vs. Day 0 
Canonicial pathway p-value 
Role of IL-17A in Psoriasis 2.92E-04 
D-myo-inositol-(1,3,4)-triphosphate Biosynthesis 5.37E-04 
Superpathway of D-myo-inositol (1,4,5)-triphosphate Metabo-
lism 
1.9E-03 
Airway pathology in chronic obstructive pulmonary disease 2.88E-03 
Oxidative Phosphorylation 5.61E-03 
 
Table 11: Top canoncial pathways day 4 p.i. 
Day 4 vs. Day 0 
Canonicial pathway p-value 
Leukocyte Extravasation Signaling 9.64E-06 
PI3K Signaling in B Lymphocytes 2.43E-04 
Role of IL-17A in Psoriasis 5.37E-04 
Gap Junction Signaling 8.72E-04 
Axonal Guidance Signaling 1.4E-03 
 
Table 12: Top canoncial pathways day 8 p.i. 
Day 8 vs. Day 0 
Canonicial pathway p-value 
T Cell Receptor Signaling 1.17E-10 
Molecular Mechanisms of Cancer 4.46E-10 
B Cell Receptor Signaling 3.88E-08 
Actin Cytoskeleton Signaling 4.57E-08 
Role of NFAT in Regulation of the Immune Response 5.02E-08 
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4.3.4 Differential expression of candidate genes involved in anemia and endothelial cell 
damage 
It is well known, that M. suis causes anemia in pigs. Therefore, we focused on parameters and 
genes that were involved in anemia and in hematological disease. On day 4 p.i., 16 genes 
were found for “Anemia” and 5 genes were found for “Aplastic Anemia”. Both clusters have a 
decreased z-score, whereas on day 8 p.i. z-score of “Anemia” increased up to 4.9. That means 
49 of 69 genes involved in anemia had an expression direction consistent with increased ane-
mia (e.g. atf2, add1, picalm, ireb2, stat5a, cd47, foxo3; Figure 13). Moreover, “Apoptosis of 
Blood Cells” only decreased on day 8 p.i. The cluster of “Hematological System Development 
and Function” showed that on day 4 p.i. the “Quantity and Aggregation of Blood Cells” had an 
z-score of 0.4 and 0.9, while on day 8 p.i. the z-score of red blood cells decreased (Differenti-
ation of Red Blood Cells -0.8, Aggregation of Blood Cells -1.6, Accumulation of Blood Cells -
1.4). On day 2 p.i. no transcripts were found involved in anemia or hematological system. 
Microscopic analysis of the vascular endothelium showed alterations on the surface of the 
vessels of M. suis infected pigs leading to the development of hemorrhage and organ failure 
(Sokoli et al., 2013). On day 2 p.i. we found evidence for “Inflammation of Endothelial Cells” 
as on day 4 p.i., respectively. Therefore, two transcripts encoding for a zinc- and calcium-
binding protein could be found (S100A8, S100A9) and on day 4 p.i. tlr4 was found, additionally. 
For “Proliferation and Differentiation of Endothelial Cells” a decreased z-score occurred to day 
2 and 4 p.i., followed by the smallest z-score of -0.8 on day 8 p.i., respectively. On day 8 p.i. 
71 genes were involved in “Endothelial Cell Development”. And last but not least, “Apoptosis 
of Endothelial Cells” increased on day 4 p.i. (z-score: 0.4), but on day 8 p.i. we had a decreased 
z-score of 1.0 for 45 transcripts. 
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Figure 13: Anemia Network: Network of genes most significantly associated with anemia in 
infected pigs. Up- and down-regulated genes are illustrated by red and green, respectively. 
The color intensity directly correlates with the difference in the expression level of the corre-
sponding gene 
 
4.3.5 Differential expression of candidate genes involved in psoriasis in pigs 
Psoriasis is an inflammatory response of the skin. Heinritzi (1990) decribes allergic skin reac-
tions (Morbus maculosus) caused by M. suis infections. Moreover, psoriasis is a T cell medi-
ated disease and regulation of local and systemic cytokines plays an important role in its path-
ogenesis (Arican et al., 2005). Many studies describe higher IL 17 levels in psoriatic patients 
than in controls (Caproni et al., 2009; Takahashi et al., 2010; Suárez Farinas et al., 2012). 
Therefore, we investigated the expression of genes known to be upregulated in IL 17 signaling, 
namely CXCL8, S100A8 and S100A9. On day 2 and 4 p.i. “Role of IL 17A in Psoriasis” were 
within the top 5 canonical pathways on these days. Nevertheless, all genes were down regu-
lated on the different days. 
4.3.6 DE genes and immune system related pathway analysis in M. suis infected animals 
Canonical pathway analysis of the DE genes was performed to characterize the effect of dif-
ferent immune pathways of M. suis inoculation during infection. On day 2 p.i., the predominant 
immune-related pathways comprised the role of “IL-17A in Psoriasis and IL-12 Signaling and 
production of macrophages”. On day 4 p.i., immune pathways included leukocyte extravasa-
tion signaling, PI3K signaling in B lymphocytes, role of Il-17A in Psoriasis, insulin receptor 
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signaling, IL-12 signaling and production of macrophages, FcyRIIB signaling in B lymphocytes, 
role of NFAT in regulation of the immune response, B cell receptor signaling and T cell receptor 
signaling. And on day 8 p.i. the following pathways were predominantly: T cell receptor signal-
ing, B cell receptor signaling, role of NFAT in regulation of the immune response, Tec kinase 
signaling, PI3K/AKT signaling, PKCᶱ signaling in T lymphocytes, PI3K signaling in B lympho-
cytes, CD28 signaling in T helper cells, NF-kB signaling, leukocyte extravasation signaling, IL-
15 production, Jak/Stat, IL-8, chemokine, IL-1, CXCR4, IL-17, IL-9, IL-12, IL-6, IL-3, IL-15, IL-
4, IL-17A, interferon, NK cell, and TNFR1 signaling, such as STAT3 pathway and role of JAK1, 
JAK2 and TYK2 interferon signaling (Table. 13, 14 and 15). 
57 networks related to the differentially expressed genes in infected versus uninfected pigs 
were identified on day 2, 4, and 8 p.i. by IPA network analysis (Supplementary Table 6). Three 
of these networks were related to immune response, including the most significantly associ-
ated network containing 16 focused genes connected with the biological functions “inflamma-
tory response, “hematological system development and function”, and “tissue morphology” 
(Figure 14). The other most significantly associated network containing 21 focused genes as-
sociated with the biological functions “cell-to-cell signaling and interaction”, “inflammatory re-
sponse”, and “DNA replication, recombination, and repair”. And the last most significantly as-
sociated network containing 33 focused genes associated with the biological functions “gene 
expression”, “cancer”, and cell-mediated immune response”. 
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Table 13: The IPA pathways significantly associated with the differentially expressed tran-
scripts in M. suis infected pigs on day 2 p.i compared with uninfected controls 
Pathway name Number Gene 
Il-17A in Psoriasis 3 CXCL8, S100A8/A9 
D-myo-inositol (1,3,4)-triophosphate Biosynthesis 3 INPP5F, ITPKC, PTEN 
airway pathology in chronic obstructive pulmonary  
disease 
2 CXCL8, MMP1 
oxidative phosphorylation 5 COX17, COX6C, COX7C, MT-ND2, NDUFS4 
triaglycerol biosynthesis 3 AGPAT5, AGPAT6, LPIN2 
glucocorticoid receptor signaling 8 CEBPB, CXCL8, FKBP5, HSPA14, MMP1, 
NCOA3, SLPI, TAF13 
CDP-diacylglycerol biosynthesis 2 AGPAT5/6 
adenine and adenosine salvage VI 1 ADK 
phosphatidylglycerol biosynthesis II 2 AGPAT5/6 
Il-12 Signaling 5 ALOX12, CEBPB, CLU, IFNA1, S100A8 
 
Table 14: The IPA pathways significantly associated with the differentially expressed tran-
scripts in M. suis infected pigs on day 4 p.i compared with uninfected controls 
Pathway name Number Gene 
leukocyte extravasation signaling 12 ARHGAP12, BMX, BTK, CD44, CXCR4, 
ICAM3, ITGB3, MMP1, OPN1SW, PECAM1, 
PLCG2, RDX 
PI3K signaling in B lymphocytes, 8 BLNK, BTK, CBL, FOXO3, PLCG2, 
PPP3CA, PTEN, TLR4 
role of Il-17A in Psoriasis 3 CXCL8, S100A8/A9 
netrin signaling 4 PPP3CA, PRKAR2A/B, PRKG1 
P2Y purinergic receptor signaling pathway 6 ITGB3, OPN1SW, PLCG2, PRKAR2A/B 
insulin receptor signaling 6 CBL, FOXO3, NPP5F, PRKAR2A/B, PTEN 
IL-12 signaling and production of macrophages 7 ALOX12, CEBPB, CLU, IFNA1/13, S100A8, 
TLR4 
FcyRIIB signaling in B lymphocytes 3 BLNK, BTK, PLCG2 
role of NFAT in regulation of the immune response 6 BLNK, BTK, CSNK1E, MS4A2, PLCG2, 
PPP3CA 
B cell receptor signaling 6 BLNK, BTK, INPP5F, PLCG2, PPP3CA, 
PTEN 
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Table 15: The IPA pathways significantly associated with the differentially expressed tran-
scripts in M. suis infected pigs on day 8 p.i compared with uninfected controls 
Pathway name Number Gene 
T cell receptor signaling 32 BCL10, BMX, BTK, CAML1, CBL, 
CD3D/E/G, CHUK, FYN, LCP2, MALT1,… 
B cell receptor signaling 41 ATF2/4, BCL10, BLNK, BTK, CALM1, 
CAMK2D/G, CD79A, CDC42, CHUK, EP300, 
… 
actin cytoskeleton signaling 41 CD79A, CDC42, CHUK, EP300, ETS1, 
GSK3B, INPP5D, MALT1, MAP3K1/3/7,… 
role of NFAT in regulation of the immune response 40 ATF2, BLMK, BTK, CALM1, CD80/86, 
CD3D/E/G, CD79A, CHUK, CSNK1A1, … 
Tec kinase signaling 37 BBX, BTK, FNBP1, FYN, GN13/5, GNAI2/3, 
GNAO1, GNAQ, GNAS, GTF2I, ITGA2/3/4, 
… 
PI3K/AKT signaling 31 CDKN1A, CHUK, CTNNB1, FOXO3, GSK3B, 
GYS2, INPPSD, ITGA2/3/4, … 
PKCᶱ signaling in T lymphocytes 30 BCL10, CAMK2D/G, CD80/86, CD3D/E/G, 
CHUK, FYN, LCP2, MALT1, … 
PI3K signaling in B lymphocytes 31 AGPAT5/ 6 ATF2/4/6, BCL10, BLNK, BTK, 
CALM1, CAMK2D/G, CBL, CD79A, CHUK, 
… 
CD28 signaling in T helper cells 29 ACTR2/3, ARPC2/3/5/1A, BCL10, CALM1, 
CD80/86/3D/3E/3G, CDC42, … 
NF-kB signaling 37 ARAF, BCL10, BMPR2, BMPR1B, BRAF, 
CHUK, EP300, FLT1, GSK3B, IRAK3/4, … 
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Figure 14: Immune reponse Network: Network of genes most significantly associated with the 
biological functions “inflammatory response, “hematological system development and func-
tion”, and “tissue morphology” Up- and down-regulated genes are illustrated by red and green, 
respectively. The color intensity directly correlates with the difference in the expression level 
of the corresponding gene 
 
4.3.7 Candidate genes involved in pigs’ immune response on M. suis 
Of interest, was the over-expression of up- and down-regulated genes associated with immune 
responses and inflammatory responses, suggesting and important role for these genes in M. 
suis infections. 99 of all DE genes were known to be involved in immune immunity and immune 
related signal transduction in pigs after M. suis infection. In Table 16, 17 and 18 all immune 
related genes were shown for the different days of infection. Most of these immune-related 
genes belong to the categories “T cell response”, “B cell receptor signaling”, “NF-kB signaling”, 
“IL-12 signaling”, “cell proliferation and apoptosis”, “cytokine and chemokine” and others in-
volved in the “cytokine-cytokine receptor interaction signaling” pathways. 
Genes involved in RLR signaling, T cell signaling, chemokine, interferon (IFN) and cytokine, 
were found significantly induced as well as inhibited in pigs after M. suis infection. Antimicrobial 
proteins, such as S100A8 and S100A9, were significantly down-regulated, indicating that M. 
suis modulates the immune response of infected pigs.  
In general, many genes in the transcription regulation group for cell proliferation and apoptosis 
were found to be up-regulated on day 8 post infection. But there are also some encoding 
genes, such as CASP1, ICAM3, and PDCD4, found to be down-regulated on day 8 p.i. in pigs 
infected with M. suis. 
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Table 16: Immune related genes for day 2 p.i. 
SEQ_ID p-value FC Change GeneName Description 
XM_001927633 0.0085283 2.92865 DDX60 DEAD (Asp-Glu-Ala-Asp) box polypep-
tide 60 
ENSSSCT00000014319 0.0457966 2.6629 MS4A2 membrane-spanning 4-domains, sub-
family A, member 2 
ENSSSCT00000018406 0.00137811 2.49955 GZMK granzyme K (granzyme 3; tryptase II) 
AK344385 0.0427426 2.26806 IBTK inhibitor of Bruton agammaglobulinemia 
tyrosine kinase 
NM_213867 0.0126869 -9.07801 IL8 interleukin 8 
NM_001177906 0.0108076 -3.87124 S100A9 S100 calcium binding protein A9 
ENSSSCT00000007219 0.0267924 -3.27085 S100A8 S100 calcium binding protein A8 
AK233692 0.00266699 -2.84871 SERPINB1 serpin peptidase inhibitor, clade B (oval-
bumin), member 1 
ENSSSCT00000023382 0.016979 -2.60802 XCR1 chemokine (C motif) receptor 1 
XM_001928870 0.021297 -2.42126 NFIL3 nuclear factor, interleukin 3 regulated 
NM_001199889 0.0147249 -2.30583 CEBPB CCAAT/enhancer binding protein 
(C/EBP), beta 
ENSSSCT00000000991 0.0389584 -2.14095 PLXNC1 plexin C1 
ENSSSCT00000010460 0.0073897 -2.10339 TNFSF13B tumor necrosis factor (ligand) superfam-
ily, member 13 
ENSSSCT00000014911 0.0352756 -2.01868 ICAM3 intercellular adhesion molecule 3 
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Table 17: Immune related genes for day 4 p.i. 
SEQ_ID p-value FC Change GeneName Description 
XM_001927633 0.00616674 3.15172 DDX60 DEAD (Asp-Glu-Ala-Asp) box polypep-
tide 60 
NM_001244227 0.000342851 2.79574 RGC32 response gene to complement 32 pro-
tein 
ENSSSCT00000014319 0.0480073 2.62859 MS4A2 membrane-spanning 4-domains, sub-
family A, member 2 
ENSSSCT00000005513 0.0324203 2.50012 FKBP3 FK506 binding protein 3, 25kDa 
NM_213867 0.000570816 -51.7838 IL8 interleukin 8 
NM_001177906 0.00449134 -5.04283 S100A9 S100 calcium binding protein A9 
ENSSSCT00000007219 0.00938924 -4.50281 S100A8 S100 calcium binding protein A8 
ENSSSCT00000017088 0.0462986 -3.61496 CXCR4 chemokine (C-X-C motif) receptor 4 
ENSSSCT00000023382 0.00420435 -3.60619 XCR1 chemokine (C motif) receptor 1 
ENSSSCT00000001727 0.0132229 -3.58331 FKBP5 FK506 binding protein 5 
AK233692 0.00143875 -3.22269 SERPINB1 serpin peptidase inhibitor, clade B 
(ovalbumin), member 1 
NM_001199889 0.00488567 -2.86139 CEBPB CCAAT/enhancer binding protein 
(C/EBP), beta 
ENSSSCT00000010460 0.0013356 -2.78968 TNFSF13B tumor necrosis factor (ligand) super-
family, member 13 
XM_001925235 0.0357997 -2.5563 SAMSN1 SAM domain, SH3 domain and nuclear 
localization signals 1 
NM_001244730 0.0102231 -2.5175 AMICA1 adhesion molecule, interacts with 
CXADR antigen 1 
NM_001113039 0.0227478 -2.46548 TLR4 toll-like receptor 4 
ENSSSCT00000014911 0.0170627 -2.31521 ICAM3 intercellular adhesion molecule 3 
ENSSSCT00000032440 0.000126928 -2.31374 KLF13 Kruppel-like factor 13 
XM_003129932 0.015657 -2.22282 CBL Cbl proto-oncogene, E3 ubiquitin pro-
tein ligase 
ENSSSCT00000014523 0.000503598 -2.13337 CD44 CD44 molecule 
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Table 18: Immune related genes for day 8 p.i. 
SEQ_ID p-value FC Change GeneName description 
EF543195 0.0032476 5.68061 TNFRSF11B tumor necrosis factor receptor super-
family, member 11b 
NM_001005149 0.0138568 3.78127 IL-1beta interleukin-1 beta 
NM_001166043 0.000680792 3.43859 IL9 interleukin 9 
ENSSSCT00000012672 0.00854758 2.58297 PPARG peroxisome proliferator-activated re-
ceptor gamma 
NM_214399 0.000562184 2,.31567 IL6 interleukin 6 (interferon, beta 2) 
ENSSSCT00000001570 0.00308497 2.23578 C4 complement C4 
NM_001113218 0.0215456 2.08218 KIR2DL1 killer cell immunoglobulin-like receptor 
GQ415071 0.000437772 2.00928 IFN-ALPHA-
17 
interferon-alpha-17 
NM_213867 0.000461134 -59.74 IL8 interleukin 8 
XM_001925235 0.000122859 -15.8488 SAMSN1 SAM domain, SH3 domain and nuclear 
localization signals 1 
ENSSSCT00000019673 0.000109699 -9.66909 COX2 cytochrome c oxidase subunit II 
ENSSSCT00000017088 0.00455801 -8.85813 CXCR4 chemokine (C-X-C motif) receptor 4 
ENSSSCT00000018327 0.000686371 -8.83083 IL7R interleukin 7 receptor 
NM_214341 0.00105087 -7.9192 IL13RA1 interleukin 13 receptor, alpha 1  
ENSSSCT00000001727 0,00136991 -7.26647 FKBP5 FK506 binding protein 5 
NM_001177907 0.000220173 -6.94351 IFNGR1 interferon gamma receptor 1 
ENSSSCT00000018422 0.00229701 -6.46812 IL6ST interleukin 6 signal transducer 
ENSSSCT00000023382 0.000539647 -6.34913 XCR1 chemokine (C motif) receptor 1 
HQ200930 0.0066805 -6.16334 IFIT3 interferon-induced protein with tetratri-
copeptide repeats 3 
AJ583829 0.00627652 -5.96871 TLR2 toll-like receptor 2 
ENSSSCT00000000709 0.00178704 -5.83462 CD69 CD69 molecule 
NM_001113039 0.000760194 -5.80804 TLR4 toll-like receptor 4 
AY675204 0.000802581 -5.75152 TXK TXK tyrosine kinase 
NM_001244363 0.00155806 -5.34226 IFIT1 interferon-induced protein with tetratri-
copeptide repeats 1 
XM_001925597 0.00131453 -5.05687 LY9 lymphocyte antigen 9 
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SEQ_ID p-value FC Change GeneName Description 
NM_001244730 0.000498051 -5.0185 AMICA1 adhesion molecule, interacts with 
CXADR antigen 1 
XM_001927700 0.0127038 -4.92119 CD101 CD101 molecule 
ENSSSCT00000017310 0.00287754 -4.88573 IFIH1 interferon induced with helicase C do-
main 1 
XM_001927927 0.0012823 -4.73133 IKZF5 IKAROS family zinc finger 5 
ENSSSCT00000007648 0.000236163 -4.71765 CNOT7 CCR4-NOT transcription complex, sub-
unit 7 
XM_003132134 0.000319266 -4.69465 NKTR natural killer-tumor recognition se-
quence 
ENSSSCT00000019670 0.00139997 -4.68997 COX1 cytochrome c oxidase subunit I 
AJ585088 0.0000256625 -4,65126 MAP3K1 mitogen-activated protein kinase kinase 
kinase 1 
AK236323 0.00324218 -4.54466 NFAT5 nuclear factor of activated T-cells 5 
NM_001008686 0.00150897 -4.50196 CD3G CD3g molecule, gamma (CD3-TCR 
complex) 
ENSSSCT00000014911 0.000979369 -4.32614 ICAM3 intercellular adhesion molecule 3 
ENSSSCT00000004215 0.000324041 -4.19861 JAK1 Janus kinase 1 
ENSSSCT00000007379 0.000371901 -4.13348 CD2 CD2 molecule 
ENSSSCT00000008935 0.00201174 -4.12844 IL-18RA interleukin-18 receptor alpha chain 
ENSSSCT00000010460 0.000201197 -4.0874 TNFSF13B tumor necrosis factor (ligand) super-
family 
AB119267 0.00225059 -3.68343 XCR1 chemokine (C motif) receptor 1 
ENSSSCT00000018124 0.0104699 -3.6663 IFRD1 interferon-related developmental regu-
lator 1 
NM_214113 0.00960159 -3.55797 JAK2 Janus kinase 2 
AK233692 0.000934195 -3.5312 SERPINB1 serpin peptidase inhibitor 
ENSSSCT00000008936 0.00514918 -3.4882 IL1RL1 interleukin 1 receptor-like 1 
NM_001246205 0.037072 -3.31777 IFI44 interferon-induced protein 44 
ENSSSCT00000013021 0.0228481 -3.29988 CD80 CD80 molecule 
ENSSSCT00000014523 0.0000289369 -3.29152 CD44 CD44 molecule 
XM_003134992 000192539 -3.19038 TAB3 TGF-beta activated kinase 1/MAP3K7 
binding protein 3 
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SEQ_ID p-value FC Change GeneName Description 
AK351777 0.00379262 -3.09362 LCP2 lymphocyte cytosolic protein 2 
ENSSSCT00000016458 0.000896658 -3.00993 CD3E CD3e molecule, epsilon 
NM_001244329 0.0000648807 -2.98676 CRLF3 cytokine receptor-like factor 3 
XM_003126363 0,00161013 -2.90153 IRAK3 interleukin-1 receptor-associated ki-
nase 3 
ENSSSCT00000016459 0.00582636 -2.75137 CD3D CD3d molecule, delta 
XM_003129890 0.00377234 -2.66011 IL10RA interleukin 10 receptor, alpha 
ENSSSCT00000013540 0.0155517 -2.49305 IGBP1 immunoglobulin (CD79A) binding pro-
tein 1 
NM_001048232 0.0259389 -2.46097 NFKB1 nuclear factor of kappa light polypep-
tide gene enhancer in B-c 
ENSSSCT00000024755 0.000202203 -2.42365 LENG8 leukocyte receptor cluster (LRC) mem-
ber 8 
ENSSSCT00000015702 0.00231107 -2.30989 IK IK cytokine, down-regulator of HLA II 
NM_001112693 0-00321754 -2.292 IRAK4 interleukin-1 receptor-associated ki-
nase 4 
AK231542 0.00873764 -2.22825 BLNK B-cell linker 
NM_001243576 0.0193156 -2.13877 BTK Bruton agammaglobulinemia tyrosine 
kinase 
AK239409 0.00580027 -2.13603 LCP1 lymphocyte cytosolic protein 1 
NM_001131046 0.0343936 -2.01055 IFI30 interferon, gamma-inducible protein 30 
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5 Discussion 
Over the last few years hemotrophic mycoplasmas (HM) have become more important for 
animals as well as for humans. HMs in pigs trigger infectious anemia, characterized by life-
long agent persistence and immune modulation including autoimmunity. These pathogenic 
routes lead to disease patterns with high economic impact especially in feeder pigs. Our 
knowledge about the basic pathomechanisms of M. suis is rather limited, particularly due to 
the uncultivability in vitro. Moreover, M. suis is capable to adapt to several host entities and life 
conditions. To understand the mechanisms responsible for all these characteristics of M. suis 
studies on the transcriptome and on the crosstalk between the pathogen and the host were 
performed. The studies will offer new insights into the life-style of M. suis and could be precur-
sors for novel therapeutic and prophylactic approaches but also for the establishment of in vitro 
culture systems. 
For the current study, splenectomized pigs were infected with M. suis strain KI_3806 contam-
inated blood. During an infection course blood samples were taken pre infection (day -2) as 
well as on day 2, 4, and 8 post infection. Pigs showed clinical signs of an acute IAP with fever, 
lethargy, remarkably reduced feed intake, skin pale, and ear cyanosis from day 4 on. All pigs 
indicated hypoglycemia and showed a massive anemia with strongly decreased RBC counts 
as well as decreased hemoglobin and hematocrit values. The acute infection was detected by 
qRT-PCR on day 4 at the latest. With these three prime examples of pigs infected with the 
highly virulent strain, we were able to demonstrate the altered gene expression profiles of M. 
suis and the pigs comparing them to non-infected animals. 
The lack of an in vitro cultivation system for HM characterizes a crucial barrier of the analyses 
of pathogeneses and immunology features of M. suis. Moreover, the mechanisms of adhesion 
and replication on the red blood cells as wells as the metabolic exchange between HM and the 
erythrocytes are still unclear (Hoelzle et al. 2008). Cultivation tests with infected blood and 
classical Mycoplasmas media showed no growth effect, only densely-packed microcolonies of 
small M. suis cells indicating nanotransformation (Schreiner et al., 2012a). On these grounds 
it is so important to look deeper into the transcriptome of M. suis and into the transcriptomic 
changea during an infection with M. suis.  
This study provides the first comprehensive transcriptomic profile and gene transcript level 
analysis of the hemotrophic M. suis strain KI_3806 during acute experimental infection of pigs. 
Subsequent connection of the transcriptomic results to bioinformatical analyses of expressed 
hypothetical proteins with unknown functions served as a source of a better knowledge on the 
M. suis pathobiology and features. Whole blood was used for RNA isolation. Blood is consid-
ered as an informative target tissue that contains the different immune cells that circulate in 
the whole body (Mach et al., 2013). Moreover, blood transcriptome profiling is an effective 
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molecular tactic to identify potential biomarkers and biological pathways during infections. For 
M. suis with its blood habitat this auspicious approach is particularly fit to develop a complete 
picture of the host response in IAP. Our analysis revealed several thousand genes differentially 
expressed during acute IAP and numerous altered pathways and cellular processes through-
out the course of host response to acute M. suis infections, thus facilitating a better under-
standing of the IAP pathogenesis. 
5.1 RNA-Seq 
Transcriptional analysis has played an important role for revealing gene expression. RNA-Se-
quencing is a powerful instrument for transcriptome profiling, which uses deep sequencing to 
directly control cDNA sequences (Wang et al., 2013; Siqueira e al., 2014; Siewert et al., 2014; 
Casey et al., 2015). Here, we describe the results of an in vivo RNA-Seq study of the transcrip-
tome of M. suis during an infection. Therefore three splenectomized pigs were experimentally 
infected with the invasive M. suis strain KI_3806. Blood was taken across a time course to 
investigate the transcriptomic profile of M. suis for better understanding the pathogenesis of 
this organism. Total RNA of three individual biological replicates were sequenced generating 
million high quality reads, which were mapped on the pigs and the M. suis genome. In the 
current study only the M. suis transcriptome were analyzed by RNA-Seq. On day 4 M. suis 
transcripts seem to be overlapped by porcine transcripts, on day 8 p.i. the majority of reads 
could be assigned to the M. suis genome As expected, the fraction of total reads mapping to 
M. suis genome from the mixed host-bacteria read pool increased at day 8 post infection.. On 
day 8 almost all genes were found to be transcribed, whereas on day 4 still 95% of the CDS 
seems to be transcribed. Overall, our results showed that the majority of genes were tran-
scribed, demonstrating a whole basal-level expression profile for M. suis. These findings are 
in concordance with Siqueira et al., 2013.  
A critical step of this study was to extract the total RNA of the porcine blood, because we could 
not distinguish between the eukaryotic swine and the prokaryotic M. suis RNA. To map the 
reads on the right genome sequence the two profiles of the host and bacteria were generated 
after a physical rRNA removal step before cDNA library construction. rRNA removal is a critical 
step for RNA-technology. The removal of rRNA reduces the coverage of mapped results and 
decreases the sequencing depth (Wang et al., 2013).  
We found 71 DE genes between day 4 and 8 p.i., among which, 51 were down-regulated and 
22 were up-regulated comparing the two days. For verifying some of these DE genes a qRT-
PCR analysis were performed. Therefore we analyzed the expression profiles of 10 hypothet-
ical genes (5 from up-regulated genes, 5 from down-regulated) plus the house keeping genes 
msg1, hspA1 and enolase. It was found that the expression patterns of qRT-PCR of 11 DE 
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genes were consistent with those of RNA-Seq, while the other 2 DE genes were not. The 
results of qRT-PCR and RNA-Seq matched in 84.6%. However not all changes in RNA-Seq 
data could be confirmed by qRT-PCR. The mismatches could be explained by using different 
samples in qRT-PCR from that in RNA-Seq and due to the variations between biological rep-
licates. 
The changes in bacterial transcriptome over a time course of infection in porcine erythrocytes 
offer an opportunity to demonstrate biological implications based on differential expression 
patterns and to compare these with known aspects of M. suis biology and pathogeneses as-
pects. Thus, RNA-Seq technology is a powerful tool and offers many possible applications for 
different questions in research. Using this method has already clarified some complexities of 
eukaryotic and prokaryotic transcriptomes. 
There are different studies where transcriptome analysis and the differences between tran-
scriptome levels were performed in vitro or in cell culture systems (Wang et al., Abromaitis et 
al., 2013; Houston-Ludlam et al., 2016, Li et al., 2016). In other studies transcriptomic analysis 
were performed by using skin models. Poynter et al. (2016) monitored an artificial infection of 
an ex-vivo skin model with Exophiala dermatitidis showing changes in transcription strongly 
affect pathways related to nutrients acquisition, energy metabolism, cell wall, morphological 
switch, and known virulence factors. Obviously there are differences in the transcriptome of in 
vivo and in vitro studies in identified differentially expressed genes (Puri et al., 2016). Moreo-
ver, it is likely that organ-specific host-pathogen interactions can occur and contribute to dif-
ferent infection courses. Therefore, Hebecker et al. (2016) performed a time-course transcrip-
tional analysis of liver, spleen, and kidney samples from mice infected intravenously with Can-
dida albicans revealing a delayed immune response in the kidney compared to liver and spleen 
and qualitative differences in the responses of these organs. 
Pettigrew et al. (2014) compares the Streptococcus pneumoniae transcriptome in biofilms re-
sulted in the upregulation of genes involved in carbohydrate metabolism and the data demon-
strate complex changes in the pneumococcal transcriptome in response to influenza A virus 
induced changes in the environment. But there are less studies which investigate parallel tran-
scriptomic changes in host and pathogen in vivo during an infection. Christensen et al. (2016) 
for example analyzed host and parasite gene expression in skin biopsies from Leishmania 
braziliensis-infected patients.  
Transcriptional changes and different gene expression levels are evident for understanding 
pathogenicity of life-threatening M. suis infections. Due to their uncultivability in vitro we are 
not able to perform the transcriptome analysis by cell culture, but we had the opportunity to 
analyze the blood transcriptome of M. suis during an infection. By applying RNA sequencing 
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technology to blood samples, we were able to capture in detail the transcriptomes simultane-
ously from the bacteria and the host during a M. suis infection.  
5.1.1 Hypothetical genes 
Almost 70% of the M. suis genome consists of hypothetical genes with unknown function (Oeh-
lerking et al., 2011). It was remarkable that many of the DE genes and RPKM genes were also 
genes with unknown function encoding for hypothetical proteins. Hypothetical proteins or pu-
tative conserved proteins show limited correlation to known annotated proteins. They are not 
functionally characterized or described biochemically and physiologically (Hawkins and Kihara, 
2007; Galperin and Koonin, 2004). We assume, that these class of genes have their own im-
portant function to complete genomic information. M. suis varies from other mycoplasmas by 
its high portion of hypothetical proteins, M. suis strain Illinois harbors 65.3% and strain KI_3806 
65.9% of the genes encode hypothetical proteins. All differences between the both M. suis 
genomes are found in the regions of hypothetical proteins. This could be evidence for ex-
changeable regions, which have no important role within the genome. Another assumption is 
that they are required for genome stability (Felder et al., 2012).  
Within the genes with the highest RPKM (on day 4 p.i.) and within the DE genes two hypothet-
ical genes (MSUIS_02610, MSUIS_06750) encoding for a membrane protein were found. 
Membrane proteins are often involved in transport systems between the bacteria and the host. 
Transport proteins play a pivotal role in cellular metabolism, as well as in virulence and intra-
cellular survival of pathogens (Shahbaaz et al., 2013; Freeman et al., 2013). Moreover, mem-
brane proteins are considered as possible vaccine targets.(Vetrivel et al., 2011). In the ab-
sence of any experimental information about the hypothetical proteins localizations, the varie-
ties of sub-cellular localization prediction tools such as PSLpred (Bhasin et al., 2005), PSORTb 
(Yu et al., 2010) and LocTree3 (Goldberg et al., 2012) can be used. 
5.1.2 DE genes 
Within the DE genes a putative competence protein was found encoded by gene 
MSUIS_04560. Many bacteria have the ability to bind and to take up exogenous DNA from its 
environment -called competence- resulting in horizontal gene transfer (Solomon and Gross-
man, 1996; Stewart and Carlson, 1986). Gene transfer could be one option for antibiotic re-
sistance among pathogens (Davies, 1994). Horizontal gene transfer was already observed 
between M. synoviae and M. gallisepticum (Vasconcelos et al., 2005). The molecular mecha-
nism by which mycoplasmas are able to transfer genes is unknown, but this could be an indi-
cation for M. suis transferring genes between other mycoplasmas or between bacteria and the 
hosts. The usage of this mechanism could be the adaption into a novel environment, e.g. blood 
(Guimaraes et al., 2014). In some species, a lot of horizontally transferred genes date back to 
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phage-, plasmid- or transposon-related sequences. In E. coli for example a significant number 
of genes found in the chromosomes associated with mobile DNA fragments from other species 
(Lawrence and Ochman, 1998).  
The subcellular localization and physiochemical factors prediction are useful for differentiation 
of genes, but we did not find enough evidences for functional prediction of all hypothetical 
genes and so further analyses were evident. Nevertheless, with our analyses we demonstrated 
due to the expression of more than 70% of hypothetical genes, that these genes play a signif-
icant role in the host-pathogen interaction and can be utilized to get more information about 
the organism´s pathogenesis. 
5.1.3 Association between expression level and gene function 
To test for the association between expression level and gene function 30 genes of the CDS 
with the highest RPKM from every animal were selected. Deduced genes were assigned to 
COG categories. One of those genes (crr) belongs to the “carbohydrate transport and metab-
olism” COG.  It is known with the rapid rise of bacteremia of M. suis, the in vitro glucose con-
sumption increases resulting in hypoglycemia (Heinritzi et al., 1984; Smith et al., 1990; Nonaka 
et al., 1996). Moreover, a study of Felder et al. (2012) identified all enzymes necessary for 
glucose uptake via the phosphotransferase system and glycolysis, whereas genes encoding 
enzymes of the pentose phosphate pathway are absent in the M. suis genome. In this study, 
some genes encoding for carbohydrate transport and metabolism were under the genes with 
the highest RPKM. Crr encodes for a protein involved in the PTS-system, which catalyzes the 
phosphorylation of incoming sugar substrates concomitantly with their translocation across the 
cell membrane. Another gene found under the DE genes is the enolase which is immunogenic 
and surface localized and could act as an adhesion factor in M. suis (Schreiner et al., 2011). 
Together with many other genes, pfkA, which catalyzes the phosphorylation of D-fructose 6-
phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis, or pykF, 
gpmI and tpiA, which are also involved in glycolysis, were up-regulated during infection. In 
addition, ldh encodes for the protein, which is involved in step 1 of the sub-pathway that syn-
thesizes (S)-lactate from pyruvate. Glycolysis ends with the production of pyruvate. That funds 
lactate is consumed by glycolysis and RNA-Seq confirmed that ldh was up-regulated during 
infection. Furthermore, msg1 similar to glyceraldehyde-3-phosphate-dehydrogenase 
(GAPDH) was up-regulated. Msg1 was identified as adhesion factor with functional properties 
similar to bacterial GAPDHs (Hoelzle et al., 2007b). All these results ratifies that M. suis is able 
to take up glucose from its host and to transport glucose through its membrane.  
Genes involved in transcription are himA, RNA polymerases rpoA and rpoBC, and rnr, which 
is an important participant in mRNA decay (Cheng and Deutscher, 2005). All four genes were 
up-regulated showing that transcription of bacteria at day 4 p.i. is still active. But only one gene, 
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involved in translation, belongs to the 30 genes with the highest RPKM – hspA1. The DnaK-
like protein of M. suis shows ATPase activity and antigenicity in experimentally infected pigs 
(Hoelzle et al., 2007a). Beneath these pathways, nucleotide transport and metabolism pathway 
was represented. A key enzyme in purine salvage pathways (IMP dehydrogenase, GuaB) en-
coded by the guaB gene (Jewett et al., 2009) and the upp gene that encodes for a uracil phos-
phoribosyltransferase were detected. Both genes were up-regulated. We also found ribosomal 
genes or called pseudogenes. Present knowledge of the origin of new genes includes infor-
mation regarding both protein-coding genes and RNA genes. These genes were transcribed, 
but only protein-coding genes were translated into proteins (Chandrasekaran and Betrán, 
2008). 
On both days genes encoding for carbohydrate transport and metabolism were identified. An-
other gene (ptsH) involved in the PTS-system was up-regulated. PtsH encodes for the Phos-
phocarrier protein HPr and is an essential phosphoryl transfer protein in the sugar-transporting 
PTS (Postma et al., 1993). This is one more indication for taking up sugars from the host even 
at the late phase of an infection with M. suis. For nucleotide transport and metabolism two 
other genes were found - MSUIS_02950 encodes for glutamine amidotransferase-domain pro-
tein and nrdI encoding for Ribonucleoprotein. Additionally, a different pathway calling inorganic 
transport and metabolism was found at day 8 post infection. Therefore, a gene encoding for 
inorganic pyrophosphatases (ppa), that catalyzes the hydrolysis of inorganic pyrophosphate 
(PPi) into inorganic phosphate (Pi), was detected. Interestingly, the activity of the enzyme is 
dependent on Mg2+ ions (Hoelzle et al., 2010). This suggests that M. suis needs to absorb 
magnesium from the host. 
5.1.4 M. suis- host interaction 
The bacterial Sec-dependent secretion system was confirmed by different expressed genes, 
like the signal recognition particle protein (ffh), the cell division protein (ftsy), and the two pre-
protein translocase subunits secE and secY. In addition, the gene encoding the ATPase sub-
unit SecA was also expressed. This system functions in the transports of secretory proteins 
across the inner membrane and inserts membrane proteins into the inner membrane of gram-
negative bacteria (Kudva et al., 2013). Furthermore, we found the gene encoding for the mem-
brane protein OxaA required for the insertion of integral inner membrane proteins and involved 
in the Sec translocase complex (Scotti et al., 2000). 
5.1.5 Expressed genes involved in transport 
In general, mycoplasmas have less transport systems than other bacteria, but they are de-
pendent on transporters to obtain metabolites and vitamins (Felder et al., 2012). M. suis as a 
highly adapted bacteria is also depending on its host to absorb essential metabolites. M. suis 
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encodes only for a few metabolite transporter, suggesting that they might have extensive sub-
strate specificity and that some CDS, not identified so far, may function as transport molecules 
through to the membrane. This could support the hypothesis that some of the hypothetical 
genes encoding for a membrane protein, are involved in nutrient scavenging or transport sys-
tems (Guimareas et al., 2011). To date, it is well known M. suis uses glucose as the main 
energy source. Thus, it is important step to clarify some of those transporters especially due 
to the establishment of an in vitro cultivation system (Dietz et al., 2015). 
Expressed genes encoding subunits of the ABC-type transporters for ferrichrome, phosphate 
(pst), spermidine/putrescine transport (potA, potB, potC, potD) and an ECF-transporter (cbiO1, 
cbiO2) with interchangeable s-Binding proteins potentially one for folate were identified. Fur-
thermore, transporters for magnesium (mgtE), potassium (trk) were expressed. Carbohydrate 
uptake is indicated by the expressed MFS-transporter and the PTS-system (ptsG, ptsH, ptsI). 
5.1.6 Expressed genes involved in defense mechanisms and phase variation 
It is known that M. suis can avoid the immune system. One more indication for avoiding the 
immune system was shown by RNA-Seq analyses. We suggest that M. suis has the oppor-
tunity to phase variation by using recombinases. Furthermore, we found a putative compe-
tence protein in the genome of M. suis, that is required for genetic transformation, for example 
in Streptococcus pneumonia (Desai and Morrison, 2007). The reduced genome of Mycoplas-
mas supports the assumption for the ability having mobile elements in their genomes, like 
retrotransposons. Hence, this opportunity could also explain the fact that the bacteria can 
evade the immune system of their hosts and sometimes not detectable via PCR analysis. 
Mechanisms like phase variation were used by pathogens to overcome immune pressure and 
to deal with rapidly varying environments (van der Woude and Baumler, 2004). Mycoplasmas 
possess a number of systems to change their surfaces including DNA slippage, site-specific 
recombination or antigenic variation like in M. synoviae (Citti et al., 2010) and many mycoplas-
mas have the ability to phase variation (Burgos and Totten, 2014; Algire et al., 2012; Chopra‐
Dewasthaly et al., 2012; Zimmermann et al., 2012). M.bovis, M.pulmonis and M.agalactiae 
developed a system, which uses a site-specific recombinase that identifies a specific DNA 
sequence as a target for rearrangement events (Lysnyansky et al., 1999; Shen et al., 2000; 
Glew et al., 2002). And an additional study showed M. penetrans has the ability to change its 
surface lipoprotein profiles frequently using a recombinase that catalyzes inversions of the mpl 
gene promoters (Horino et al., 2009). For M. suis we identified two different recombinase, a 
MSUIS_03130, probable YqaJ family viral recombinase and a recA. RecA recombinase sug-
gests that M. suis undergoes phase variation through recombination. 
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Transcriptome as well as proteome data support the expression of Restriction modification 
(RM) systems, which are cytoplasmic gene products that can also be modulated by phase 
variation (Algire et al., 2012). Expression of different genes, belonging to the RM system, like 
hsdM, hsdR, hsdS, hsdS_2, MSUIS_07470 and MSUIS_02240 were confirmed. RM systems 
were used by bacteria to protect themselves from foreign DNA with the help of two different 
enzymatic activities (Wilson and Murray, 1991; Raleigh and Brooks, 1998; Algire et al., 2012). 
First, a restriction endonuclease cutting DNA at a specific recognition site is necessary. There-
fore, two specific genes encoded for restriction endonucleases were found (MSUIS_07590, 
apn1). And second, expression of methyltransferases (mstyD4I, rsmA, trmD) preventing de-
struction of bacteria’s own DNA by the restriction endonucleases and marking its own DNA by 
adding methyl groups were indicated (Dryden et al., 2001). A Type III RM system was also 
identified in M. mycoides subsp. capri (Algire et al., 2012). So bacteria could use phase varia-
tion to evade the host immune response. 
Beside the RM system M. suis expresses an abortive infection family protein (MSUIS_02970), 
which belongs to the ABI-system. ABI-systems avoid phage multiplication and promote bacte-
rial cell death during phage infection (Fineran et al., 2009). Moreover, M. suis expresses genes 
with functional similarities to phage tail measure proteins (MSUIS_00360, MSUIS_01380), that 
function in the injection of DNA into the host cell during early infection (Belcaid et al., 2011). 
This could also facilitate some bacteria to overcome the host defense, like Neisseria gonor-
rhoeae. The pili of Neisseria gonorrhoeae is able to change its genetic material, called pilin 
switching, when attacking the host cells, then resulting in evading the immune system (Seifert 
et al., 1988). 
5.1.7 Expressed genes involved in horizontal gene transfer (HGT)/ replication, 
recombination and repair 
Another mechanism used by M. suis is the SOS-response to DNA damage mediated by the 
products of recA and lexA genes (Kalderon et al., 2014). For this repair-system the following 
genes were found in the genome of M. suis: recombinase A (recA), recombinase U (recU), 
helicase complex (ruvA, ruvB), 5'-3' exonuclease (polA) and DNA-helicase (uvrD), but we 
didn´t find any other homologs of known regulators of the bacterial SOS-system (LexA, Butala 
et al., 2009) in the analyzed genome of M. suis. Rickettsiae and the Mycoplasmataceae have 
lost their own lexA genes due to the selective pressure towards genomic reduction (Mertens 
et al., 2005; Renesto et al., 2005). This suggests that part of the RecA-LexA complex can be 
sometimes replaced by adapting other stress-sensitive regulatory networks (Erill et al., 2007). 
With the existing genes M. suis seems to be well furnished to prevent DNA damage. However, 
a study of Burgos et al. (2012) concludes that recA has a preferential role in recombination 
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leading to phase variation, but less in DNA repair. By inactivation of recA in M. genitalium 
almost no effect on survival after exposure to mitomycin C and UV irradiation was detected. 
Mycoplasmas are characterized by their minimal genomes. The question is, whether these 
genomes have mobile elements that serve as sources of genetic viability (Loreto et al., 2007). 
Interestingly, a gene (MSUIS_02340) similar to retrotransposon peptidase family protein could 
be expressed. This retrotransposon could be similar to LTR-retrotransposons. Wu et al. (2004) 
described the existence of retrotransposon-like elements in the genome of Wolbachia pipientis 
wMel. This indicates that this class of retrotransposons may also occur in bacteria. Retrotrans-
posons has transposable elements within the genome and uses RNA. For transposition re-
trotransposons require a protease, a reverse transcriptase, an RNase H and an integrase - 
except of reverse transcriptase all of them could be detected by RNA-seq on as well as by 
proteome analyses (lon, MSUIS_03000, MSUIS_01320, MSUIS_00980). Although mycoplas-
mas possess reduced genomes, it looks like they have mobile elements, perhaps as a mech-
anism for genetic variability. 
5.1.8 Operons 
We predicted 794 operons throughout the whole M. suis genome. Operons are important in 
bacterial genomes due to transcription of adjoining genes (Wang et al., 2013). Only a few 
operons are conserved in most of the bacterial genomes, like the ribosomal protein operons 
(Huynen and Snel, 2000; Wolf et al., 2001). In the present study MSUIS_813447 operon in-
cludes 21 ribosomal genes in our M. suis genome. 
A large number of predictions were for translation-related and replication/repair-related func-
tions, presumably because operons coding for components of these systems show greater 
evolutionary conservation than those coding for other types of cellular functions (Wolf et al., 
2001). 
Interestingly one of our highly expressed hypothetical genes (MSUIS_06590) belongs together 
with the enolase and two other genes (pfkA and pykF), fitting to the glycolysis pathway, to the 
same operon. The α-enolase is presumably involved in the adhesion of M. suis to porcine red 
blood cells (Schreiner et al., 2012). Another hypothetical gene (MSUIS_00560) belongs to-
gether with the tpiA gene to operon 813364. MSUIS_00560 is predicted for a member of mem-
brane proteins and tpiA encodes for a protein that is involved in the gluconeogenesis pathway 
and synthesizes D-glyceraldehyde 3-phosphate from glycerone phosphate. This hypothetical 
membrane protein could be involved into the glucose uptake from the host (Guimares et al., 
2011; Hoelzle et al., 2014).  
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All together this is the first study using a pig model for transcriptomic analyses of M. suis strain 
KI_3806 during an infection course. Simultaneous host and parasite expression over an infec-
tion course provides new insights into the biology and pathogeneses of M. suis infection and 
therefore serves as a new approach for cultivating of M. suis and for new vaccine strategies. 
Our data showed that on different time points of infection, genes encoding for proteins with 
unknown function were the largest group of genes found, indicating that those hypothetical 
genes play a major role during an infection. Moreover, mechanisms like “Carbohydrate 
transport and metabolism”, “transcription”, “translation”, “DNA, replication, recombination and 
repair”, and “Energy metabolism” dominate the days during infection, demonstrating the glu-
cose uptake from the host and probably that M. suis is still proliferating at the end of an infec-
tion. 
5.2 Microarrays 
Blood transcriptome has become known as a useful and practical tool for exploring the immune 
system in health and disease (Chaussabel, 2015). To date, there have been less reports in-
vestigating the whole blood transcriptome of pigs’ immune response (Tuggle et al, 2011; Mach 
et al., 2013) on different pathogens. This is the first study using Affymetrix GeneChip Porcine 
Genome Array to investigate the transcriptional response to M. suis infection by comparing the 
gene expression profiles of whole blood sampled from pigs before and during an infection. A 
GeneChip Porcine Genome Array is a very powerful instrument to detect host transcriptional 
defense against bacteria pathogens (Wang et al., 2007). 
The present data aimed to identify genes involved in the immune response against M. suis. By 
generating a complex transcriptomic profile during different infection time points of M. suis in 
the host cells, we wanted to get more information about the underlaying molecular interactions 
and signaling pathways in the M. suis infection process. 
Our results showed that using microarray technology expression of more than 7000 DE genes 
from infected pigs were reproducibly detected in this analysis. On the basis of IPA, several 
genes were found belonging to a variety of functional categories and signal pathways, includ-
ing genes for T and B cell receptor response, NF-kB and IL-12 signaling response, and others 
involved in the cytokine-cytokine receptor interaction signaling pathways. These findings show 
that the expressed transcripts in this study characterize a great section of the porcine genomic 
response to M. suis infection within pigs blood. 
5.2.1 Biological function and cluster analysis 
The 23,256 transcripts on the porcine GeneChip have not been fully annotated because of 
limited availability of full-length porcine cDNA and many human or mouse genes do not have 
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functional annotation (Wang et al., 2007). Gene clusters generated by grouping genes of sim-
ilar expression patterns can help to create gene networks, which show the regulatory mecha-
nisms of involved genes. 
In this study, IPA cluster analysis were performed for each time point of infection. 500 subclus-
ters were identified for each day. On day 2 p.i., many genes in these clusters were annotated 
with immune and inflammatory response, which is a main indicator of immune response during 
infection. One of the characeristics of the early host response to infection we observed, is the 
domination of many genes that are involved in inflammatory response. This might be evidence 
that M. suis suppresses the inflammation of the host at an early stage of infection. However, 
genes annotated with immune response are clearly involved in the humoral immune response, 
what is presented in the increased “B cell quantity”. Another evidence for activation of the 
humoral immune system is the subcluster with a high z-score for “response of liver”. 
Furthermore, there is a distinct increase in glucose/carbohydrate metabolism, indicating that 
the host tries to compensate the blood glucose levels absorbed by M. suis (Heinritzi et al., 
1990; Simth et al., 1990). Future analysis of genes involved in this metabolism may help to 
better understand the early host response into cellular processes. 
The increasing z-score on day 4 p.i. for “apoptosis of leukemia cells” and the decreasing z-
score for “cell viability” of these cells supports the assumption of Zachary and Smith (1985) 
that M. suis suppresses the T cell blastogenic response. “Quantity of B lymphocytes and IgG 
antibodies” had an increased expression pattern verifying the activation of B cells and IgGs 
during an infection.  
Sokoli et al. (2013) revealed that M. suis infections can cause endothelial cell damage. An 
evidence for these alterations showed the increased expression of the “apoptosis of endothe-
lial cells” on day 4 post infection. Another cluster, which was activated at this stage of infection 
was the “hematological system and development”. Herfore, the “quantity of blood cells” raised, 
while the “activation and differentiation of blood cells and platelets” dropped indicating a de-
velopment of an anemia. One reason for the activation of the “aggregation of blood cells”, could 
be the blood withdrawal that was taken every second day. This could also be an explanation 
for the increased expression of Ca2+ ions, which were involved in blood coagulation. Addition-
ally, inflammation response was still suppressed on day 4 p.i. 
At the end of infection, when pigs were euthanized, it is reproducible immune system of pigs 
doesn’t work properly and B and T cell production, such as antibody response decreased at 
this time point. But another explanation for the decreased clusters could be the massive bac-
teremia that let the pigs no chance to resist against the Mycoplasmas. Moreover, this fact 
resulted in severe anemia (Zachary and Basgall, 1985; Messick, 2004), which was demon-
strated by the increasing subcluster of “anemia”. At the end apoptosis rate increased over time, 
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(day 2 p.i. z-score: -1.751, day 4 p.i. z-score: -1.335, day 8 p.i. z-score: 0,925) indicating that 
apoptosis is activated. 
5.2.2 Anemia 
M. suis is known for target RBCs of a wide range of mammalian species (Neimark et al., 2001; 
Hoelzle, 2008) and its resulting disease as IAP (Hoelzle et al., 2014 review). Anemia can cause 
eryptosis. Eryptosis is a physiological mechanism eliminating defective erythrocytes in order 
to prevent hemolysis and subsequent release of hemoglobin into circulating blood (Lang and 
Lang, 2015). Moreover, eryptosis is characterized by cell shrinkage, membrane blebbing and 
cell membrane phospholipid scrambling (Foeller et al., 2009; Lang et al., 2008). Excessive 
eryptosis again causes anemia as soon as eryptotic erythrocytes are cleared from circulating 
blood (Foeller et al., 2008; Foeller et al., 2009; Lang et al., 2012; Lang et al., 2015). Evidence 
for eryptose is an increase in cytosolic Ca2+ activity (Calabro et al., 2014; Bissinger et al., 
2014). In our study, calcium signaling-related transcripts were up-regulated including Ca2+ 
transporting ATPases (atp2b2, atp2b4), Calsarcin 1 (LOC733663), Calmodulin dependent pro-
tein kinase (LOC100626014), calbindin 1 (calb1), lipocalin 9 (lcn9), two calcium binding pro-
teins (s100a7, cabp7) and anoctamin 1 (ano1) on day 8 post infection. Increased cytosolic 
Ca2+ activity stimulates caspases and calpain leading to degradation of the cytoskeleton by 
eryptosis (Lang et al., 2014; Pant et al., 1983). Moreover, some other transcripts involved in 
the signaling pathway of eryptosis are kinases. Eryptosis is regulated by AMP-activated ki-
nase, cGMP-dependent protein kinase, Janus-activated kinase 3, casein kinase 1α, p38 ki-
nase, and p21-activated kinase 2 (Lang et al., 2014). There is evidence that a number of tran-
scripts encoding genes for these kinases were down-regulated (jak2, ampk, cgmp, csnk1a1, 
pak2, pak7). 
5.2.3 Oxidative stress causes apoptosis and inflammation 
Oxidative stress is defined as the imbalance between the production of reactive oxygen spe-
cies (ROS) and antioxidant defenses (Wong et al., 2015). By using RNA microarray analyses, 
specific gene expression patterns associated with oxidative stress were detected, e.g. apop-
tosis and inflammation. It is recognized that viral and bacterial infections induce oxidative 
stress in the infected host (Aiyaz et al., 2014; Peterhans, 1997; Schwarz, 1996). The role of 
oxidative stress in pigs is described for weaning (Tanghe et al., 2014), high density housing 
(Marco-Ramell et al., 2011) and for different infectious diseases responsible for pneumonia, 
enteritis and sepsis (Lykkesfeldt and Svendsen, 2007). Moreover, there are also some studies 
showing Mycoplasmas induces oxidative stress (Schott et al., 2014; Bai et al., 2013). Oxidative 
stress plays also a special role in the present study on response to M. suis infections in pigs. 
Genes, involved in the antioxidant system, were detected on day 8 post infection. For example, 
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Glutathione S-transferase A2 (gsta2) was significantly up-regulated. This enzyme has multiple 
roles in xenobiotics metabolism, drug biotransformation, and protection against peroxidative 
damage (Hayes and Strange, 1995). Another important enzyme protecting cells from oxidative 
damage is catalase (cat) (Chelikani et al., 2004), which was significantly down-regulated. Fur-
thermore, a myeloperoxidase (mpo, up-regulated) was found considered to reflect the strength 
of oxidative stress (Wei et al., 2004). These three enzymes are involved in cellular antioxidants 
and are markers for oxidative stress (Ambrosone et al., 2005; Michiels et al., 1994). A transcript 
encoding a stress-response protein was also significantly down-regulated. This hypoxia induc-
ible factor (hif1a) is regulated by prolyl hydroxylases leading to ubiquitination and proteasomal 
degradation (Wang et al., 2014). Heat shock proteins (encoded by genes hspa14 and dnajc19), 
which stabilize and repair damaged protein structures, were up-regulated on day 4 p.i, and on 
day 8 p.i. (dnajc5b), respectively (De Maio, 1999). The transcription factor tumor-suppressor 
protein p53 (tp53) was significantly up-regulated on day 4 p.i. P53 plays an important role in 
the cells’ response to genotoxic stress, can block the progression of the cell cycle and initiates 
DNA repair and apoptosis (Burns and El-Deiry, 1999; Vogelstein and Kinzler, 1992; Bennett 
et al., 1998). There is also evidence for transcripts involved in DNA recombination and repair. 
Rad51, which is homolog to bacteria’s protein recA, was significantly up-regulated on day 8 
p.i. (Galkin et al., 2006). Organisms are exposed to ROS. ROS can cause crucial damage to 
DNA, proteins or lipids, when occur at high and/or sustained levels. So, organisms developed 
several defense mechanisms against it. Sometimes these defense mechanisms are not ade-
quate, resulting in oxidative stress and then in apoptosis as a protective mechanism (Martin-
dale and Holbrook, 2002). There are also some transcripts, which only function in the positive 
regulation of apoptosis. Apoptosis regulates the homeostatic balance between cell proliferation 
and cell death for development and maintenance of multicellular organisms. 39 genes and 146 
genes, known to be involved in apoptosis, were up-regulated on day 4 and 8 after M. suis 
infection. Apoptosis antagonizing transcription factor (aatf) and programmed cell death protein 
4 (pdcd4), which both were involved in apoptosis, were up-regulated on day 4 post infection. 
However, on day 8 p.i., we found different sequence homologies to the well characterized acid 
sphingomyelinase (smpdl3a, asah2, sgms2), which is a key signaling molecule in several 
apoptotic and stress-related pathways (Traini et al., 2014 in: Zeidan and Hannun, 2010). Bcl2-
associated athanogene 3 (bag3) that functions in anti-apoptotic activity mediated as a co-chap-
erone in protein delivery to the proteasome (Rosati et al., 2007; Rosati et al., 2011), was sig-
nificantly up-regulated on day 8 p.i. These data suggest that M. suis infected pigs induced pro-
apoptotic stress response mechanisms by producing oxidative stress. 
In addition, microscopic analysis of the vascular endothelium showed alterations on the sur-
face of the vessels of M. suis infected pigs. These alterations result in development of hemor-
rhage and organ failure (Sokoli et al., 2013). However, whether oxidative stress occurs on M. 
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suis infected endothelial cells in pigs it is still unknown. Oxidative stress can alter cellular func-
tion, receptor signals and immune responses and during an infection it can even cause pro-
gressive endothelial damage through growth and migration of vascular smooth muscle, inflam-
matory cells, alteration of extracellular matrix, apoptosis of endothelial cells, activation of tran-
scription factors (NF-κB), over-expression of inflammatory cytokines and through adhesion 
molecules (icam3, amica1) (Urso and Caimi, 2011). Activation of endothelial cells functions in 
expression of pro-inflammatory genes and in the canonical NF-κB pathway (Collins et al., 
1995). The profile of cytokines produced by M. suis indicates that the bacterium induces the 
production of inflammatory cytokines, i.e., IL-1, IL-6 and IL-17 and IL-10. IL-1β and IL-6, both 
pro-inflammatory cytokines, were up-regulated on day 8 p.i. and IL-10RA, a receptor of IL-10, 
were down-regulated on day 8 p.i., respectively. IL-10 plays a central role in suppressing im-
mune function by blocking the synthesis of pro-inflammatory cytokines (e.g., IL-1, IL-6, IFN-γ, 
and TNF-α) in T cells, monocytes, and macrophages (Josephson et al., 2001). These finding 
suggest that M. suis induces the production of pro-inflammatory cytokines. Furthermore, acti-
vation of NF-kB determines cellular survival or apoptosis (Garg and Aggarwall, 2002). Six key 
members of NF-κB family (flt1, ntrk2, bmpr1b, kdr, pik3c2g, tnfrsf11b) were up-regulated in 
infected pigs. Moreover, we supposed that expression of cell adhesion molecules (CAM) are 
stimulated by oxidative stress. It is often described that oxidative stress stimulates NFκB-in-
duced CAMs expression (Heidland et al., 2001; Sarada et al., 2008). There was also an ex-
pression of the adhesion molecules amica1 and icam3, which were both down-regulated on 
day 8 p.i. Another regulator for oxidative stress, which is highly expressed in liver, is Vanin-1 
(vnn1) and its antagonism peroxisome proliferator-activated receptor-γ (pparg) (Jansen et al., 
2009). Vnn1 is an epithelial sensor of stress that controls immune response in mouse tissues, 
but vnn1 deficiency has been reported to be protective for intestinal inflammation (Berruyer et 
al., 2006). Vnn2 is known to be involved in inflammation and leukocyte migration (Sayasith et 
al., 2013). In this study, vnn1 and vnn2 were almost down-regulated 20-fold, while transcript 
of pparg was up-regulated. For this, there is the option that M. suis regulates the oxidative 
stress response and therefore down-regulates some genes involved in oxidative stress. And 
last but not least there is a complex antioxidant system against ROS to protect cells and tissues 
to neutralize free radicals. These include antioxidant enzymes, metal binding proteins and pol-
ysaccharides (Wang and Luo, 2007; Ming et al., 2009). Many transcripts of the solute carrier 
family, which are membrane transport proteins located in the cell wall, were up-regulated. 
Slc8a3, slc9a4, slc22a5, slco6a1, slc35f4, slc30a10, slc6a17, slc24a2, slc25a19, just as zinc 
transporter slc30a8, monocarboxylic acid transporter slc16a4, amino acid transporter slc6a19 
and oligopeptide transporter slc15a1 were all up-regulated. H+ ATPase (atp5l), Na+/K+ ATPase 
(atp1a3) and Ca++ ATPase (atp2b2) were also up-regulated, as well as many transcripts for 
potassium channels (kcnk17, kcne2, kcnh5, kcnd3, kcnh4). In addition, a transporter of zinc 
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(slc30a8) was up-regulated, while iron transporter (ireb2) was down-regulated. These trans-
porters are an evidence for the increase in metabolism. There was also an increase in lipid 
metabolism. Lipids, which were damaged by oxidative stress, were replaced as a reaction of 
oxidative stress. A lot of transcripts found for lipid metabolism, like calbindin 1 (calb1), prion 
protein (prnp), parathyroid hormone (pth) and vascular endothelial growth factor A (vegfa) were 
up-regulated. These results suggest that M. suis causes oxidative stress in infected pigs and 
that it could influence host response. 
Interestingly, a defected iron metabolism due to chronic inflammation and cytokine imbalance 
(Canavesi et al., 2012), as well as glucose 6-phosphate dehydrogenase deficiency, causes an 
insufficient supply of NADPH in RBCs, resulting in anemia. Immune responses in some auto-
immune diseases also cause anemia. Furthermore, autoimmune hemolytic anemia is often 
accompanied with systemic lupus erythematosus (SLE), whereby antibodies attack RBCs (Fu-
jii et al., 2015). ROS results in sulfhydryl oxidation, which is another potential cause for anemia. 
Consequential, Fujii et al. (2015) concluded that oxidative stress is responsible for SLE. SLE 
is similar to Morbus maculosus, which is also caused by IAP. 
5.2.4 Psoriasis – Morbus maculosus 
Allergic skin reactions (Morbus maculosus) were observed in M. suis infections (Heinritzi, 
1990) since then. In addition, M. suis suppresses the T-lymphocyte blastogenic response 
(Zachary and Smith, 1985). It is well known that T cell-cytokine production or T cell activation 
play a big role in psoriasis (similar to Morbus maculosus), means that suppression or inhibition 
of T cells can alleviate psoriasis (Abrams et al., 2000; Ghoreschi et al., 2002). In this study 
“Role of IL 17A in Psoriasis” were within the top 5 canonical pathways, but genes of this path-
way were all down-regulated. For the infection of the animals we used the KI_3806 very inva-
sive strain, by which all animals have died after 8 days p.i., which could be an explanation for 
the absence of skin alterations. However, genetic disposition for psoriasis or for morbus mac-
ulosus could be recognized. Three transcripts encoding for psoriasis were detected on all three 
days of infection (CXCL8, S100A9, S100A8). Other findings associated with psoriasis indi-
cated in some interferons and cytokines. IFNα -17 (up-regulated 2.01-fold) is produced by 
macrophages and belongs to gene family of IFN-α (Kim et al., 2003). Nakayma et al. (1986) 
showed that increased levels of IFN-α expression has been reported in patients infected with 
M. pneumoniae as early as in the 1980. And it is described that IFN-α was detected in sera of 
patients with SLE (Preble et al., 1982; Hooks et al., 1982). SLE is the human form of Morbus 
maculosus. Furthermore, some experiments have shown that many inflammatory cytokines 
secreted by CD4+ T cells, like IFN-γ and IL-17 are involved in the pathogenesis of autoimmune 
diseases. Recent findings have indicated that IL-9 (up-regulated 3.4-fold) is also involved in 
several autoimmune diseases (Ouyang et al. 2013; Yanaba et al., 2011). Ouyang et al. (2013) 
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showed that plasma concentration and mRNA levels of IL-9 were significantly raised in SLE 
patients compared with the healthy controls. Singh et al. (2013) found increased IL-9R and IL-
9 expression in skin and intradermal IL-9 injection induced Th17-related inflammation. Moreo-
ver, they observed that IL-9R expression in lesional skin from psoriasis patients was evidently 
higher than in healthy skin from control subjects. Thus, IL-9 may play a role in the development 
of psoriatic lesions through Th17-associated inflammation and angiogenesis. This is another 
evidence for the skin response morbus maculosus triggered by M. suis. 
5.2.5 Immune and inflammatory Pathway analysis 
The major significance of IAP lies in generating subclinical cases, an once infected animal 
remain lifelong carrier leading to a higher susceptibility to other infections, especially of the 
respiratory and digestive tract (Heinritzi, 1989; Hoelzle, 2008). This fact could influence the 
development of disease during coinfection of swine involving M. suis and other pathogens. 
There are several evidences M. suis avoids the immune system by different tricks. But those 
mechanisms involved in the interaction between M. suis and its host are poorly understood 
and sparse data are available about misdirected immunologic responses of the host or the role 
of parasitic immunoregulation (Zachary and Smith, 1985). Only Zachary and Smith (1985) de-
scribed a suppression of T-lymphocyte blastogenic response indicating that T-helper lympho-
cyte activities may be altered during an infection with M. suis. Simultaneously, the activation 
of polyclonal B-lymphocytes and production of CAs occurs, misdirected against the injured 
RBC´s and not against M. suis. In addition, IgG antibodies are upregulated during an infection 
recognizing the host actin, leading to a misregulation of the host’s immune response and help-
ing M. suis to avoid destruction (Felder et al., 2010; Hoelzle et al., 2006). However, the mech-
anisms involved during an M. suis infection have not been fully examined and still remain con-
troversial. Some more details about the immunology are identified in some other Mycoplas-
mas. M. suis as well as M. gallisepticum are capable to invade erythrocytes (Groebel et al., 
2009; Vogl et al., 2008), thereby evading the immune system. Other studies about M. bovis 
demonstrated that the bacteria attach to and invade bovine peripheral blood mononuclear cells 
(PMBC) lead to an overall suppression of lymphocyte proliferation, but not altering functional 
responses in terms of cytokine production. M. bovis is even able to inhibit PMBC proliferation, 
still increasing the IFN-γ production (Van der Merwe et al., 2010). Hence, the invasion of cir-
culating immune cells and erythrocytes could play an important role in pathogenesis and 
transport mechanisms of Mycoplasmas to other tissues within the host. 
The number of genes among our DE gene list being involved in immune and inflammatory 
response pathways were dramatically increased. These data may be useful in finding novel 
genes controlling immune response in M. suis infected pigs. RLR signaling plays an essential 
role in innate immune response. DDX60 (up-regulated 2.93-fold, day 2/4) was found to form a 
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complex with RLRs, promoting signaling. The DDX60 helicase domain was observed to bind 
to viral RNA and DNA. Furthermore, DDX60 is necessary for type I IFN expression after DNA 
virus infection (Miyashita et al., 2011). So DDX60 plays a fundamental role in pathogen recog-
nition and activation of innate immune response. MS4A2 (up-regulated 2.66-fold, day 2/4) is a 
high affinity receptor that binds to the Fc region of immunoglobulin (Ig)E. The beta-chain of 
FcepsilonR1 enhances receptor maturation and signal transduction capacity, leading to the 
release of pro-inflammatory mediators and cytokines involved in immune and inflammatory 
responses (Kim et al., 2006). Complement component C4 (up-regulated 2.24-fold, day 8) plays 
a central role in the activation of the classical and the lectin complement pathway. Findings 
from Loos and Brunner (1979) indicate that alveolar macrophages become attracted as a re-
sponse to intranasal infection with M. pneumonia, which could lead to a local increase in indi-
vidual complement components. Furthermore, alveolar macrophages and exudate macro-
phage-like free alveolar cells competent for C4 production increased after transnasal infection 
of guinea pigs with Listeria monocytogenes (Barber and Burkholder, 1978). Reaction of M. 
pneumonia with complement has consequences for the mycoplasma and the host. The myco-
plasma cells were killed or were inhibited in their proliferation and in addition, the surviving 
cells were not able to adhere to erythrocytes and probably also to other cells (Bredt and Bitter-
Suermann, 1975). These findings imply that the host´s innate immune response take effect on 
early stage of M. suis infection.  
Many genes in this study are involved in the inflammatory response, including IL-1β, IL-9, 
COX6C, IL-17F, COX17, IL-6, etc. Moreover, on day 2 p.i., five genes involved in IL-12 signal-
ing pathway were found and, on day 4 p.i., eight genes involved in the PI3K signaling pathway 
in B lymphocytes, seven in IL-12 signaling and production of macrophages, three in FcyRIIB 
signaling in B lymphocytes, six in NFAT regulation and six in B cell receptor signaling were 
found. On day 8 p.i., 32 genes involved in T cell receptor signaling, 41 in B cell receptor sig-
naling, 37 in Tec kinase signaling, 31 genes in PI3K signaling in B lymphocytes, 30 in PKCᶱ 
signaling in T lymphocytes, 29 in CD28 signaling in T helper cells and 37 genes NF-kB signal-
ing pathway were found to be regulated. This reflects the upstream signal cascades that could 
lead to secretion of inflammatory cytokines and to development of T and B cells. 
T cell signaling plays a crucial role in the adaptive immune response (Sloan and Jerome, 
2007). In this study, the expression level of most genes involved in T cell signaling were down-
regulated, including BMX non-receptor tyrosine kinase, E3 ubiquitin protein ligase, Bruton 
agammaglobulinemia tyrosine kinase, CD3D, CD3E, CD3G, NFKB1, NFAT5, phosphatidylin-
ositol-4-phosphate 3-kinase, and many more. However, FKBP3 is up-regulated (2.50-fold) on 
day 4 p.i., but FKBP3 inhibits proliferative T-cell responses by decreased IL-2 production (Jo-
hansson and Möller, 1990; Bierer et al., 1990). Previous studies indicated that FKBP3 sup-
presses pro-inflammatory cascades (Kawano et al., 1994; Garcia-Criado et al., 1998). These 
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findings suggest that T cell signaling pathway is significantly inhibited during infection by M. 
suis. 
It is increasingly recognized that for many bacterial species, cytokine induction is a major vir-
ulence mechanism (Henderson et al., 1996). Cytokines and their sub-group chemokines play 
a central role during host-pathogen interaction, by eliminating invading microorganisms. In this 
study the expression levels of many chemokines like XCR1, CXCL8, CXCR4, CRLF3 an IK 
were downregulated during M. suis infection. XCR1 is a chemokine receptor belonging to the 
G protein-coupled receptor superfamily (Maghazachi, 1999). C chemokines have the potential 
to chemoattract monocytes and T lymphocytes (Oppenheim et al., 1991; Kennedy et al., 1998). 
Chemokine CXCL8, also known as IL-8 is a CXC chemokine. IL-8 is a member of a structurally 
related group of proinflammatory mediators (Baggiolini and Clark-Lewis, 1992). CXCL8 is act-
ing preferentially on neutrophils and have additional activities towards basophil and eosinophil 
granulocytes and T lymphocytes (Oppenheim et al., 1991; Baggiolini et al., 1995). CXCR4, a 
cell surface antigen, is expressed on mononuclear leukocytes and shows structural similarities 
to the IL-8 receptor (Bleul ert al., 1996; Oberlin and Amara, 1996). A study of Möhle et al. 
(1998) suggests that CXCR4 is involved in the trafficking of malignant hematopoietic cells. And 
IK cytokine inhibits MHC Class II antigen induction by IFN-gamma (Krief et al., 1994). Moreo-
ver, IK proteins play a key role in the constitutive expression of MHC class II antigens 
(Vedrenne et al., 1997). The down-regulation of these chemokines suggests that M. suis af-
fects the adaptive immune functions of the host by regulating the secretion of chemokines. 
Another group of important immunoregulators are Interferons (IFNs), which have the ability to 
interfere with viral replication and inhibit cell growth. IFN-α is mainly secreted by mononuclear 
phagocytes and leukocytes and inhibits viral replication (Razin et al., 1998; Yang et al., 2004). 
IFNα -17 (up-regulated 2.01-fold) is produced by macrophages and belongs to gene family of 
IFN-α (Kim et al., 2003). Nakayma et al. (1986) shows that increased levels of IFN-α expres-
sion has been reported in patients infected with M. pneumoniae as early as in the 1980. More-
over, it is described that IFN-α was detected in the sera of patients with SLE (Preble et al., 
1982; Hooks et al., 1982). This goes along with the findings of Heinritzi (1990). He also de-
scribed an allergic skin response (Morbus maculosus) caused by M. suis infections.  
We already know from the capital of oxidative stress that M. suis induces the production of 
proinflammatory cytokines, but rather inhibits the production of IFN-γ. IFN-γ functions in inhib-
iting viral replication, enhancing phagocytosis, inducing the expression of class I and II MHC 
molecules, promoting the division of Th1 cells while inhibiting the growth of Th2 cells and in-
ducing class switch to IgG2a in proliferating B cells (Razin et al., 1998; Yang et al., 2004). 
Several types of Interferones (IFNGR1 down-regulated -6.94-fold, IFIT3 down-regulated -6.16, 
IFIT1 down-regulated -5.34, IFIH1 down-regulated -4.89) were down-regulated in the present 
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study. Different studies reported that M. bovis and M. pneumoniae suppresses the production 
of IFN-γ (Mulongo et al., 2014; Martin et al., 2001). In addition, IFN-γ plays an important role 
in host defense in tuberculosis, and suppression of IFN-γ-induced macrophage responses by 
Mycobacterium tuberculosis has a big influence of course of infection (Pai et al., 2003). Fol-
lowing these perceptions, inhibition of IFN-γ could be one option for M. suis to evade detection 
by CD4+ T cells and may contribute to long-term persistence of the parasite.  
Besides modulation of MHC molecules on the surface of macropahges, numerous studies 
have led to the suggestion that mycoplasmas additionally have the ability to evade phagocy-
tosis (Marshall et al., 1995; Howard and Taylor, 1983). This could be one more reason for 
chronic persistent infection. And not all mycoplasma infections were associated with a strong 
inflammatory response, some mycoplasmas colonize the respiratory and urogenital tracts with 
no apparent clinical symptoms (Rottem, 2003). All together this suggests that mycoplasmas 
trigger the production of downregulating cytokines to withdraw of the immune system and per-
sist in different organs or tissues to colonize or to proliferate. 
IL-1β and TNF-α are acute-proinflammatory cytokines, which can produce fever, inflammation, 
tissue destruction, and, in some cases, shock and death (Dinarello, 2000). IL-1β and TNF-α 
have the ability to activate T and B lymphocytes, promote lymphocyte proliferation and differ-
entiation into effector cells. They can also upregulate the cytocidal activity of macrophages and 
large granular NK cells and enhance the metabolic activity of ploymorphonuclear cells. In ad-
dition, IL-1β and TNF-α provoke local necrosis and tissue destruction (Razin et al., 1998), 
explaining the increased necrosis rates on day 8 post infection. 
IL-6, another proinflammatory cytokine, induced by many mycoplasmas (e.g. M. arginini, M. 
arthritidis, M. fermentas, M. hypopneumoniae, M. penetrans; Razin et al., 1998), is produced 
by monocytes and macrophages as well as by T and B lymphocytes and targets hepatocytes 
to induce the synthesis of acute-phase proteins (Razin et al., 1998; Yang et al., 2004). Simul-
taneously, IL-6 promotes Th2 differentiation and inhibits Th1 polarization (Diehl and Rincón, 
2002).  
Th17 cells are a distinct lineage of effector CD4+ T cells characterized by their production of 
interleukin IL-17. IL-17F, produced by Th17 cells, is an important player in host defense and 
autoimmunity. Thus, IL-17F may be uniquely positioned at the interface of adapted and innate 
immunity (Kolls and Linden, 2004). Liang et al. (2006) showed that Th17 cell differentiation is 
initiated by TGF-β signaling in the context of proinflammatory cytokines, particularly IL-6 as 
well as IL-1β and TNF-α. In conclusion, the upregulated genes IL-1β, IL-6, IL-17F and 
TNFRSF11B are all involved into Th17 lineage, which plays a pathogenic role in autoimmune 
diseases and has a protective role in immunosurveillance (Park et al., 2005; Betteli et al., 2006; 
Murphy et al., 2003).  
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IL-8 is a chemoattractant and activator of neutrophils, monocytes, and T lymphocytes (Yang 
et al., 2004). Like IL-1β, TNF-α and IL-6, IL-8 plays also an important role in shaping the in-
flammatory response against pathogens. Previous studies confirmed an expression of these 
three mediators (Muneta et al., 2008; Lorenzo et al., 2006). These four molecules are able to 
chemo-attract and activate leukocytes at the site of infection (Baggiolini and Clark-Lewis, 1992; 
Medina et al., 2005). This is one more evidence for alteration the immune response of pigs by 
inducing several cytokines by M. suis.  
IL-18, structurally similar to IL-1, plays an important role in TH1 response by inducing IFN-γ 
production in T and NK cells and thus participating in both innate and acquired immunity (Di-
narello, 1999). IL-18 also inhibits IgE production by induction of IFN-γ production of activated 
B cells (Yoshimoto et al., 1997). In our study, IL-18RA is downregulated which, in turn, stimu-
lates IgE production in B cells and implies that M. suis preferentially induces a host Th2 immu-
nological response. 
IL13RA1 (FC -7.92) was expressed on day 8 post infection. IL-13 is a highly pleiotropic cyto-
kine, which has anti-inflammatory effects on monocytes and stimulates the humoral response 
through B lymphocytes. Therefore, IL-13 contributes to the TH2 cell response (Minty et al., 
1993). IL-13 also has an effect on primary immune cells inducing immunoglobulin production. 
Interestingly, an unidentified mycoplasma species can induce mRNA expression for IL-13 in 
cultured human skin fibroblasts (Zurita-Salinas et al., 1996). Up to now, there is not known 
which Mycoplasma species is capable of inducing IL-13. But in fact, down-regulating cytokines 
like IL-13, have inhibitory effects on macrophages, on the production of proinflammatory cyto-
kines, on T cell proliferation and on the balance between Th1 and Th2 cell responses (Razin 
et al., 1998). 
In conclusion, whole blood transcriptomics have been emphasized as a useful approach for 
measuring the immune response. Our study has tried to detect the features of host gene ex-
pression profiling during M. suis infection at different infection time points and to explain the 
mechanisms by which M. suis can avoid the hosts immune response and develop a carrier 
state in the host, what is important for chronic stages of M. suis infections. Moreover, through 
these changes especially in the host pathways, researchers should have in mind that M. suis 
infections could lead to an altered immune response when using pig models (do Nascimento 
et al., 2018). 
By using Microarray analysis, DE genes were identified in porcine blood transcriptome during 
infection and several specific structures of host responses were revealed by gene networks 
and pathway analysis. Understanding these extensive response mechanisms to M. suis infec-
tions is critical to maximizing livestock production and protecting pigs health. 
 
99 
 
 
Finally, transcriptomic investigations together with genomic, proteomic and metabolic data will 
create novel opportunities for the research of M. suis regarding novel target genes for patho-
genesis, cultivation and therapeutic tactics. 
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6 Summary 
Mycoplasma suis (M. suis) is a uncultivable hemotrophic bactreia parasiting red blood cells in 
pigs and a small range of other animals. It becomes more and more important because of 
leading to big economic losses in swine industry. M. suis causes anemia in pigs and is accom-
panied with other immunosuppressive diseases. A once infected animals is a life-long carrier 
and could infect other animals as well. To date, there is less information about the pathogen-
esis and reproduction of the bacteria and it is not possible to cultivate M. suis in vitro. 
One objective of the present study was to get more information about the transcriptomic 
changes in a pig during an infection course. Therefore, 3 splenectomized piglets were infected 
with the highly virulent strain KI_3806. After 2, 4 and 8 days post infection (p.i.) blood samples 
were taken and total RNA of blood was extracted. Microarray analyses were performed with a 
commercial Affymetrix array. Using microarrays more than 7000 DE genes from infected pigs 
could be detected. With M. suis in its host cells – the erythrocyte – we had a perfect model 
showing molecular interactions or signaling pathways in the M. suis infection process. With the 
help of the Ingenuity pathway analyses service many genes involved in immune and inflam-
matory response were found. Moreover typical genes involved in anemia, psoriasis and endo-
thelial cell damage could be observed. The detection of these genes verified the depression 
and alteration of the immune system by M. suis resulting in evading the immune system and 
therefore in persisting among the organism.  
Another aim was to go deeper on the transcriptional level of M. suis and to get insights of the 
behavior of the bacteria at the time point of and after infection. RNA Sequencing was per-
formed on a HiSeq 2000 Genome Analyzer from Illumina an resulting reads were mapped to 
reference sequences M. suis KI_3806 and Sus scrofa. Moreover, differential expression anal-
ysis was performed using the edgeR package. After mapping, it could be observed that on day 
4 p.i. M. suis transcripts seem to be overlapped by porcine transcripts, whereas on day 8 p.i. 
most of the reads could be allocated to the M. suis genome resulting in almost all M. suis genes 
were found to be transcribed at the end of infection. When looking at the COG categories the 
group of proteins with “unknown function” (hypothetical proteins) represented the largest group 
on both days. Also a high number within the differentially expressed genes were hypothetical 
genes showing that these genes play an important role during infection. Further investigations 
are needed to confirm that the hypothetical genes also are involved in M. suis replication and 
recombination. 
In conclusion, our analysis revealed several thousand genes differentially expressed during 
acute IAP and numerous altered pathways and cellular processes throughout the course of 
host response to acute M. suis infections, thus contributing to a better understanding of the 
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IAP pathogenesis. Moreover, this could lead to new approaches towards cultivation of M. suis 
as well as therapeutic treatments. 
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7 Zusammenfassung 
Mycoplasma suis (M. suis) gehört zu den unkultivierbaren hemotrophen Bakterien, welche die 
roten Blutkörperchen von Schweinen und anderen Tierarten parasitieren. Die Krankheit be-
ginnt zunehmend an Bedeutung, da mit ihr hohe wirtschaftliche Verluste in der Schweinpro-
duktion einhergehen. M. suis verursacht Anämien in Schweinen und wird zudem von anderen 
immunsuppresiven Krankheiten begleitet. Ein einmal infiziertes Tier bleibt sein Leben lang 
Träger des Erregers und kann so andere Tiere infizieren. Zum jetzigen Zeitpunkt gibt es kaum 
Information zur Pathogenese und zu Vermehrungsstrategie von M. suis. Außerdem lässt sich 
das Bakterium noch nicht in vitro kultvieren. 
Ein Ziel dieser Studie war es mehr Informationen über die transkriptionellen Änderungen wäh-
rend einer Infektion auf der Wirts-, als auch auf der Erregerseite zu erhalten. Dafür wurden 
drei splenektomierte Schweine mit dem hoch infektiösen Stamm KI_3806 via subkutaner Blu-
tinjektion infiziert. Es wurde jeweils nach 2, 4 und 8 Tagen Blut entnommen und die Gesamt 
RNA des Blutes isoliert. Dann wurden Microarray Analysen mit einem kommerziellen Array 
von Affymetrix durchgeführt, wodurch 7000 differentiell exprimierte Gene in den infizierten 
Schweinen gefunden werden konnten. Durch das Tiermodell dieser Studie konnten die Sig-
nalwege und molekularen Einblicke während einer M. suis Infektion perfekt nachgestellt wer-
den. Das Programm Ingenuity Pathway Analyses zeigte, dass viele dieser Gene an der „Im-
mune und inflammatory response“ beteiligt sind. Darüber hinaus konnten Gene gefunden wer-
den, die unter anderem für die Anämie, für  Psoriasis und die Endothelzellschädigung verant-
wortlich sind. Die Auswertung dieser Gene bestätigt die Aussage, dass M. suis das Immun-
system unterdrückt. Dadurch kann M. suis dem Immunsystem entgehen und wird nicht von 
diesem eliminiert, was die Persistenz des Erregers erklärt. 
Ein weiteres Ziel lag darin einen tieferen Einblick in die Transkriptionsebene des Erregers 
während einer Infektion zu erhalten. Dafür wurde eine RNA-Sequenzierung auf einem HiSeq 
2000 Genome Analyzer von Illumina durchgeführt. Die gemessenen „reads“ wurden anschlie-
ßend gegen das M. suis KI_3806 und das Sus scrofa Genom gemappt. Anschließend wurde 
eine differentielle Expressionsanalyse mittels dem edgeR Paket durchgeführt. Nach dem Map-
pen der Gene konnte festgestellt werden, dass die M. suis Transkripte an Tag 4 nach der 
Infektion von den Schweinetranskripten überlagert werden. Wohingegen an Tag 8 nach der 
Infektion die meisten Transkripte dem M. suis Genom zugeordnet werden konnten. Nahezu 
alle Gene konnten an Tag 8 am Ende der Infektion transkribiert werden. Auffälligerweise konn-
ten die meisten Gene Proteinen mit „unknown function“ zugeordnet werden. Auch innerhalb 
der differentiell exprimierten Gene haben wir eine große Anzahl an hypothetischen Genen ge-
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funden, was beweist, dass sie eine große Rolle während einer Infektion spielen. Weitere Stu-
dien sind notwendig um zu bestätigen, dass die hypothetischen Gene auch an der Vermehrung 
und Replikation von M.suis beteiligt sind.  
Durch die Transkriptionsanalysen dieser Studie konnten einige tausend differentiell expri-
mierte Gene während einer M. suis Infektion gefunden werden, ebenso wurden zahlreiche 
Signalwege und zelluläre Prozesse im Hinblick auf eine Immunantwort gegen  
M. suis aufgezeigt. Diese neuen Einblicke bringen uns ein Stück näher die Pathogenese der 
infektiösen Anämie der Schweine zu verstehen und neue Ansätze für ein Kultursystem und 
Behandlungsstrategien zu entwickeln. 
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Supplement  
Supplementary Table 1 (excerpt): Functional analyses of expressed genes and proteins based on different online resources 
 
(Full data of Supplementary Table 1 can be found as excel format on attached CD) 
  
a locus tag a GI accession numberaNCBI description b PATRIC b PATRIC ID b Start b End b Lenght significant expressed genes* c a03a07_rawCount
Animal 1
4 d.p.i.
MSUIS_02960 325989648 MSUIS_02960, conserved hypothetical protein PRTase superfamily II motifNC_015153 fig|708248.3.peg.308246684 247721 1038 81
MSUIS_05520 325989900 MSUIS_05520, hypothetical proteinNC_015153 fig|708248.3.peg.586473249 473812 564 9
MSUIS_05230 325989871 MSUIS_05230, hypothetical proteinNC_015153 fig|708248.3.peg.552454449 454949 501 167
MSUIS_03420 325989690 MSUIS_03420, hypothetical proteinNC_015153 fig|708248.3.peg.360295816 296292 477 47
MSUIS_00820 325989439 MSUIS_00820, hypothetical proteinNC_015153 fig|708248.3.peg.8482382 83437 1056 29
MSUIS_00830 325989440 MSUIS_00830, hypothetical proteinNC_015153 fig|708248.3.peg.8583442 84467 1026 7
MSUIS_00840 325989441 MSUIS_00840, hypothetical proteinNC_015153 fig|708248.3.peg.8684471 84845 375 8
MSUIS_00930 325989450 MSUIS_00930, hypothetical proteinNC_015153 fig|708248.3.peg.9594535 94798 264 12
MSUIS_04910 325989839 MSUIS_04910, hypothetical proteinNC_015153 fig|708248.3.peg.520427587 429095 1509 21
MSUIS_05160 325989864 MSUIS_05160, hypothetical proteinNC_015153 fig|708248.3.peg.545449427 450035 609 12
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Supplementary Table 2 (excerpt): Functional analyses of highly expressed genes and DE genes encoding hypothetical proteins 
 
(Full data of Supplementary Table 2 can be found as excel format on attached CD) 
  
NAME UniProt ID NCBI ID Proteome MW (Da) theoretical PI Extinction 
coeff.  M-1 cm-
1
Instability 
index
Aliphatic 
index
GRAVY 
Hydropathicity
BLAST
MSUIS_06750 F0V287 CBZ40768 experimentally 
validated
30926.7 9.35 50560 30.77 stable 108.90 0.790 putative membrane 
protein (M. suis str. 
Il l inois
MSUIS_06590 F0V271 CBZ40752 experimentally 
validated
24467.7 5.00 18450 53.24 
unstable
87.10 -0.720 HP, HMs und andere 
Mykoplasmen
MSUIS_01630 F0V334 CBZ40256 experimentally 
validated
29028.9 4.66 37720 69.19 
unstable
68.33 -0.757 HP, unique M. suis 
KI3806 und Il l inois
MSUIS_00090 F0V2N0 CBZ40102 predicted 7380.9 10.01 4470 44.72 
unstable
113.02 -0.037 HP andere HMs und 
Anaplasma marginale
MSUIS_05230 F0V1T5 CBZ40616 experimentally 
validated
18383.1 4.58 10220 47.67 
unstable
62.83 -0.770 HP, unique M. suis 
KI3806
MSUIS_05440 F0V1V6 CBZ40637 predicted 7512.6 5.00 13980 32.85 stable 78.82 -0.274 HP, unique M. suis 
KI3806
MSUIS_07510 F0V2G3 CBZ40844 experimentally 
validated
40792.7 8.80 76345 30.24 stable 80.19 -0.525 HP, 
MSUIS_06430 F0V255 CBZ40736 predicted 11062.8 9.4 4470 30.33 stable 94.32 -0.032 HP
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Supplementary Table 3 (excerpt): Total genes expressed by Microarray analyses 
 
(Full data of Supplementary Table 3 can be found as excel format on attached CD) 
 
Supplementary Table 4: IPA top functions and corresponding bio-functions up- or down-regulated by M. suis infection. 
Top functions and bio-
functions 
P-value Predicted Z-score Modulated genes Number of 
genes 
Cell Death and Survival 
Day 2 
     
apoptosis of leukocytes 2,14E-03 Decreased -2,396 BLNK,CAMLG,CD44,CEBPB,CXCL8,IFNA1/IFNA13,KLF13,LGALS3,MS4A2,PMEL,P
TEN,SIGLEC5,SLPI,TNFSF13B 14 
cell death of immune 
cells 
2,58E-03 Decreased -2,413 BLNK,CAMLG,CBL,CD44,CEBPB,CLU,CXCL8,IFNA1/IFNA13,KLF13,LGALS3,MS4A
2,NFIL3,PMEL,PTEN,SIGLEC5,SLPI,TBC1D15,TNFSF13B 18 
Cell Death and Survival 
Day 4 
     
apoptosis of leukocytes 
8,71E-07 Decreased -2,344 BLM,BLNK,BTG1,BTK,CAMLG,CD2,CD44,CEBPB,CXCL8,CXCR4,FOXO3,IFNA1/IF
NA13,KLF13,LGALS3,MS4A2,MSH2,NQO1,PE-
CAM1,PLCG2,PTEN,SIGLEC5,TLR4,TNFSF13B 
23 
ID gene_assignmentG e SymbolRefSeq GO_biological_processGO_cellular_componentGO_mol cular_functionmrna_assignmenttra script_cluster_idunigene animal 1, D0 animal 1, D2 animal 1, D4 animal 1, D8 animal 2, D0
15180001 --- --- --- --- --- --- 15180001 --- 4.66514 3.5248 3.39114 4.30399 2.8688
15180003 --- --- --- --- --- --- 15180003 --- 3.91122 3.63449 3.79596 3.76016 3.45459
15180005 --- --- --- --- --- --- 15180005 --- 4.11651 2.47693 3.03871 2.19909 2.72258
15180007 --- --- --- --- --- --- 15180007 --- 3.09235 1.90034 1.89254 2.724 1.68571
15180009 --- --- --- --- --- --- 15180009 --- 1.27221 2.27828 3.08415 2.7138 1.37844
15180011 --- --- --- --- --- --- 15180011 --- 2.08586 2.24688 2.18831 2.40278 2.15425
15180013 --- --- --- --- --- --- 15180013 --- 4.70245 4.10341 4.76276 3.71355 3.35181
15180015 --- --- --- --- --- --- 15180015 --- 1.49034 2.50848 2.50056 2.75359 1.56635
15180017 --- --- --- --- --- --- 15180017 --- 2.41094 2.90673 3.2832 2.71465 2.85249
15180019 --- --- --- --- --- --- 15180019 --- 2.75435 3.61808 3.69966 3.23543 3.08684
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apoptosis of mononu-
clear leukocytes 
3,57E-05 Decreased -2,296 BLM,BLNK,BTK,CAMLG,CD2,CD44,CXCR4,FOXO3,KLF13,LGALS3,MS4A2,MSH2,
NQO1,PECAM1,PLCG2,PTEN,TNFSF13B 
17 
Cell Death and Survival 
Day 4      
apoptosis of lympho-
cytes 
8,58E-05 Decreased -2,109 BLM,BLNK,BTK,CAMLG,CD2,CD44,CXCR4,FOXO3,KLF13,LGALS3,MSH2,NQO1,P
ECAM1,PLCG2,PTEN,TNFSF13B 
16 
apoptosis of leukocytes 
8,71E-07 Decreased -2,344 BLM,BLNK,BTG1,BTK,CAMLG,CD2,CD44,CEBPB,CXCL8,CXCR4,FOXO3,IFNA1/IF
NA13,KLF13,LGALS3,MS4A2,MSH2,NQO1,PE-
CAM1,PLCG2,PTEN,SIGLEC5,TLR4,TNFSF13B 
23 
 
Cellular Growth and Proliferation 
proliferation of tumor cell 
lines 
1,58E-08 Decreased -2,375 AATF,ADAM15,ANG-
PTL4,BCCIP,BIN1,BMX,CBL,CD44,CEBPB,CIRBP,CLU,COPS2,CSNK1E,CXCL8,CX
CR4,DACH1,DLGAP5,EEF1B2,EIF3H,FKBP5,FOLR1,FOXO3,H2AFZ,INPP5F,LGAL
S3,mir-21,MKI67,MMP1,MYBL1,NCOA3,NOTCH2,NQO1,NUMB,PDCD4,PE-
CAM1,PFKFB3,PLCG2,POLK,PRKAR2B,PRKG1,PTEN,PTPRO,RFX1,SDCBP,SET,
SGMS1,TCF4,TES,TGFA,TLR4,TNFSF13B,TPM1,TXN,WNT10B 
54 
formation of cells 1,25E-04 Decreased -2,153 ADAM19,ANGPTL4,BIN1,CALD1,CD44,CE-
BPB,CLU,CXCL8,CXCR4,DOCK8,MAML1,mir-
21,NFIL3,PECAM1,PTEN,S100A8,SMAP2,TPM1,TXN 
19 
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Cell Death and Survival 
Day 8      
cell viability 
2,18E-24 Decreased -6,039 ABCC1,ABCG2,ACSL5,ADCYAP1,ADIPOR1,ADNP,AGO2,AGPS,A-
KAP13,ALOX12,ANG-
PTL1,AP2B1,APC,AREG,ASS1,ATF2,ATF6,ATP7A,ATRX,BAG3,BCL10,BCLAF1,BC
R,BDNF,BMP7,BRAF,BRD2,BTK,C5,CA2,CALB1,CAMK2D,CAMK2G,CAMLG,CASK,
CASP1,CAT,CBL,CCNG1,CCNI,CD3E,CD44,CD47,CD55,CD79A,CD80,CD86,CDC4
2,CDC42BPA,CDK7,CDK8,CDKL3,CDKN1A,CHD4,CHUK,CKAP5,CLOCK,COL17A1,
COL1A1,COMP,COPB2,CTNNB1,CXCL12,CXCL8,CXCL9,CXCR4,CYR61,DCLRE1A
,DGKA,DHX9,DNM1,DNM1L,DNMT1,DOCK8,DPP4,DPYD,E2F4,EIF2AK3,EIF3E,EIF
4A3,EP300,EPHB2,EPHB4,EPO,ESCO1,ETV6,EWSR1,EXOC2,EYA3,EZR,F2R,FAT
1,FBXO9,FGF2,FKBP5,FLT1,FOXO3,FTH1,FYN,GCG,GCLC,GFRA2,GLP1R,GLUD1
,GSK3B,GSR,HIF1A,HMGB1,HMGB2,HNRNPU,HPSE,ID2,ID4,IDE,IFIH1,IFNB1,IG-
FBP3,IK,IKZF2,IL17F,IL21,IL6,IL6ST,IL7R,IL9,INPP4A,INPP5D,IQGAP1,IRAK4,ITGB
1,JAK1,JAK2,KDR,KIF1B,KIR-
REL,KITLG,LDHA,LEF1,LGALS3,LIF,LRRK2,MALT1,MAP3K1,MAP3K7,MAPK1,MCL
1,MCOLN2,MDM2,MED1,MED21,MEF2C,MICAL2,MIF,mir-10,mir-148,mir-15,mir-
155,mir-17,mir-181,mir-
21,MITF,MMP1,MSR1,MTDH,MUC4,MYC,NBN,NCSTN,NEFH,NFAT5,NFATC2,NFE
2L2,NFIL3,NFKB1,NR2C2,NRAS,NRN1,NTF3,NTF4,NTRK2,NUP210,OGT,PAK2,PA
RP14,PDK1,PEG3,PHKA2,PIK3C3,PIK3CD,PIK3IP1,PLCG2,PLG,POSTN,POU2F1,P
OU5F1,PPARD,PPARG,PPBP,PPP1CB,PPP2CA,PPP2R2A,PPP2R5A,PPP2R5C,PP
P3CA,PPP6C,PRDX6,PRKAR1A,PRKCQ,PRKD1,PRNP,PROM1,PSAP,PSEN1,PSIP
1,PTEN,PTH,PTP4A2,PTPN1,PTPRC,PTPRE,PTPRN,PTPRZ1,RAB11A,RAD50,RA
D51,RASA1,RASSF8,RB1,RBP1,REL,RICTOR,RIT1,RNA-
SEL,ROR1,RRM1,RSF1,RUNX1,RUNX1T1,SELL,SETDB1,SETX,SFN,SFTPD,SLFN
11,SMAD4,SMARCA4,SMC3,SMN1/SMN2,STAM,STAM2,STAMBP,STAT1,STAT4,S
TAT5A,STC1,STK11,TAF4B,TANK,TBC1D9,TEC,TGFA,TGFB1,TGFBR1,TLR2,TLR4
280 
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,TNFAIP8,TNFRSF11B,TNFSF13B,TOP1,TOP2B,TPTE2,TRPM8,TXN,TXNIP,TYK2,
UGCG,USP8,VEGFA,VIP,XRCC5 
cell survival 5,94E-24 Decreased -6,364 ABCC1,ABCG2,ACSL5,ADCYAP1,ADIPOR1,ADNP,AGO2,AGPS,A-
KAP13,ALOX12,ANG-
PTL1,AP2B1,APC,AREG,ASS1,ATF2,ATF4,ATF6,ATP7A,ATRX,BAG3,BCL10,BCLA
F1,BCR,BDNF,BMP7,BRAF,BRD2,BTK,C5,C8orf44-
SGK3/SGK3,CA2,CALB1,CAMK2D,CAMK2G,CAMLG,CASK,CASP1,CAT,CBL,CCN
G1,CCNI,CD3E,CD44,CD47,CD55,CD79A,CD80,CD86,CDC42,CDC42BPA,CDK7,C
DK8,CDKL3,CDKN1A,CHD4,CHUK,CKAP5,CLK2,CLOCK,COL17A1,COL1A1,COMP
,COPB2,CTNNB1,CXCL12,CXCL8,CXCL9,CXCR4,CYR61,DCLRE1A,DDX3X,DGKA,
DHX9,DNM1,DNM1L,DNMT1,DOCK8,DPP4,DPYD,E2F4,EIF2AK3,EIF3E,EIF4A3,EP
300,EPHB2,EPHB4,EPO,ESCO1,ETV6,EWSR1,EXOC2,EYA3,EZR,F2R,FAT1,FBXO
9,FGF2,FKBP5,FLT1,FOXO3,FTH1,FYN,GCG,GCLC,GFRA2,GLP1R,GLUD1,GRB10
,GSK3B,GSR,HIF1A,HMGB1,HMGB2,HNRNPU,HPSE,ID2,ID4,IDE,IFIH1,IFNB1,IG-
FBP3,IK,IKZF2,IL17F,IL21,IL6,IL6ST,IL7R,IL9,INPP4A,INPP5D,IQGAP1,IRAK4,ITGB
1,JAK1,JAK2,KDR,KIF1B,KIR-
REL,KITLG,LDHA,LEF1,LGALS3,LIF,LIMS1,LRRK2,LYZ,MALT1,MAP3K1,MAP3K7,
MAPK1,MCL1,MCOLN2,MDM2,MED1,MED21,MEF2C,MICAL2,MIF,mir-10,mir-
148,mir-15,mir-155,mir-17,mir-181,mir-
21,MITF,MMP1,MSR1,MTDH,MUC4,MYC,NBN,NCSTN,NEFH,NFAT5,NFATC2,NFE
2L2,NFIL3,NFKB1,NOS3,NOTCH2,NR2C2,NRAS,NRN1,NTF3,NTF4,NTRK2,NUP21
0,OGT,OPN1SW,PAK2,PARP14,PDCD4,PDK1,PEG3,PHKA2,PHLPP1,PIK3C3,PIK3
CD,PIK3IP1,PLCG2,PLG,POSTN,POU2F1,POU5F1,PPARD,PPARG,PPBP,PPP1CB,
PPP2CA,PPP2R2A,PPP2R5A,PPP2R5C,PPP3CA,PPP6C,PRDX6,PRKAR1A,PRKC
Q,PRKD1,PRNP,PROM1,PSAP,PSEN1,PSIP1,PTEN,PTH,PTP4A2,PTPN1,PTPRC,P
TPRE,PTPRN,PTPRZ1,RAB11A,RAD50,RAD51,RASA1,RASSF8,RB1,RBP1,REL,RI
CTOR,RIT1,RNA-
SEL,ROR1,RRM1,RSF1,RUNX1,RUNX1T1,SELL,SET,SETDB1,SETX,SFN,SFTPD,S
LFN11,SMAD4,SMARCA4,SMC3,SMN1/SMN2,SNCB,STAM,STAM2,STAMBP,STAT
297 
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1,STAT4,STAT5A,STC1,STK11,TAF4B,TANK,TBC1D9,TBX3,TEC,TGFA,TGFB1,TG
FBR1,TLR2,TLR4,TNFAIP8,TNFRSF11B,TNFSF13B,TNKS,TOP1,TOP2B,TPTE2,TR
PM8,TXN,TXNIP,TYK2,UCP2,UGCG,USP8,VEGFA,VIP,XRCC5 
cell viability of leukocytes 2,74E-14 Decreased -3,249 ADCYAP1,BCL10,BTK,C5,CAMK2G,CAMLG,CBL,CD3E,CD44,CD47,CD79A,CD80,
CD86,CLOCK,CXCL12,CXCL8,CXCR4,DOCK8,F2R,FGF2,FOXO3,GSK3B,HIF1A,H
MGB1,IFNB1,IKZF2,IL21,IL6,IL7R,IL9,INPP5D,JAK1,JAK2,KITLG,LEF1,LGALS3,MA
LT1,MCL1,MEF2C,MIF,mir-15,mir-
155,MSR1,MYC,NFIL3,NFKB1,PARP14,PIK3C3,PIK3CD,PLCG2,PPBP,PRDX6,PRK
CQ,PTPRC,RASA1,REL,SMAD4,SMARCA4,STAM,STAM2,STAT1,STAT4,STAT5A,S
TK11,TAF4B,TGFB1,TLR4,TNFRSF11B,TNFSF13B,TYK2,VIP 
71 
cell viability of blood cells 4,66E-14 Decreased -2,955 ADCYAP1,BCL10,BTK,C5,CAMK2G,CAMLG,CBL,CD3E,CD44,CD47,CD79A,CD80,
CD86,CLOCK,CXCL12,CXCL8,CXCR4,DOCK8,EPO,F2R,FGF2,FOXO3,GSK3B,HIF
1A,HMGB1,IFNB1,IKZF2,IL21,IL6,IL7R,IL9,INPP5D,JAK1,JAK2,KDR,KITLG,LEF1,LG
ALS3,MALT1,MCL1,MEF2C,MIF,mir-15,mir-
155,MSR1,MYC,NFIL3,NFKB1,PARP14,PIK3C3,PIK3CD,PLCG2,PPBP,PRDX6,PRK
CQ,PTPRC,RASA1,REL,RUNX1,RUNX1T1,SMAD4,SMARCA4,STAM,STAM2,STAT
1,STAT4,STAT5A,STK11,TAF4B,TGFB1,TLR4,TNFRSF11B,TNFSF13B,TYK2,VEGF
A,VIP 
76 
cell viability of mononu-
clear leukocytes 
5,73E-14 Decreased -2,642 ADCYAP1,BCL10,BTK,CAMK2G,CAMLG,CBL,CD3E,CD44,CD47,CD79A,CD80,CD8
6,CLOCK,CXCL12,CXCL8,DOCK8,F2R,FOXO3,GSK3B,HMGB1,IFNB1,IKZF2,IL21,I
L6,IL7R,IL9,INPP5D,KITLG,LEF1,LGALS3,MALT1,MCL1,MEF2C,MIF,mir-
155,MYC,NFIL3,NFKB1,PARP14,PIK3C3,PIK3CD,PLCG2,PPBP,PRKCQ,PTPRC,RE
L,SMAD4,SMARCA4,STAM,STAM2,STAT1,STAT4,STAT5A,STK11,TAF4B,TGFB1,T
NFSF13B,VIP 
58 
cell viability of lympho-
cytes 
8,56E-14 Decreased -2,452 ADCYAP1,BCL10,BTK,CAMK2G,CAMLG,CBL,CD3E,CD44,CD47,CD79A,CD80,CD8
6,CLOCK,CXCL12,DOCK8,F2R,FOXO3,GSK3B,HMGB1,IFNB1,IKZF2,IL21,IL6,IL7R,
IL9,INPP5D,KITLG,LEF1,LGALS3,MALT1,MCL1,MEF2C,MIF,mir-
155,MYC,NFIL3,NFKB1,PARP14,PIK3C3,PIK3CD,PLCG2,PRKCQ,PTPRC,REL,SMA
56 
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D4,SMARCA4,STAM,STAM2,STAT1,STAT4,STAT5A,STK11,TAF4B,TGFB1,TNFSF1
3B,VIP 
cell death of blood cells 5,08E-13 Decreased -2,570 ABCC1,ADCYAP1,ANXA1,APC,ATF2,BCL10,BCR,BLNK,BNIP3L,BTG1,BTK,C5,CA
MK2G,CAMLG,CASP1,CAST,CAT,CBL,CD2,CD3E,CD44,CD47,CD69,CD79A,CD80,
CD86,CDC42,CDKN1A,CHUK,CLOCK,COL1A1,CST3,CTNNB1,CXCL12,CXCL8,CX
CR4,DOCK8,E2F4,EP300,EPO,ETS1,ETV6,EZR,F2R,FGF2,FGL2,FOXO3,FTH1,FY
N,GNAS,GSK3B,HIF1A,HMGB1,ID2,IFIH1,IFNA1/IFNA13,IFNB1,IFNGR1,IKZF2,IL21
,IL6,IL6ST,IL7R,IL9,INPP5D,IRAK3,IRF3,ITGA4,ITGB1,JAK1,JAK2,KIR2DL1/KIR2DL
3,KITLG,KL,KLF13,LEF1,LGALS3,LGALS8,LYZ,MALT1,MCL1,MDM2,MEF2C,MIF,mi
r-15,mir-155,mir-17,mir-
363,MPO,MSR1,MYC,NBN,NFAT5,NFATC2,NFE2L2,NFIL3,NFKB1,NFYA,NRAS,NU
MB,OGT,PARP14,PCBP2,PIK3AP1,PIK3C3,PIK3CD,PLCG2,PPARG,PPBP,PRDX6,
PRKCQ,PTEN,PTPRC,RASA1,RB1,REL,RNA-
SEL,RUNX1,SATB1,SFN,SFTPD,SH3GLB1,SIGLEC5,SMAD4,SMARCA4,ST3GAL1,
STAM,STAM2,STAT1,STAT4,STAT5A,STK11,STK17B,TAF4B,TGFB1,TLR2,TLR4,T
LR7,TNFAIP8L2,TNFRSF11B,TNFSF13B,TYK2,TYR,UBD,VAV3,VEGFA,VIP,XRCC5 
148 
cell death of immune 
cells 
9,96E-13 Decreased -2,633 ABCC1,ADCYAP1,ANXA1,BCL10,BCR,BLNK,BTG1,BTK,C5,CAMK2G,CAMLG,CAS
P1,CAST,CAT,CBL,CD2,CD3E,CD44,CD47,CD69,CD79A,CD80,CD86,CDC42,CDKN
1A,CHUK,CLOCK,COL1A1,CST3,CTNNB1,CXCL12,CXCL8,CXCR4,DOCK8,EP300,
EPO,ETS1,ETV6,EZR,F2R,FGF2,FGL2,FOXO3,FTH1,FYN,GNAS,GSK3B,HIF1A,HM
GB1,ID2,IFIH1,IFNA1/IFNA13,IFNB1,IFNGR1,IKZF2,IL21,IL6,IL6ST,IL7R,IL9,INPP5D
,IRAK3,IRF3,ITGA4,ITGB1,JAK1,JAK2,KIR2DL1/KIR2DL3,KITLG,KLF13,LEF1,LGAL
S3,LGALS8,LYZ,MALT1,MCL1,MDM2,MEF2C,MIF,mir-15,mir-155,mir-17,mir-
363,MPO,MSR1,MYC,NBN,NFAT5,NFATC2,NFE2L2,NFIL3,NFKB1,NRAS,NUMB,O
GT,PARP14,PCBP2,PIK3AP1,PIK3C3,PIK3CD,PLCG2,PPARG,PPBP,PRDX6,PRKC
Q,PTEN,PTPRC,RASA1,RB1,REL,RNA-
SEL,RUNX1,SATB1,SFN,SFTPD,SH3GLB1,SIGLEC5,SMAD4,SMARCA4,ST3GAL1,
STAM,STAM2,STAT1,STAT4,STAT5A,STK11,STK17B,TAF4B,TGFB1,TLR2,TLR4,T
LR7,TNFAIP8L2,TNFRSF11B,TNFSF13B,TYK2,TYR,UBD,VAV3,VEGFA,VIP,XRCC5 
142 
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cell viability of tumor cell 
lines 
3,94E-11 Decreased -5,200 ABCC1,ABCG2,ACSL5,ADNP,AGO2,AGPS,A-
KAP13,ALOX12,ATF2,ATF6,ATRX,BAG3,BCLAF1,BDNF,BRAF,CA2,CAMK2D,CASK
,CASP1,CAT,CBL,CCNG1,CD44,CD55,CDC42BPA,CDK8,CDKL3,CDKN1A,CKAP5,
COL1A1,COPB2,CTNNB1,CXCL12,CXCL8,CXCL9,CXCR4,DGKA,DHX9,DNM1,DPP
4,EIF2AK3,EIF3E,EIF4A3,EP300,EPHB4,EPO,ESCO1,EWSR1,FBXO9,FGF2,FKBP5
,FLT1,FTH1,FYN,GCLC,GLUD1,GSK3B,HIF1A,HMGB1,ID2,ID4,IFNB1,IG-
FBP3,IK,IL6,INPP4A,IRAK4,ITGB1,JAK1,KDR,KITLG,LEF1,LGALS3,LIF,MAP3K1,MA
P3K7,MCL1,MCOLN2,MDM2,MED1,MICAL2,mir-10,mir-148,mir-15,mir-155,mir-
17,mir-181,mir-
21,MTDH,MUC4,MYC,NBN,NCSTN,NFE2L2,NFKB1,NRAS,NTF3,NTF4,NTRK2,NUP
210,PARP14,PHKA2,POU5F1,PPP2CA,PPP2R2A,PPP2R5A,PPP2R5C,PPP6C,PRK
CQ,PRNP,PROM1,PTEN,PTP4A2,PTPN1,PTPRE,PTPRN,PTPRZ1,RAB11A,RAD51,
RASA1,RASSF8,REL,RIC-
TOR,RIT1,ROR1,RRM1,RSF1,SETX,SFN,SFTPD,SLFN11,SMARCA4,SMN1/SMN2,
STAT5A,STC1,TBC1D9,TEC,TGFA,TGFB1,TNFAIP8,TNFSF13B,TOP1,TPTE2,TRP
M8,TXN,UGCG,USP8,VEGFA 
148 
cell death of muscle 5,48E-10 Decreased -2,025 ADCY5,ATF6,ATP2B4,BACH1,BMP7,BNIP3L,CACNB2,CAMK2D,CASP1,CAT,CBL,C
DKN1A,CRYAB,CTNNB1,CXCL12,CXCL8,CYR61,DMD,DPP4,EEF1A1,EPO,ETS1,F
GF2,FOXO3,GCG,GLP1R,GNAI2,GNAQ,GNAS,GSK3B,HIF1A,HMGB1,ID2,IL6,IL6S
T,IRAK4,IVNS1ABP,JAK2,KITLG,KL,KNG1,let-
7,LIF,LIMS1,MAML1,MAP3K1,MAP3K7,MAPK1,MCL1,MDM2,mir-1,mir-133,mir-
21,mir-
34,MPO,MTPN,MYC,NOS3,NRAS,PDCD4,PPARG,PPP3CA,PTEN,RB1,RPS6KB1,S
GCG,SLC8A3,SLK,SMN1/SMN2,SORT1,SPTLC2,STAT1,STK4,TERF2,TGFB1,TLR4
,TXNIP,VEGFA,WTAP 
79 
necrosis of muscle 1,03E-09 Decreased -2,025 ADCY5,ATF6,ATP2B4,BACH1,BMP7,BNIP3L,CACNB2,CAMK2D,CASP1,CAT,CBL,C
DKN1A,CRYAB,CTNNB1,CXCL12,CXCL8,CYR61,DMD,DPP4,EEF1A1,EPO,ETS1,F
GF2,FOXO3,GCG,GLP1R,GNAI2,GNAQ,GNAS,GSK3B,HIF1A,HMGB1,ID2,IL6,IL6S
78 
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T,IRAK4,IVNS1ABP,JAK2,KITLG,KL,KNG1,let-
7,LIF,LIMS1,MAML1,MAP3K1,MAP3K7,MAPK1,MCL1,MDM2,mir-1,mir-133,mir-
21,mir-
34,MPO,MTPN,MYC,NOS3,PDCD4,PPARG,PPP3CA,PTEN,RB1,RPS6KB1,SGCG,S
LC8A3,SLK,SMN1/SMN2,SORT1,SPTLC2,STAT1,STK4,TERF2,TGFB1,TLR4,TXNIP
,VEGFA,WTAP 
cell viability of B lympho-
cytes 
4,37E-09 Decreased -2,413 BCL10,BTK,CAMLG,CBL,CD44,CD47,CD79A,CLOCK,CXCL12,IKZF2,IL21,IL6,INPP
5D,LEF1,LGALS3,MALT1,MCL1,MEF2C,MIF,MYC,NFIL3,NFKB1,PARP14,PIK3CD,P
LCG2,REL,STAT5A,TAF4B,TGFB1,TNFSF13B 
30 
apoptosis of fibroblast 
cell lines 
9,73E-08 Decreased -2,494 ABCE1,ATF2,ATF6,BNIP3L,CALB1,CCNG1,CD2,CDKN1A,COMP,COPS5,CTNNB1,
CYR61,DDX3X,DNMT1,EEF1A1,EIF2A,EIF2AK3,EIF3H,ETS1,EWSR1,FAF1,FOXO3
,FTH1,FYN,GCG,GLP1R,GNA13,GNAQ,GRB10,GSK3B,HIF1A,HIPK1,HPSE,ID2,IFI1
6,ITGB1,LEF1,MAP3K1,MAP3K7,MCL1,MDM2,MYC,NFE2L2,NFKB1,NRAS,PLG,PP
P3CA,PRNP,PSEN1,PSMD6,PTEN,PTH,PTPN1,QKI,RAI14,RB1,RBL1,REL,RHOT1,
RNASEL,RUNX1,STAT1,STK17B,STK38,STK4,STRADB,TGFB1,TRPS1,TXNIP 
69 
cell death of leukemia 
cells 
1,29E-06 Increased 2,979 BLNK,BTK,CASP1,CAT,CD44,CD47,GSK3B,HIF1A,IL21,IL6,JAK2,MAPK1,MCL1,MIF
,mir-15,MYC,PIK3CD,PTEN,RPS3A,RUNX1,SELL,SMARCA4,TNFSF13B,TXN 
24 
cell death of sarcoma 
cells 
1,30E-06 Increased 2,762 BLNK,BTK,CASP1,CAT,CD44,CD47,GSK3B,HIF1A,IL21,IL6,JAK2,KDR,MAPK1,MCL
1,MIF,mir-15,MYC,PIK3CD,PTEN,RPS3A,RUNX1,SELL,SMARCA4,TNFSF13B,TXN 
25 
apoptosis of leukemia 
cells 
2,41E-06 Increased 3,055 BLNK,BTK,CASP1,CAT,CD44,GSK3B,HIF1A,IL21,IL6,JAK2,MAPK1,MCL1,MIF,mir-
15,MYC,PIK3CD,PTEN,RUNX1,SELL,SMARCA4,TNFSF13B,TXN 
22 
apoptosis of sarcoma 
cells 
2,47E-06 Increased 2,810 BLNK,BTK,CASP1,CAT,CD44,GSK3B,HIF1A,IL21,IL6,JAK2,KDR,MAPK1,MCL1,MIF,
mir-15,MYC,PIK3CD,PTEN,RUNX1,SELL,SMARCA4,TNFSF13B,TXN 
23 
Cancer 
cell transformation 
3,89E-10 Decreased -4,281 ACOX1,AFF4,AKAP13,AKAP9,APC,ARAF,ARH-
GEF12,BCL10,BCR,BRAF,BTK,CAT,CBL,CCDC6,CDC42,CDKN1A,COL1A1,COL1A
101 
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2,CTNNB1,CYR61,DMTF1,DNMT1,E2F4,EIF3H,EP300,EPS15,ETS1,ETV6,EWSR1,
F2R,FGF2,FLT1,FOXO3,FTH1,GNA13,GNAI2,GNAO1,GNAQ,GRB10,GTF2I,HBP1,H
EY1,ID2,INCENP,ITGB1,JAK2,LDHA,LGALS3,MAPK1,MDM2,MIF,mir-
21,MITF,MLLT3,MLLT4,MOS,MXI1,MYC,NBN,NCOA3,NFKB1,NRAS,PAK2,PBX2,PD
CD4,PIK3CD,PLCG2,PPARG,PRKAR1A,PTEN,PTPN1,PTPRE,PTTG1,RAP1A,RAS
A1,RAS-
GRP1,RB1,RBL1,REL,RIT1,ROCK2,RPS3A,RUNX1,RUNX1T1,SDCBP,SMC3,SOS2,
STK11,TAB3,TBX3,TGFA,TGFB1,TLR4,TOP1,TPM3,TRAF6,TRRAP,USP7,VAV3,VE
GFA,ZNF384 
transformation of fibro-
blast cell lines 
5,48E-09 Decreased -2,439 ACOX1,AKAP13,AKAP9,ARAF,ARH-
GEF12,BCR,BRAF,BTK,CBL,CCDC6,CDC42,CDKN1A,COL1A1,CTNNB1,DMTF1,D
NMT1,EP300,ETS1,ETV6,EWSR1,F2R,FGF2,FLT1,FOXO3,FTH1,GNA13,GNAI2,GN
AO1,HBP1,HEY1,INCENP,LDHA,MAPK1,MDM2,mir-
21,MITF,MOS,MXI1,MYC,NBN,NRAS,PIK3CD,PLCG2,PRKAR1A,PTEN,PTPN1,PTT
G1,RAP1A,RAS-
GRP1,RB1,RBL1,RIT1,RPS3A,RUNX1,RUNX1T1,SMC3,SOS2,TAB3,TGFB1,TPM3,
ZNF384 
61 
neck neoplasm 6,11E-09 Increased 2,162 A-
MOT,ANXA1,APC,BRAF,CCDC6,CD44,CDKN1A,COPS2,CTNNB1,CXCR4,DAP3,E2
F4,EPHB4,ETS1,FGF2,FLT1,GABBR2,GNAS,KDR,LGALS3,LIFR,LIMD2,mir-155,mir-
181,MT-ND1,MT-ND2,MT-ND3,MT-ND4,MT-
ND5,MYC,NBN,NCOA4,NRAS,NTRK2,PCM1,POU5F1,PPARD,PPARG,PRDX6,PRK
AR1A,PTEN,PTPN4,PTPRC,PTTG1,RB1,RPS6KB1,RUNX2,SDHD,SMAD4,TGFB1,T
GFBR1,TLR2,TLR4,TOP2B,TUBB1 
55 
thyroid gland tumor 1,11E-07 Increased 2,162 A-
MOT,APC,BRAF,CCDC6,CDKN1A,COPS2,CTNNB1,CXCR4,DAP3,E2F4,EPHB4,ET
S1,FGF2,FLT1,GABBR2,GNAS,KDR,LGALS3,LIFR,LIMD2,mir-155,mir-181,MT-
ND1,MT-ND2,MT-ND3,MT-ND4,MT-
50 
115 
 
 
ND5,MYC,NBN,NCOA4,NRAS,NTRK2,PCM1,POU5F1,PPARD,PPARG,PRDX6,PRK
AR1A,PTEN,PTPN4,PTPRC,PTTG1,RB1,RPS6KB1,RUNX2,SMAD4,TGFB1,TGFBR
1,TOP2B,TUBB1 
Cellular Growth and Proliferation 
proliferation of cells 
4,90E-32 Decreased -4,588 ABCB7,ABCC1,ABCC2,ABCG2,ABI1,ACAN,ACSL4,ACSL5,ACTN1,ACVR1B,ADAM1
5,ADAM28,ADCYAP1,ADCYAP1R1,ADIPOR1,ADI-
POR2,ADNP,AGGF1,AGK,AGO2,AGO4,AGPS,AHNAK,AK4,A-
KAP13,AKR1C1/AKR1C2,ALOX12,AMBN,AMOT,ANGPTL1,ANG-
PTL4,ANXA1,ANXA2,ANXA7,APC,ARAF,AREG,ARHGDIB,ARH-
GEF12,ARID1A,ARID1B,ARID4A,ARIH2,ARL6IP5,ARNT,ARNT2,AR-
RDC3,ARV1,ASAH2,ASIC1,ATF2,ATF4,ATF6,ATP5F1,ATP7A,ATXN2,B4GALT1,BC
L10,BCLAF1,BCR,BDNF,BLNK,BMP7,BMPR1B,BMPR2,BMX,BRAF,BRAP,BTG1,BT
K,BTNL2,BUB3,C5,C8orf44-SGK3/SGK3,CALB1,CALCB,CALD1,CALM1 (includes 
others),CAMK2D,CAMKK2,CAPRIN1,CASK,CASP1,CAST,CAT,CAV2,CBL,CCDC6,C
CDC88A,CCNG1,CCNH,CCNI,CD164,CD2,CD3E,CD3G,CD44,CD47,CD55,CD6,CD
69,CD79A,CD80,CD86,CDA,CDC14A,CDC25C,CDC42,CDC42BPA,CDK7,CDK8,CD
KN1A,CDX2,CFDP1,CHD4,CHD8,CHUK,CIB1,CIRBP,CLASP2,CLEC7A,CLK1,CLK2,
CLOCK,CNOT2,CNOT6L,CNOT7,COL14A1,COL1A1,COL1A2,COL4A2,COL4A3BP,
COL8A1,COMP,COPS2,COPS5,COPZ1,COX17,CRLF3,CRYAB,CSNK1A1,CSNK1E,
CSNK1G3,CST3,CTNNB1,CTSL,CUL4B,CUL5,CXCL12,CXCL8,CXCL9,CXCR4,CYR
61,DACH1,DAP3,DBI,DCLRE1A,DCS-
TAMP,DDAH1,DDX21,DDX3X,DGKA,DHX15,DIAPH1,DIXDC1,DKK3,DLG1,DMTF1,
DNM1L,DNMT1,DOCK3,DOCK8,DPP4,DSPP,DYRK1A,E2F4,E-
APP,EEF1A1,EEF1B2,EFS,EGLN1,EI24,EIF2AK3,EIF3E,EIF3H,ELF1,EML4,EN-
PEP,ENTPD1,EP300,EPHB2,EPHB4,EPO,EPS15,EPS15L1,ERAP1,ERBB2IP,ES-
RRB,ETS1,ETV6,EWSR1,EXOC4,EZR,F2R,FABP7,FADS3,FAM107A,FBN1,FBXO11
,FBXO9,FBXW4,FGF2,FGL2,FKBP5,FLT1,FMR1,FNDC3B,FOXO3,FRS2,FST,FTH1,
FTL,FUT8,FYN,GA-
BARAP,GAL,GBX2,GCG,GCLC,GFRA2,GLP1R,GLS,GNA13,GNA15,GNAI2,GNAO1,
672 
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GNAQ,GNAS,GNMT,GNRHR,GRB10,GREB1,GSK3B,GSTA2,GTF2I,H2AFY,H2AFZ,
HAND1,HBP1,HEY1,HIF1A,HIPK1,HLTF,HMGB1,HMGB2,HMGCR,HNRNPA1,HNRN
PD,HNRNPU,HOXB3,HPGD,HPSE,IBSP,I-
CAM3,ICK,ID2,ID4,IDE,IFI16,IFI30,IFIT3,IFNA1/IFNA13,IFNB1,IFNGR1,IGBP1,IG-
FBP3,IG-
FBP4,IKZF2,IL10RA,IL13RA1,IL17F,IL1RL1,IL21,IL6,IL6ST,IL7R,IL9,ILF3,INPP4A,IN
PP5D,IQGAP1,IRAK4,IRF3,IRX6,ITGA11,ITGA2,ITGA3,ITGA4,ITGB1,ITGB6,ITGB7,I
TGB8,ITIH4,IT-
PKC,IVNS1ABP,JAK1,JAK2,JARID2,KARS,KAT6B,KCNA3,KCND3,KCNJ1,KCNMA1,
KCNN4,KDM3A,KDR,KI-
DINS220,KIF2C,KITLG,KL,KLF13,KLF3,KNG1,LAMB1,LARP7,LATS1,LCP1,LCP2,LD
HA,LEF1,let-
7,LGALS3,LGR5,LIF,LIFR,LIMS1,LIN28A,LIPA,LMNB1,LRP1B,LRP2,LRRK2,LY9,LY
Z,MADD,MALT1,MAML1,MAP3K1,MAP3K3,MAP3K7,MAPK1,MAPRE1,MARCH8,MB
L2,MCL1,MCM9,MDM2,MED1,MEF2C,MEST,MGEA5,MICU1,MIF,mir-1,mir-10,mir-
130,mir-133,mir-145,mir-148,mir-15,mir-155,mir-17,mir-181,mir-183,mir-193,mir-
21,mir-224,mir-30,mir-34,mir-363,mir-
9,MITF,MLLT3,MMP1,MORF4L1,MSMB,MSR1,MT-
ND2,MTCH1,MTDH,MTF2,MTPN,MTTP,MUC4,MXI1,MYC,MYCBP,MYL9,MY-
LIP,NACA,NAGA,NAP1L1,NBN,NCKAP1L,NCOA1,NCOA2,NCOA3,NCOA4,NCSTN,
NEFH,NEO1,NFAT5,NFATC2,NFE2L2,NFIL3,NFIX,NFKB1,NFYA,NOL8,NOS3,NOT
CH2,NPAS3,NR1H4,NR2C2,NR2E1,NR2F2,NR5A2,NRAS,NRD1,NRN1,NTF3,NTF4,
NTRK2,NTS,NUB1,NUMB,NXF2/NXF2B,OCA2,OGT,OSTF1,P3H2,PA2G4,PAFAH1B
1,PAG1,PAK2,PAK7,PAX5,PDCD4,PDK1,PDX1,PFKFB3,PGAM2,PGK1,PHF6,PHLP
P1,PIK3AP1,PIK3C2B,PIK3C3,PIK3CD,PIK3IP1,PIP4K2A,PLCB2,PLCG2,PLEKHO1,
PLG,PLXNB3,PNN,POLK,POSTN,POU4F3,POU5F1,PPAP2C,PPARD,PPARG,PPBP
,PPP1CB,PPP2CA,PPP2R5C,PPP3CA,PRDM14,PRKAR1A,PRKAR2B,PRKCQ,PRK
D1,PRKG2,PRNP,PRRC2C,PRUNE,PSAP,PSEN1,PTBP1,PTEN,PTH,PTP4A2,PTP
N1,PTPRC,PTPRE,PTPRN,PTPRZ1,PTTG1,PYGO2,RAB11A,RAB22A,RAB27A,RAB
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35,RAD50,RAD51,RANBP9,RAPH1,RASA1,RAS-
GRP1,RB1,RBBP6,RBFOX2,RBL1,RBM5,RBM6,RBP1,RBPJ,RC3H1,REL,RGS2,RIC
TOR,RING1,RIT1,RLIM,RNA-
SEL,RNF10,RNF111,RNF139,RNF14,ROCK2,ROR1,RORA,RPS3A,RPS6KA3,RPS6
KB1,RRM1,RSL1D1,RUNX1,RUNX1T1,RUNX2,S100A7,SAMSN1,SAT1,SATB1,SCA
F11,SDCBP,SEC61A1,SELL,SEMA5A,SENP1,SER-
PINB7,SET,SETDB1,SFN,SFRP5,SFTPD,SGMS1,SLAMF1,SLC12A2,SLC20A1,SLC
22A4,SLC29A1,SLC30A6,SLC9A3R1,SLK,SMAD4,SMARCA4,SMARCA5,SMARCD3
,SMC3,SMN1/SMN2,SNRK,SNX1,SOX13,SP110,SPAST,SPRY1,SRSF5,SSR1,SST
R2,ST8SIA4,STAG2,STAM,STAM2,STAMBP,STAT1,STAT4,STAT5A,STC1,STC2,ST
IM2,STK11,STK17B,STK38,STK4,STRN,STT3B,SULT2A1,SUZ12,T,TAB3,TAC3,TAF
4B,TANK,TBRG1,TBX3,TEC,TERF2,TET2,TFAM,TGFA,TGFB1,TGFBI,TGFBR1,TJP
2,TJP3,TLR2,TLR4,TLR7,TMEFF1,TMEFF2,TNC,TNFAIP8,TNFAIP8L2,TNFRSF11B,
TNFSF13B,TNKS,TNKS2,TNMD,TNN,TOP1,TOP2B,TO-
PORS,TPM1,TPM3,TRA2A,TRAF6,TRPM7,TRPS1,TRRAP,TSPAN3,TXK,TXN,TXNI
P,TYK2,TYR,UBD,UBE3A,UCP2,UGCG,USP1,USP37,USP47,USP7,USP8,VAV3,VE
GFA,VIP,VPS39,WASF2,WDR48,WTAP,XRCC5,XRN2,ZDHHC17,ZFP36L1,ZIC2,ZM
IZ1,ZMYND11 
proliferation of tumor cell 
lines 
1,88E-18 Decreased -2,656 ABCB7,ACSL4,ACSL5,ADAM15,ADCYAP1,AGK,AMOT,ANG-
PTL4,ANXA1,ANXA2,ANXA7,APC,ARAF,AREG,ARID1A,ARID4A,ARIH2,ARNT,AR-
RDC3,ATF2,ATP7A,BCL10,BCR,BDNF,BMP7,BMPR1B,BMPR2,BMX,BRAF,CALCB,
CASP1,CAT,CBL,CCDC6,CCDC88A,CD44,CD80,CDC42,CDK8,CDKN1A,CDX2,CH
D8,CIRBP,COL14A1,COL1A1,COL4A2,COMP,COPS2,COPS5,COPZ1,CSNK1A1,CS
NK1E,CSNK1G3,CTNNB1,CXCL12,CXCL8,CXCR4,CYR61,DACH1,DDX21,DKK3,D
MTF1,DPP4,EEF1A1,EEF1B2,EIF3E,EIF3H,ENTPD1,EP300,EPO,EPS15,ERBB2IP,
ETS1,ETV6,EWSR1,EZR,FBXO9,FGF2,FKBP5,FLT1,FOXO3,FST,FTH1,FTL,FUT8,F
YN,GAL,GCG,GNA15,GNAQ,GNAS,GNMT,GSK3B,GTF2I,H2AFY,H2AFZ,HAND1,H
BP1,HIF1A,HMGB1,HMGCR,HNRNPA1,HOXB3,HPGD,HPSE,ID2,IDE,IFI16,IFNB1,I
293 
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GBP1,IGFBP3,IG-
FBP4,IL21,IL6,IL6ST,IL9,ILF3,INPP5D,IQGAP1,ITGB1,ITGB8,JAK1,JAK2,KCNN4,KD
R,KIDINS220,KITLG,KNG1,LATS1,LCP1,LEF1,let-
7,LGALS3,LIF,LRP1B,MADD,MAP3K7,MAPK1,MAPRE1,MBL2,MDM2,MED1,MGEA5
,MICU1,MIF,mir-1,mir-10,mir-130,mir-133,mir-145,mir-148,mir-15,mir-155,mir-17,mir-
181,mir-183,mir-193,mir-21,mir-34,mir-363,mir-9,MLLT3,MMP1,MSMB,MT-
ND2,MUC4,MXI1,MYC,MYCBP,MYL9,NCOA1,NCOA3,NCSTN,NEO1,NFATC2,NFE2
L2,NFKB1,NOTCH2,NR1H4,NR2C2,NR5A2,NRAS,NTF3,NTF4,NTRK2,NTS,NUB1,N
UMB,OGT,PA2G4,PDCD4,PDX1,PFKFB3,PHF6,PHLPP1,PIK3C2B,PIK3C3,PIK3CD,
PIP4K2A,PLCG2,PLG,POLK,POSTN,POU5F1,PPARD,PPARG,PPP2R5C,PRDM14,
PRKAR1A,PRKAR2B,PRKCQ,PRKD1,PRNP,PSEN1,PTBP1,PTEN,PTPN1,PTPRE,P
TPRZ1,PTTG1,RAD51,RANBP9,RASGRP1,RB1,RBBP6,RBL1,RBM5,REL,RIC-
TOR,RNF111,RNF14,ROR1,RORA,RPS6KB1,RRM1,RUNX1,RUNX1T1,RUNX2,S10
0A7,SAT1,SATB1,SDCBP,SENP1,SET,SETDB1,SFN,SGMS1,SLC9A3R1,SMAD4,S
MARCA4,SMN1/SMN2,SNRK,SP110,SPAST,SRSF5,SSTR2,STAG2,STAT1,STAT5A
,STK11,STK38,STK4,SULT2A1,SUZ12,TAB3,TBX3,TGFA,TGFB1,TGFBR1,TLR2,TL
R4,TMEFF1,TMEFF2,TNFAIP8,TNFSF13B,TNKS2,TOP1,TPM1,TRA2A,TRPM7,TRR
AP,TXN,TXNIP,TYK2,TYR,UGCG,USP37,VAV3,VEGFA,VIP,WDR48,XRCC5,ZMIZ1 
proliferation of blood 
cells 
9,79E-13 Decreased -2,001 ABI1,ADCYAP1,AHNAK,AKAP13,ANXA1,APC,ARHG-
DIB,ATF2,BCL10,BCLAF1,BCR,BLNK,BRAF,BTG1,BTK,BTNL2,CALCB,CAT,CBL,C
D2,CD3E,CD3G,CD44,CD47,CD55,CD6,CD69,CD79A,CD80,CD86,CDC42,CDKN1A,
CSNK1A1,CTNNB1,CXCL12,CXCL8,CXCR4,DGKA,DIAPH1,DLG1,DMTF1,DOCK8,
DPP4,E2F4,EFS,ELF1,EP300,EPO,ERAP1,ETS1,EZR,FGF2,FGL2,FOXO3,FTL,FYN
,GAL,GNAI2,GSK3B,HIF1A,HMGB1,HOXB3,ID2,IFNA1/IFNA13,IFNB1,IFNGR1,IKZF
2,IL10RA,IL13RA1,IL17F,IL1RL1,IL21,IL6,IL6ST,IL7R,IL9,INPP4A,INPP5D,IRAK4,IT
GB1,JAK1,JAK2,KCNA3,KCNN4,KDR,KITLG,KLF3,LCP1,LCP2,LEF1,LGALS3,LIF,L
Y9,MALT1,MAP3K1,MBL2,MDM2,MEF2C,MIF,mir-155,mir-17,mir-
21,MLLT3,MXI1,MYC,NCKAP1L,NCSTN,NFAT5,NFATC2,NFIL3,NFKB1,NRAS,PAG
1,PIK3AP1,PIK3CD,PLCB2,PLCG2,PPARG,PPP3CA,PRKCQ,PRKD1,PTEN,PTH,PT
171 
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PRC,PTPRN,RAS-
GRP1,RC3H1,REL,RGS2,RUNX1,RUNX1T1,SAMSN1,SATB1,SELL,SET,SFN,SFTP
D,SLAMF1,SLC29A1,SMAD4,SMARCA4,SOX13,STAM,STAM2,STAT1,STAT4,STAT
5A,STK11,STK17B,STK4,SUZ12,TANK,TEC,TGFB1,TGFBR1,TLR2,TLR4,TLR7,TNF
RSF11B,TNFSF13B,TRAF6,TXK,TXN,TXNIP,TYK2,TYR,VAV3,VEGFA,VIP,XRCC5,Z
FP36L1 
proliferation of immune 
cells 
2,70E-12 Decreased -2,689 ABI1,ADCYAP1,AHNAK,AKAP13,ANXA1,ARHG-
DIB,ATF2,BCL10,BCLAF1,BCR,BLNK,BRAF,BTG1,BTK,BTNL2,CALCB,CAT,CBL,C
D2,CD3E,CD3G,CD44,CD47,CD55,CD6,CD69,CD79A,CD80,CD86,CDC42,CDKN1A,
CSNK1A1,CTNNB1,CXCL12,CXCL8,CXCR4,DGKA,DIAPH1,DLG1,DMTF1,DOCK8,
DPP4,EFS,ELF1,EP300,EPO,ERAP1,ETS1,EZR,FGF2,FGL2,FOXO3,FTL,FYN,GAL,
GNAI2,GSK3B,HIF1A,HMGB1,ID2,IFNA1/IFNA13,IFNB1,IFNGR1,IKZF2,IL10RA,IL13
RA1,IL17F,IL1RL1,IL21,IL6,IL6ST,IL7R,IL9,INPP5D,IRAK4,ITGB1,JAK1,JAK2,KCNA
3,KCNN4,KDR,KITLG,KLF3,LCP1,LCP2,LEF1,LGALS3,LY9,MALT1,MAP3K1,MBL2,
MDM2,MEF2C,MIF,mir-155,mir-17,mir-
21,MLLT3,MXI1,MYC,NCKAP1L,NCSTN,NFAT5,NFATC2,NFIL3,NFKB1,PAG1,PIK3
AP1,PIK3CD,PLCB2,PLCG2,PPARG,PPP3CA,PRKCQ,PRKD1,PTEN,PTPRC,PTPR
N,RAS-
GRP1,RC3H1,REL,RGS2,RUNX1,SAMSN1,SATB1,SELL,SFN,SFTPD,SLAMF1,SLC
29A1,SMAD4,SMARCA4,SOX13,STAM,STAM2,STAT1,STAT4,STAT5A,STK11,STK
17B,STK4,TANK,TEC,TGFB1,TGFBR1,TLR2,TLR4,TLR7,TNFRSF11B,TNFSF13B,T
RAF6,TXK,TXN,TXNIP,TYK2,TYR,VAV3,VEGFA,VIP,XRCC5,ZFP36L1 
161 
proliferation of mononu-
clear leukocytes 
4,77E-12 Decreased -2,883 ABI1,ADCYAP1,AHNAK,AKAP13,ANXA1,ARHG-
DIB,ATF2,BCL10,BCLAF1,BCR,BLNK,BRAF,BTK,BTNL2,CALCB,CBL,CD2,CD3E,C
D3G,CD44,CD47,CD55,CD6,CD69,CD79A,CD80,CD86,CDC42,CDKN1A,CSNK1A1,
CTNNB1,CXCL12,CXCR4,DGKA,DIAPH1,DLG1,DMTF1,DOCK8,DPP4,EFS,ELF1,E
P300,EPO,ERAP1,ETS1,EZR,FGL2,FOXO3,FTL,FYN,GAL,GNAI2,GSK3B,HIF1A,HM
GB1,ID2,IFNA1/IFNA13,IFNB1,IFNGR1,IKZF2,IL10RA,IL13RA1,IL17F,IL1RL1,IL21,IL
6,IL6ST,IL7R,IL9,INPP5D,IRAK4,ITGB1,KCNA3,KCNN4,KDR,KITLG,KLF3,LCP1,LC
151 
120 
 
 
P2,LEF1,LGALS3,LY9,MALT1,MAP3K1,MBL2,MDM2,MEF2C,MIF,mir-155,mir-
17,MXI1,MYC,NCKAP1L,NCSTN,NFAT5,NFATC2,NFIL3,NFKB1,PAG1,PIK3AP1,PIK
3CD,PLCB2,PLCG2,PPARG,PPP3CA,PRKCQ,PRKD1,PTEN,PTPRC,PTPRN,RAS-
GRP1,RC3H1,REL,RGS2,RUNX1,SAMSN1,SATB1,SELL,SFN,SFTPD,SLAMF1,SMA
D4,SMARCA4,SOX13,STAM,STAM2,STAT1,STAT4,STAT5A,STK11,STK17B,STK4,
TANK,TEC,TGFB1,TGFBR1,TLR2,TLR4,TLR7,TNFRSF11B,TNFSF13B,TRAF6,TXK,
TXN,TXNIP,TYK2,TYR,VAV3,VEGFA,VIP,XRCC5 
proliferation of lympho-
cytes 
1,04E-11 Decreased -3,001 ABI1,ADCYAP1,AHNAK,AKAP13,ANXA1,ARHG-
DIB,ATF2,BCL10,BCLAF1,BCR,BLNK,BRAF,BTK,BTNL2,CALCB,CBL,CD2,CD3E,C
D3G,CD44,CD47,CD55,CD6,CD69,CD79A,CD80,CD86,CDC42,CDKN1A,CSNK1A1,
CTNNB1,CXCL12,CXCR4,DGKA,DIAPH1,DLG1,DMTF1,DOCK8,DPP4,EFS,ELF1,E
P300,EPO,ERAP1,ETS1,EZR,FGL2,FOXO3,FTL,FYN,GAL,GNAI2,GSK3B,HIF1A,HM
GB1,ID2,IFNA1/IFNA13,IFNB1,IFNGR1,IKZF2,IL13RA1,IL17F,IL1RL1,IL21,IL6,IL6ST
,IL7R,IL9,INPP5D,IRAK4,ITGB1,KCNA3,KCNN4,KDR,KITLG,KLF3,LCP1,LCP2,LEF1
,LGALS3,LY9,MALT1,MAP3K1,MDM2,MEF2C,MIF,mir-155,mir-
17,MXI1,MYC,NCKAP1L,NCSTN,NFAT5,NFATC2,NFIL3,NFKB1,PAG1,PIK3AP1,PIK
3CD,PLCB2,PLCG2,PPARG,PPP3CA,PRKCQ,PRKD1,PTEN,PTPRC,RAS-
GRP1,RC3H1,REL,RGS2,RUNX1,SAMSN1,SATB1,SELL,SFN,SFTPD,SLAMF1,SMA
D4,SMARCA4,SOX13,STAM,STAM2,STAT1,STAT4,STAT5A,STK11,STK17B,STK4,
TANK,TEC,TGFB1,TGFBR1,TLR2,TLR4,TLR7,TNFRSF11B,TNFSF13B,TRAF6,TXK,
TXN,TXNIP,TYK2,TYR,VAV3,VEGFA,VIP,XRCC5 
148 
proliferation of T lympho-
cytes 
1,99E-10 Decreased -2,065 ABI1,ADCYAP1,AHNAK,AKAP13,ANXA1,ARHG-
DIB,ATF2,BCL10,BCLAF1,BRAF,BTNL2,CALCB,CBL,CD2,CD3E,CD3G,CD44,CD47,
CD55,CD6,CD69,CD79A,CD80,CD86,CDC42,CDKN1A,CSNK1A1,CTNNB1,CXCL12,
CXCR4,DGKA,DIAPH1,DLG1,DOCK8,DPP4,EFS,ELF1,ERAP1,ETS1,FGL2,FOXO3,
FTL,FYN,GNAI2,GSK3B,HMGB1,ID2,IFNA1/IFNA13,IFNB1,IFNGR1,IL17F,IL1RL1,IL
21,IL6,IL6ST,IL7R,IL9,INPP5D,IRAK4,ITGB1,KCNA3,KCNN4,KDR,KITLG,LCP1,LCP
2,LGALS3,LY9,MALT1,MIF,mir-155,mir-
17,MXI1,MYC,NCKAP1L,NCSTN,NFAT5,NFATC2,NFKB1,PAG1,PIK3CD,PLCB2,PP
123 
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ARG,PPP3CA,PRKCQ,PRKD1,PTEN,PTPRC,RAS-
GRP1,RC3H1,REL,RGS2,RUNX1,SAMSN1,SATB1,SELL,SFTPD,SLAMF1,SMARCA
4,SOX13,STAM,STAM2,STAT1,STAT4,STAT5A,STK11,STK17B,STK4,TGFB1,TGFB
R1,TLR2,TLR4,TNFRSF11B,TNFSF13B,TRAF6,TXK,TXN,TXNIP,TYR,VAV3,VEGFA,
VIP,XRCC5 
proliferation of B lympho-
cytes 
2,99E-09 Decreased -3,103 ARHG-
DIB,BCL10,BCR,BLNK,BTK,CBL,CD3E,CD44,CD79A,CD80,CD86,CDKN1A,CXCL12
,EP300,ETS1,EZR,FYN,HIF1A,IFNA1/IFNA13,IFNB1,IKZF2,IL13RA1,IL21,IL6,IL7R,IL
9,INPP5D,IRAK4,KITLG,KLF3,LCP1,LEF1,MAP3K1,MDM2,MEF2C,MIF,mir-
155,MYC,NCKAP1L,NFATC2,NFKB1,PIK3AP1,PIK3CD,PLCG2,PPARG,PTEN,PTPR
C,RC3H1,REL,SAMSN1,SFN,SFTPD,SLAMF1,STAT1,STAT5A,STK11,TANK,TEC,T
GFB1,TLR2,TLR4,TLR7,TNFSF13B,TRAF6,TXN,TYK2,VAV3 
67 
expansion of cells 2,16E-08 Increased 2,262 AREG,BTK,CBL,CD2,CD3E,CD55,CD69,CD80,CD86,CDC42,CDKN1A,CHUK,CTNN
B1,CXCL12,EPO,FGF2,FOXO3,HMGB1,IFNGR1,IL10RA,IL21,IL6,IL6ST,IL7R,IL9,IR
X6,KCNN4,KDR,KITLG,KNG1,LCP1,LCP2,LIF,LRRK2,LY9,mir-155,mir-
21,MLLT3,MYC,NFATC2,NTRK2,PAX5,PIK3CD,PPARG,PTEN,PTH,PTPRC,RB1,RB
L1,RUNX1,RUNX1T1,RUNX2,SER-
PINB7,SET,SLAMF1,SMAD4,STAT4,STAT5A,STK11,TGFB1,TGFBR1,TLR2,TNFSF
13B,TYR,VEGFA,VIP 
66 
generation of blood cells 
3,73E-07 Decreased -2,531 BCL10,BCR,CD69,CD80,CD86,CTNNB1,FUT8,FYN,ID2,IFNB1,IL10RA,IL21,IL6,IL7R
,IL9,ITGA4,KITLG,MIF,NFE2L2,NFIL3,NOTCH2,PPARG,PRKCQ,PTEN,RB1,RBL1,R
C3H1,REL,RORA,STAT1,STAT4,STK11,TGFB1,TLR4,TLR7,TNFSF13B,TRAF6,VIP 
38 
generation of leukocytes 5,70E-07 Decreased -2,417 BCL10,CD69,CD80,CD86,CTNNB1,FUT8,FYN,ID2,IFNB1,IL10RA,IL21,IL6,IL7R,IL9,I
TGA4,KITLG,MIF,NFE2L2,NFIL3,NOTCH2,PPARG,PRKCQ,PTEN,RB1,RBL1,RC3H1
,REL,RORA,STAT1,STAT4,STK11,TGFB1,TLR4,TLR7,TNFSF13B,TRAF6,VIP 
37 
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generation of mononu-
clear leukocytes 
1,40E-06 Decreased -2,539 BCL10,CD69,CD80,CD86,CTNNB1,FUT8,FYN,ID2,IFNB1,IL10RA,IL21,IL6,IL7R,IL9,I
TGA4,MIF,NFIL3,NOTCH2,PPARG,PRKCQ,RB1,RBL1,RC3H1,REL,RORA,STAT4,S
TK11,TGFB1,TLR4,TLR7,TNFSF13B,TRAF6,VIP 
33 
generation of lympho-
cytes 
2,14E-06 Decreased -2,420 BCL10,CD69,CD80,CD86,CTNNB1,FUT8,FYN,ID2,IFNB1,IL10RA,IL21,IL6,IL7R,IL9,I
TGA4,MIF,NFIL3,NOTCH2,PPARG,PRKCQ,RB1,RBL1,RC3H1,REL,RORA,STAT4,S
TK11,TGFB1,TLR4,TNFSF13B,TRAF6,VIP 
32 
Gastrointestinal Disease 
formation of polyp 
2,36E-06 Increased 2,412 APC,CASP1,CDX2,CTNNB1,DNMT1,GSK3B,PPARD,PPARG,PTEN,SMAD4,STK11 11 
Gene Expression 
expression of RNA 
5,70E-27 Decreased -3,227 ABLIM1,ACTR2,ACTR3,ACVR1B,ADCYAP1,AFF3,AFF4,AGO2,ALOX12,APC,ARH-
GAP35,ARID1A,ARID1B,ARID2,ARID4A,ARNT,ARNT2,ATF2,ATF4,ATF6,ATF7IP,AT
P2B4,ATP2C1,ATRX,ATXN3,ATXN7,ATXN7L3,BACH1,BAZ2A,BCL10,BCLAF1,BCR,
BDNF,BEX1,BLNK,BMP7,BMPR1B,BMPR2,BMX,BPTF,BRAF,BRD2,BRD8,BTAF1,B
TF3,BTG1,BTK,C8orf44-
SGK3/SGK3,CAMK2D,CAMK2G,CAMKK2,CAPN3,CASK,CASP1,CBFA2T2,CBL,CC
NH,CCNT2,CCPG1,CD3D,CD3E,CD44,CD47,CD86,CDC42,CDK7,CDK8,CDKN1A,C
DX2,CEBPZ,CHD1,CHD2,CHD3,CHD4,CHD8,CHUK,CIRBP,CLOCK,CNOT1,CNOT2
,CNOT7,COL1A1,COL4A2,COPS2,COPS5,COPZ1,CREB3L1,CRLF3,CSNK1E,CTN
NB1,CXCR4,DACH1,DDX20,DDX3X,DEK,DHX9,DIAPH1,DIXDC1,DKK3,DMD,DMTF
1,DNMT1,DYRK1A,E2F4,E-
APP,EEF1B2,EIF2A,EIF2AK3,EIF3D,EIF3E,EIF3H,EIF4A3,EIF5B,ELF1,EP300,EPO,
ES-
RRB,ETS1,ETV6,EVX1,EWSR1,EZH1,F2R,FGF2,FHL5,FMR1,FOXN3,FOXO3,FST,F
UBP1,GATAD2A,GCG,GCLC,GLO1,GLP1R,GNA13,GNAQ,GNRHR,GPR39,GSK3B,
GTF2A1,GTF2H1,GTF2I,H2AFY,H2AFZ,HAND1,HBP1,HEY1,HIF1A,HIPK1,HIPK3,HI
VEP2,HLTF,HMGB1,HMGB2,HMGN2,HNRNPA1,HPSE,HSBP1,ID2,ID4,IFI16,IFNA1/
406 
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IFNA13,IFNB1,IFRD1,IGBP1,IG-
FBP3,IKZF2,IL17F,IL6,IL6ST,IL7R,ILF3,INPP5D,IQGAP1,IQGAP3,IRAK4,IREB2,IRF
3,ITGA3,IVNS1ABP,JAK1,JAK2,JARID2,JMJD1C,KAT6A,KAT6B,KAT7,KDM1B,KDM
3A,KLF13,KNG1,LCP2,LEF1,LHX2,LIF,LPIN2,LRPPRC,LY9,MALT1,MAML1,MAP3K
1,MAP3K3,MAP3K7,MAPK1,MATR3,MDM2,MED1,MED13,MED20,MED21,MED23,M
ED7,MEF2A,MEF2C,MEIS2,MGEA5,MIF,mir-1,mir-
155,MITF,MSL3,MTDH,MTERF3,MTPN,MXI1,MYC,MYCBP,MYSM1,NACA,NCOA1,
NCOA2,NCOA3,NCOA4,NCOA6,NCOA7,NEO1,NFAT5,NFATC2,NFE2L2,NFIL3,NFI
X,NFKB1,NFYA,NIPBL,NO-
BOX,NOTCH2,NPAS3,NR0B1,NR1H4,NR2C2,NR2E1,NR2F2,NR5A2,NRAS,NSD1,N
TF3,NTRK2,OGT,ONE-
CUT2,PA2G4,PAIP1,PAK2,PAX5,PBX2,PDCD4,PDLIM1,PDX1,PDZD8,PHF12,PI-
CALM,PKN2,POU2F1,POU4F3,POU5F1,PPARD,PPARG,PPP2R5A,PPP2R5C,PPP3
CA,PRDM6,PRKAG1,PRKAR1A,PRKAR2B,PRKCQ,PRKD1,PSEN1,PSIP1,PTEN,PT
H,PTTG1,PYGO2,QKI,RAP1A,RASA1,RAS-
GRP1,RB1,RBBP6,RBFOX2,RBL1,RBM14,RBM39,RBM4,RBPJ,RCOR1,REL,RFWD
2,RFX5,RGS2,RING1,RIT1,RLF,RLIM,RNA-
SEL,RNF10,RNF111,RNF14,RORA,RPL19,RPS17,RPS3A,RPS6KA3,RPS6KB1,RSF
1,RUNX1,RUNX1T1,RUNX2,SAMD4A,SARS,SATB1,SCAF8,SCAP,SEC61A1,SENP
1,SET,SETDB1,SGMS1,SIM1,SLA2,SLBP,SLC20A1,SMAD4,SMARCA4,SMARCA5,
SMARCD3,SMYD1,SNX6,SP3,SSB,STAT1,STAT4,STAT5A,STK4,SUZ12,T,TAF1A,T
AF2,TAF4B,TANK,TBX3,TCEA1,TERF2,TFAM,TGFA,TGFB1,TGFBR1,TLR2,TLR4,T
LR8,TMEM173,TNC,TNKS,TOP1,TO-
PORS,TOX3,TRAF6,TRAK2,TROVE2,TRPS1,TRRAP,TXK,TXN,TXNIP,UBA3,UBE3
A,UBN1,UBP1,USP47,VAV3,VEGFA,VEZF1,VGLL2,VPS39,WNT8B,WWP1,XRCC5,
YLPM1,YWHAB,ZFP36L1,ZFPM2,ZIC2,ZMIZ1,ZMYND11,ZNF292,ZNF384,ZNF653 
transcription 1,64E-25 Decreased -4,131 ABLIM1,ACTR2,ACTR3,ACVR1B,AFF3,AFF4,AKAP13,APC,ARH-
GAP35,ARID1A,ARID1B,ARID2,ARID4A,ARNT,ARNT2,ATF2,ATF4,ATF6,ATF7IP,AT
P2B4,ATP2C1,ATRX,ATXN3,ATXN7,ATXN7L3,BACH1,BAZ2A,BCL10,BCLAF1,BCR,
368 
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BDNF,BEX1,BLNK,BMP7,BMPR1B,BMPR2,BMX,BPTF,BRAF,BRD2,BRD8,BTAF1,B
TF3,BTG1,BTK,C8orf44-
SGK3/SGK3,CAMK2D,CAMKK2,CAPN3,CASK,CASP1,CBFA2T2,CBL,CCNH,CCNT
2,CCPG1,CD3D,CD3E,CD44,CDC42,CDK7,CDK8,CDKN1A,CDX2,CEBPZ,CHD1,CH
D2,CHD3,CHD4,CHD8,CHUK,CLOCK,CNOT1,CNOT2,CNOT7,COL4A2,COPS2,CO
PS5,CREB3L1,CRLF3,CSNK1E,CTNNB1,CXCR4,DACH1,DDX20,DDX3X,DEK,DHX
15,DHX9,DIXDC1,DKK3,DMD,DMTF1,DNMT1,DYRK1A,E2F4,E-
APP,EIF4A3,ELF1,ELMO1,EP300,EPO,ES-
RRB,ETS1,ETV6,EVX1,EWSR1,EZH1,F2R,FGF2,FHL5,FOXN3,FOXO3,FST,FUBP1,
GATAD2A,GCG,GCLC,GLO1,GLP1R,GNA13,GNAQ,GNRHR,GPR39,GSK3B,GTF2A
1,GTF2H1,GTF2I,H2AFY,H2AFZ,HAND1,HEY1,HIF1A,HIPK1,HIPK3,HIVEP2,HLTF,
HMGB1,HMGB2,HMGN2,HNRNPA1,HPSE,HSBP1,ID2,ID4,IFI16,IFNA1/IFNA13,IFN
B1,IFRD1,IGBP1,IKZF2,IL17F,IL6,IL6ST,ILF3,INPP5D,IQGAP1,IRF3,IVNS1ABP,JAK
1,JAK2,JARID2,JMJD1C,KAT6A,KAT6B,KAT7,KDM3A,KLF13,KNG1,LCP2,LEF1,LH
X2,LIF,LPIN2,LRPPRC,LY9,MALT1,MAML1,MAP3K1,MAP3K3,MAP3K7,MAPK1,MA
TR3,MDM2,MED1,MED13,MED20,MED21,MED23,MED7,MEF2A,MEF2C,MEIS2,MG
EA5,MIF,mir-
155,MITF,MSL3,MTDH,MTERF3,MTPN,MXI1,MYC,MYCBP,MYSM1,NCOA1,NCOA2,
NCOA3,NCOA4,NCOA6,NCOA7,NEO1,NFAT5,NFATC2,NFE2L2,NFIL3,NFIX,NFKB1
,NFYA,NIPBL,NO-
BOX,NOTCH2,NPAS3,NR0B1,NR1H4,NR2C2,NR2E1,NR2F2,NR5A2,NRAS,NSD1,N
TF3,OGT,ONE-
CUT2,PA2G4,PAK2,PAX5,PBX2,PDCD4,PDLIM1,PDX1,PDZD8,PHF12,PI-
CALM,PKN2,POU2F1,POU4F3,POU5F1,PPARD,PPARG,PPP3CA,PRDM6,PRKAR1
A,PRKAR2B,PRKCQ,PRKD1,PSEN1,PSIP1,PTEN,PTH,PTTG1,PYGO2,R3HDM1,RA
P1A,RASA1,RAS-
GRP1,RB1,RBBP6,RBFOX2,RBL1,RBM14,RBM17,RBM25,RBM39,RBM5,RBPJ,RC
OR1,REL,RFWD2,RFX5,RING1,RIT1,RLF,RLIM,RNA-
SEL,RNF10,RNF111,RNF14,RORA,RPL12,RPS6KA3,RPS6KB1,RSF1,RUNX1,RUN
X1T1,RUNX2,SATB1,SCAF8,SCAP,SEC61A1,SENP1,SET,SETDB1,SIM1,SLA2,SLC
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20A1,SMAD4,SMARCA4,SMARCA5,SMARCD3,SMYD1,SNX6,SP3,SRSF6,SSB,STA
T1,STAT4,STAT5A,STK4,SUPT16H,SUZ12,T,TAF1A,TAF2,TAF4B,TANK,TBX3,TCE
A1,TFAM,TGFA,TGFB1,TGFBR1,TLR2,TLR4,TMEM173,TNKS,TOP1,TO-
PORS,TOX3,TRAF6,TRAK2,TROVE2,TRPS1,TRRAP,TXK,TXN,TXNIP,UBA3,UBE3
A,UBN1,UBP1,USP47,VAV3,VEGFA,VEZF1,VGLL2,VPS39,WWP1,XRCC5,YLPM1,Y
WHAB,ZFPM2,ZIC2,ZMIZ1,ZMYND11,ZNF292,ZNF384,ZNF653 
transcription of RNA 9,60E-24 Decreased -3,764 ABLIM1,ACTR2,ACTR3,ACVR1B,AFF3,AFF4,APC,ARH-
GAP35,ARID1A,ARID1B,ARID2,ARID4A,ARNT,ARNT2,ATF2,ATF4,ATF6,ATF7IP,AT
P2B4,ATP2C1,ATRX,ATXN3,ATXN7,ATXN7L3,BACH1,BAZ2A,BCL10,BCLAF1,BCR,
BDNF,BEX1,BLNK,BMP7,BMPR1B,BMPR2,BMX,BPTF,BRAF,BRD2,BRD8,BTAF1,B
TF3,BTG1,BTK,C8orf44-
SGK3/SGK3,CAMK2D,CAMKK2,CAPN3,CASK,CASP1,CBFA2T2,CBL,CCNH,CCNT
2,CCPG1,CD3D,CD3E,CD44,CDC42,CDK7,CDK8,CDKN1A,CDX2,CEBPZ,CHD1,CH
D2,CHD3,CHD4,CHD8,CHUK,CLOCK,CNOT1,CNOT2,CNOT7,COL4A2,COPS2,CO
PS5,CREB3L1,CRLF3,CSNK1E,CTNNB1,CXCR4,DACH1,DDX20,DDX3X,DEK,DIXD
C1,DKK3,DMD,DMTF1,DNMT1,DYRK1A,E2F4,EAPP,EIF4A3,ELF1,EP300,EPO,ES-
RRB,ETS1,ETV6,EVX1,EWSR1,EZH1,F2R,FGF2,FHL5,FOXN3,FOXO3,FST,FUBP1,
GATAD2A,GCG,GCLC,GLO1,GLP1R,GNA13,GNAQ,GNRHR,GPR39,GSK3B,GTF2A
1,GTF2H1,GTF2I,H2AFY,H2AFZ,HAND1,HEY1,HIF1A,HIPK1,HIPK3,HIVEP2,HLTF,
HMGB1,HMGB2,HMGN2,HNRNPA1,HPSE,HSBP1,ID2,ID4,IFI16,IFNA1/IFNA13,IFN
B1,IFRD1,IGBP1,IKZF2,IL17F,IL6,IL6ST,ILF3,INPP5D,IQGAP1,IRF3,IVNS1ABP,JAK
1,JAK2,JARID2,JMJD1C,KAT6A,KAT6B,KAT7,KDM3A,KLF13,KNG1,LCP2,LEF1,LH
X2,LIF,LPIN2,LRPPRC,LY9,MALT1,MAML1,MAP3K1,MAP3K3,MAP3K7,MAPK1,MA
TR3,MDM2,MED1,MED13,MED20,MED21,MED23,MED7,MEF2A,MEF2C,MEIS2,MG
EA5,MIF,mir-
155,MITF,MSL3,MTDH,MTERF3,MTPN,MXI1,MYC,MYCBP,MYSM1,NCOA1,NCOA2,
NCOA3,NCOA4,NCOA6,NCOA7,NEO1,NFAT5,NFATC2,NFE2L2,NFIL3,NFIX,NFKB1
,NFYA,NIPBL,NO-
BOX,NOTCH2,NPAS3,NR0B1,NR1H4,NR2C2,NR2E1,NR2F2,NR5A2,NRAS,NSD1,N
357 
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TF3,OGT,ONE-
CUT2,PA2G4,PAK2,PAX5,PBX2,PDCD4,PDLIM1,PDX1,PDZD8,PHF12,PI-
CALM,PKN2,POU2F1,POU4F3,POU5F1,PPARD,PPARG,PPP3CA,PRDM6,PRKAR1
A,PRKAR2B,PRKCQ,PRKD1,PSEN1,PSIP1,PTEN,PTH,PTTG1,PYGO2,RAP1A,RAS
A1,RAS-
GRP1,RB1,RBBP6,RBFOX2,RBL1,RBM14,RBM39,RBPJ,RCOR1,REL,RFWD2,RFX
5,RING1,RIT1,RLF,RLIM,RNA-
SEL,RNF10,RNF111,RNF14,RORA,RPS6KA3,RPS6KB1,RSF1,RUNX1,RUNX1T1,R
UNX2,SATB1,SCAF8,SCAP,SEC61A1,SENP1,SET,SETDB1,SIM1,SLA2,SLC20A1,S
MAD4,SMARCA4,SMARCA5,SMARCD3,SMYD1,SNX6,SP3,SSB,STAT1,STAT4,STA
T5A,STK4,SUZ12,T,TAF1A,TAF2,TAF4B,TANK,TBX3,TCEA1,TFAM,TGFA,TGFB1,T
GFBR1,TLR2,TLR4,TMEM173,TNKS,TOP1,TO-
PORS,TOX3,TRAF6,TRAK2,TROVE2,TRPS1,TRRAP,TXK,TXN,TXNIP,UBA3,UBE3
A,UBN1,UBP1,USP47,VAV3,VEGFA,VEZF1,VGLL2,VPS39,WWP1,XRCC5,YLPM1,Y
WHAB,ZFPM2,ZIC2,ZMIZ1,ZMYND11,ZNF292,ZNF384,ZNF653 
transactivation 1,06E-15 Decreased -4,255 ACVR1B,A-
KAP13,APC,ARID1A,ARNT,ATF2,ATF6,BCR,BDNF,BMP7,BMPR1B,BMPR2,BRD2,B
RD8,CAMK1D,CBL,CCNH,CD44,CD6,CD80,CD86,CDC42,CDK7,CEP350,CHD4,CH
UK,CTNNB1,CXCL8,CYB5A,DAP3,DDX20,DHX9,DMTF1,DNM1,DPP4,E2F4,EP300,
EPO,ETS1,ETV6,EWSR1,FGF2,FOXO3,GLRX3,GNA13,GSK3B,GTF2A1,GTF2I,HBP
1,HIF1A,HMGB1,HNRNPA1,IFI16,IG-
FBP4,IL6,ILF3,INPP5D,IRF3,JAK1,KAT7,KHDRBS3,KLF13,KNG1,LCP2,LEF1,MAP3
K3,MAP3K7,MAPK1,MDM2,MED1,MED7,MEF2C,MITF,MYC,MYCBP2,N4BP1,NAP1
L1,NCOA1,NCOA2,NCOA3,NCOA4,NCOA6,NEK9,NEO1,NFATC2,NFE2L2,NFKB1,N
OTCH2,NR0B1,NR1H4,NR2C2,NR5A2,NRAS,PA2G4,PDX1,PKN2,POU2F1,POU5F1
,PPARD,PPARG,PPP2R5C,PPP3CA,PRKAR2B,PRKCQ,PSEN1,PTEN,PTH,PTPN1,
PTTG1,RB1,RBM39,RBPJ,REL,RGS18,RNF14,RORA,RUNX1,RUNX2,SIM1,SMAD4,
SMARCA4,SRPK3,STAMBP,STAT1,STAT5A,TAF4B,TGFA,TGFB1,TGFBR1,TRAF6,
TRPS1,TRRAP,TXN,UBA3,UCHL5,UCP2,WWP1,XRCC5,ZNF384 
139 
127 
 
 
expression of DNA 1,14E-15 Decreased -2,340 ABLIM1,ACVR1B,AFF3,AFF4,ALOX12,ARH-
GAP35,ARID1A,ARID1B,ARID2,ARID4A,ARNT,ARNT2,ATF2,ATF4,ATF6,ATF7IP,AT
RX,ATXN7,ATXN7L3,BACH1,BCL10,BCLAF1,BEX1,BMP7,BMPR2,BPTF,BRD2,BRD
8,BTF3,CAMKK2,CAPN3,CASK,CBFA2T2,CBL,CCNH,CCPG1,CD3D,CD44,CD55,C
DK7,CDX2,CEBPZ,CHD1,CHD2,CHD3,CHD4,CHD8,CLOCK,CNOT1,CNOT2,CNOT7
,COL4A2,COPS2,COPS5,CREB3L1,CRLF3,CTNNB1,DACH1,DDX20,DDX3X,DEK,D
KK3,DMD,DNMT1,E2F4,EIF4A3,ELF1,EP300,EPO,ES-
RRB,ETS1,ETV6,EVX1,EZH1,F2R,FGF2,FHL5,FOXN3,FOXO3,FST,FUBP1,GATAD
2A,GCLC,GLO1,GLP1R,GTF2A1,GTF2H1,GTF2I,H2AFY,H2AFZ,HAND1,HEY1,HIF1
A,HIPK1,HIPK3,HIVEP2,HLTF,HMGB1,HMGB2,HSBP1,ID2,ID4,IFI16,IFNB1,IGBP1,I
KZF2,IL17F,IL6,IL7R,ILF3,IQGAP3,IRF3,ITGA3,IVNS1ABP,JARID2,JMJD1C,KAT6A,
KAT6B,KAT7,KDM1B,KDM3A,KLF13,LEF1,LHX2,LIF,LPIN2,MAML1,MAP3K1,MDM2
,MED1,MED13,MED20,MED21,MED23,MED7,MEF2A,MEF2C,MEIS2,MITF,MSL3,M
TDH,MTERF3,MXI1,MYC,MYCBP,MYSM1,NCOA1,NCOA2,NCOA3,NCOA6,NCOA7,
NEO1,NFAT5,NFATC2,NFE2L2,NFIL3,NFIX,NFKB1,NFYA,NIPBL,NO-
BOX,NOTCH2,NPAS3,NR0B1,NR1H4,NR2C2,NR2E1,NR2F2,NR5A2,NSD1,NTF3,N
TRK2,ONECUT2,PA2G4,PAX5,PBX2,PDCD4,PDLIM1,PDX1,PHF12,PI-
CALM,POU2F1,POU4F3,POU5F1,PPARD,PPARG,PPP3CA,PRDM6,PRKAG1,PRKA
R1A,PRKCQ,PRKD1,PSIP1,PTH,PTTG1,QKI,RB1,RBFOX2,RBL1,RBM14,RBM39,R
BPJ,RCOR1,REL,RING1,RLF,RLIM,RNA-
SEL,RNF10,RNF111,RNF14,RORA,RSF1,RUNX1,RUNX1T1,RUNX2,SATB1,SCAF8,
SENP1,SET,SGMS1,SIM1,SLA2,SMAD4,SMARCA4,SMARCA5,SMARCD3,SMYD1,
SNX6,SP3,STAT1,STAT4,STAT5A,SUZ12,T,TAF1A,TAF2,TAF4B,TBX3,TCEA1,TFA
M,TGFB1,TGFBR1,TLR2,TLR4,TMEM173,TNC,TNFSF13B,TNKS,TOP1,TO-
PORS,TOX3,TRAF6,TRAK2,TROVE2,TRPS1,TRRAP,TXK,TXN,TXNIP,UBA3,UBE3
A,UBN1,UBP1,USP47,VEGFA,VEZF1,VGLL2,WNT8B,WWP1,XRCC5,YLPM1,YWHA
B,ZFPM2,ZIC2,ZMIZ1,ZMYND11,ZNF292,ZNF384 
279 
transcription of DNA 4,96E-15 Decreased -2,120 ABLIM1,ACVR1B,AFF3,AFF4,ARH-
GAP35,ARID1A,ARID1B,ARID2,ARID4A,ARNT,ARNT2,ATF2,ATF4,ATF6,ATF7IP,AT
265 
128 
 
 
RX,ATXN7,ATXN7L3,BACH1,BCL10,BCLAF1,BEX1,BMP7,BMPR2,BPTF,BRD2,BRD
8,BTF3,CAMKK2,CAPN3,CASK,CBFA2T2,CBL,CCNH,CCPG1,CD3D,CDK7,CDX2,C
EBPZ,CHD1,CHD2,CHD3,CHD4,CHD8,CLOCK,CNOT1,CNOT2,CNOT7,COL4A2,CO
PS2,COPS5,CREB3L1,CRLF3,CTNNB1,DACH1,DDX20,DDX3X,DEK,DKK3,DMD,D
NMT1,E2F4,EIF4A3,ELF1,EP300,EPO,ES-
RRB,ETS1,ETV6,EVX1,EZH1,F2R,FGF2,FHL5,FOXN3,FOXO3,FST,FUBP1,GATAD
2A,GCLC,GLO1,GLP1R,GTF2A1,GTF2H1,GTF2I,H2AFY,H2AFZ,HAND1,HEY1,HIF1
A,HIPK1,HIPK3,HIVEP2,HLTF,HMGB1,HMGB2,HSBP1,ID2,ID4,IFI16,IFNB1,IGBP1,I
KZF2,IL17F,IL6,ILF3,IRF3,IVNS1ABP,JARID2,JMJD1C,KAT6A,KAT6B,KAT7,KDM3A
,KLF13,LEF1,LHX2,LIF,LPIN2,MAML1,MAP3K1,MDM2,MED1,MED13,MED20,MED2
1,MED23,MED7,MEF2A,MEF2C,MEIS2,MITF,MSL3,MTDH,MTERF3,MXI1,MYC,MY
CBP,MYSM1,NCOA1,NCOA2,NCOA3,NCOA6,NCOA7,NEO1,NFAT5,NFATC2,NFE2
L2,NFIL3,NFIX,NFKB1,NFYA,NIPBL,NO-
BOX,NOTCH2,NPAS3,NR0B1,NR1H4,NR2C2,NR2E1,NR2F2,NR5A2,NSD1,NTF3,O
NECUT2,PA2G4,PAX5,PBX2,PDCD4,PDLIM1,PDX1,PHF12,PI-
CALM,POU2F1,POU4F3,POU5F1,PPARD,PPARG,PPP3CA,PRDM6,PRKAR1A,PRK
CQ,PRKD1,PSIP1,PTH,PTTG1,RB1,RBFOX2,RBL1,RBM14,RBM39,RBPJ,RCOR1,R
EL,RING1,RLF,RLIM,RNA-
SEL,RNF10,RNF111,RNF14,RORA,RSF1,RUNX1,RUNX1T1,RUNX2,SATB1,SCAF8,
SENP1,SET,SIM1,SLA2,SMAD4,SMARCA4,SMARCA5,SMARCD3,SMYD1,SNX6,SP
3,STAT1,STAT4,STAT5A,SUZ12,T,TAF1A,TAF2,TAF4B,TBX3,TCEA1,TFAM,TGFB1,
TGFBR1,TLR2,TLR4,TMEM173,TNKS,TOP1,TO-
PORS,TOX3,TRAF6,TRAK2,TROVE2,TRPS1,TRRAP,TXK,TXN,TXNIP,UBA3,UBE3
A,UBN1,UBP1,USP47,VEGFA,VEZF1,VGLL2,WWP1,XRCC5,YLPM1,YWHAB,ZFPM
2,ZIC2,ZMIZ1,ZMYND11,ZNF292,ZNF384 
activation of DNA endog-
enous promoter 
5,73E-15 Decreased -2,765 AB-
LIM1,ACVR1B,AFF4,ARID2,ARID4A,ARNT,ARNT2,ATF2,ATF4,ATF6,ATF7IP,ATXN7
,BEX1,BMP7,BMPR2,BPTF,BRD2,BRD8,BTF3,CASK,CBFA2T2,CCNH,CCPG1,CD3
D,CDK7,CDX2,CEBPZ,CHD1,CHD2,CHD3,CHD4,CHD8,CLOCK,CNOT1,CNOT2,CN
204 
129 
 
 
OT7,COPS2,COPS5,CREB3L1,CRLF3,CTNNB1,DACH1,DDX20,DDX3X,DEK,DNMT
1,EIF4A3,ELF1,EP300,EPO,ES-
RRB,ETS1,EVX1,EZH1,FGF2,FOXO3,FST,FUBP1,GLO1,GLP1R,GTF2A1,GTF2H1,
GTF2I,H2AFY,H2AFZ,HAND1,HEY1,HIF1A,HIPK1,HIPK3,HLTF,HMGB1,HMGB2,HS
BP1,ID2,ID4,IFI16,IFNB1,IGBP1,IKZF2,IL17F,IL6,IRF3,IVNS1ABP,JARID2,KDM3A,K
LF13,LEF1,LHX2,LIF,LPIN2,MAML1,MAP3K1,MDM2,MED1,MED13,MED20,MED21,
MED23,MED7,MEF2A,MEF2C,MEIS2,MITF,MSL3,MTDH,MXI1,MYC,MYSM1,NCOA
1,NCOA2,NCOA3,NCOA6,NCOA7,NFAT5,NFATC2,NFE2L2,NFIL3,NFIX,NFKB1,NF
YA,NIPBL,NOBOX,NR0B1,NR1H4,NR2C2,NR2E1,NR2F2,NR5A2,NSD1,NTF3,ONE-
CUT2,PAX5,PBX2,PDX1,PHF12,POU2F1,POU4F3,POU5F1,PPARD,PPARG,PPP3C
A,PRKAR1A,PRKD1,PSIP1,PTH,PTTG1,RB1,RBL1,RBM14,RBPJ,RCOR1,RLF,RLIM
,RNA-
SEL,RNF10,RNF14,RORA,RUNX1,RUNX2,SATB1,SCAF8,SENP1,SLA2,SMAD4,SM
ARCA4,SMARCA5,SMARCD3,SP3,STAT1,STAT4,STAT5A,SUZ12,T,TAF1A,TAF2,T
AF4B,TBX3,TCEA1,TFAM,TGFB1,TLR2,TLR4,TMEM173,TNKS,TRAF6,TRAK2,TRO
VE2,TRPS1,TXK,TXN,TXNIP,UBE3A,UBN1,UBP1,VEGFA,VEZF1,VGLL2,YLPM1,ZF
PM2,ZMIZ1,ZMYND11,ZNF292,ZNF384 
transactivation of RNA 4,50E-14 Decreased -4,131 ACVR1B,A-
KAP13,APC,ARID1A,ARNT,ATF2,ATF6,BCR,BDNF,BMP7,BMPR1B,BMPR2,BRD2,C
AMK1D,CBL,CCNH,CD44,CD6,CD80,CD86,CDC42,CDK7,CEP350,CHD4,CHUK,CT
NNB1,CXCL8,CYB5A,DAP3,DDX20,DHX9,DMTF1,DNM1,DPP4,E2F4,EP300,ETS1,
ETV6,EWSR1,FGF2,FOXO3,GLRX3,GNA13,GTF2A1,GTF2I,HBP1,HIF1A,HMGB1,H
NRNPA1,IFI16,IG-
FBP4,IL6,ILF3,INPP5D,IRF3,JAK1,KAT7,KHDRBS3,KLF13,LEF1,MAP3K7,MAPK1,M
DM2,MED1,MED7,MEF2C,MITF,MYC,MYCBP2,NAP1L1,NCOA1,NCOA2,NCOA3,N
COA4,NCOA6,NEK9,NEO1,NFATC2,NFE2L2,NFKB1,NOTCH2,NR0B1,NR1H4,NR2
C2,NR5A2,PA2G4,PDX1,PKN2,POU2F1,POU5F1,PPARD,PPARG,PPP2R5C,PPP3
CA,PRKAR2B,PRKCQ,PSEN1,PTPN1,PTTG1,RBM39,RBPJ,REL,RGS18,RNF14,RO
RA,RUNX1,RUNX2,SIM1,SMAD4,SMARCA4,SRPK3,STAMBP,STAT1,STAT5A,TAF
128 
130 
 
 
4B,TGFA,TGFB1,TGFBR1,TRAF6,TRPS1,TRRAP,TXN,UBA3,UCHL5,UCP2,WWP1,
XRCC5,ZNF384 
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Supplementary Table 5: Over-represented functional GO terms for DE genes on day 2, 4 and 8 p.i. analysed by DAVID database 
 
(Full data of Supplementary Table 5 can be found as excel format on attached CD) 
 
 
Supplementary Table 6: Networks related to the DE genes in infected versus uninfected pigs on day 2, 4, and 8 p.i. analysed by IPA 
 
(Full data of Supplementary Table 6 can be found as excel format on attached CD) 
 
Sublist Category Term RT Genes Count % P-Value Benjamini
SP_PIR_KEYWORDSphosphoprotein RT 63 2,0 4,4E-7 9,9E-5
GOTERM_BP_FATinflammatory response RT CEPB, S100A8,A9, XCR1, IL8, MS4A2, SELS, SGMS18 0,3 4 0E-3 9,6E-1
SP_PIR_KEYWORDSinflammation RT S100A8,A9, IL8 3 0,1 7,3E-3 5,6E-1
UP_SEQ_FEATUREdomain:FHA RT 3 0,1 1,2E-2 9,9E-1
INTERPRO Forkhead-associated RT 3 0,1 1,3E-2 9,7E-1
SMART FHA RT 3 0,1 1,5E-2 6,9E-1
GOTERM_BP_FATresponse to wounding RT CEPB, S100A8,A9, XCR1, IL8, MS4A2, SELS, SGMS1, NOTCH29 0,3 1 7E-2 1,0E0
GOTERM_BP_FATcell cycle RT BCCIP, MPHOSPH9, NOTCH2, TTK, MKI67, DLGAP5, IL8, KIF11, PSMD14, RGS2, SGOL211 0,3 2,2E-2 1,0E0
ID Analysis Molecules in Network Score Focus Molecules Top Diseases and Functions
1 E13R048_2 vs. 0_05_15_589_filtered_1 - 2014-07-18 03:54 PM60S ribosomal subunit,ACAP1,ACSL1,ADAM15,ADAM19,ADK,AKAP13,Akt,CCNG1,CD44,Collagen type IV,DACH1,DYNC1I2,EPB41L2,FKBP5,FOLR1,Growth hormone,ICAM3,Laminin,LGALS3,MARCH8,mediator,Metalloprotease,N-cor,PDCD4,PSMD14,RPL30,RPLP1,RPLP2,SAA,STXBP2,TCF,TCF4,Tnf (family),TTC343 24 Tissue Development, Cardiovascular System Development and Function, Organ Morphology
1 E13R048_4 vs. 0_05_15_703_filtered - 2014-07-18 03:55 PM26  Proteasome,ACSL1,ADAM19,ARPC1A,CENPI,Cg,COPS2,DLGAP5,FBXO7,FOXO3,FSH,GABARAPL1,Gsk3,HERC3,HISTONE,IKK (complex),KIF11,Lh,MKI67,MOV10,MPHOSPH10,NCOA3,NUMB,PHKA2,phosphatase,PSMF1,PTEN,SET,SUCLG1,TBC1D15,TRPS1,TTK,Ubiquitin,UCHL3,Vegf43 25 Cell Cycle, Cancer, rganismal Injury and Abnormalities
1 E13R048_8 vs. 0_05_15_5998_filtered - 2014-07-18 03:57 PMABLIM1,BCL2L13,BPTF,CCPG ,CDKAL1,CFD 1,CPSF6,DAZAP2,DNTTIP2,ERLIN2,EWSR1,FBXO38,GBX2,HECTD1,HELZ,HMGCR,HP1BP3,KEL,LGALS3,LRRC8C,MAGEL2,MARCH6,MGEA5,OXR1,POU5F1,PPARG,RBM14,RING1,RNA polymerase II,SCAF8,SUZ12,UBN2,UBP1,USP7,WNT8B39 34 Cellular Development, Cellular Growth and Proliferation, ndocrine System Development and Function
2 E13R048_2 vs. 0_05_15_589_filtered_1 - 2014-07-18 03:54 PM26  Proteasome,APC (complex),ATPase,BMX,CD200R1,CENPF,COMMD1,CXCL8,DLGAP5,elastase,estrogen receptor,FBXO5,Fibrin,HERC3,IBTK,Ikb,JUN/JUNB/JUND,KIF1B,KIF20B,mir-27,Mmp,MMP1,MYCBP,NFkB (complex),PFKFB3,POLK,PSMC6,REV1,RGS2,RPS6KA3,SCFD1,TEC/BTK/ITK/TXK/BMX,TGFA,trypsin,Ubiquitin38 22 ellular Assembly and Organization, Cellular Function and Maintenance, Tissue Development
2 E13R048_8 vs. 0_05_15_5998_filtered - 2014-07-18 03:57 PMAGO2,ARL6IP ,CENPI,DAP3,DDX6,EEF1A1,EXOSC10,FSH,FST,GNRHR,ILF3,KIF5B,KLHL29,let-7,LIN28A,MEX3A,mir-10,mir-363,MRPS10,PABPC1,PAIP1,PHYHIP,PSIP1,PSME4,RAB14,RAD23B,RBM5,RDH10,RPS6KA,RSF1,SCAF11,SSR1,STAU2,XRN2,ZCCHC63 33 Embryonic Development, Organ Development, Organismal Development
2 E13R048_4 vs. 0_05_15_703_filtered - 2014-07-18 03:55 PMAATF,ADAM15,Alpha catenin,ATE1,ATPase,BLM,caspase,CLASP1,CPD,DNAJC19,HSP,Hsp70,Hsp90,HSPA14,IFN alpha/beta,IFN Beta,IFN type 1,IFNA1/IFNA13,KIF1B,KIF20B,MHC Class II (complex),MSH2,NEK1,p70 S6k,Pkc(s),POLK,PP2A,PSMC6,REV1,S100A8,S100A9,SLC26A6,STXBP3,Tlr,TLR434 21 Cell-To-Cell Signaling and Interaction, Inflammatory Response, DNA Replication, Recombination, and Repair
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